["if a patient with hodgkin lymphoma has cd30 +, one recommended therapy is doxorubicin + dacarbazine + vinblastine + brentuximab vedotin. therapy type: chemotherapy + chemotherapy + targeted therapy + targeted therapy. therapy strategy: topoisomerase inhibition + nonclassical alkylating chemotherapy + vinca alkaloid chemotherapy + target cd30 antigens. indication: adcetris is indicated for adult patients with previously untreated cd30+ stage iii or iv hodgkin lymphoma (hl) in combination with doxorubicin, vinblastine and dacarbazine (avd). approval url: https://www.ema.europa.eu/en/documents/product-information/adcetris-epar-product-information_en.pdf", "if a patient with hodgkin lymphoma has cd30 +, one recommended therapy is brentuximab vedotin. therapy type: targeted therapy. therapy strategy: target cd30 antigens. indication: adcetris is indicated for the treatment of adult patients with cd30+ hl at increased risk of relapse or progression following autologous stem cell transplant (asct). approval url: https://www.ema.europa.eu/en/documents/product-information/adcetris-epar-product-information_en.pdf", "if a patient with hodgkin lymphoma has cd30 +, one recommended therapy is brentuximab vedotin. therapy type: targeted therapy. therapy strategy: target cd30 antigens. indication: adcetris is indicated for the treatment of adult patients with relapsed or refractory cd30+ hodgkin lymphoma (hl): (i) following asct, or (ii) following at least two prior therapies when asct or multi-agent chemotherapy is not a treatment option. approval url: https://www.ema.europa.eu/en/documents/product-information/adcetris-epar-product-information_en.pdf", "if a patient with cutaneous t-cell lymphoma has cd30 +, one recommended therapy is brentuximab vedotin. therapy type: targeted therapy. therapy strategy: target cd30 antigens. indication: adcetris is indicated for the treatment of adult patients with cd30+ cutaneous t-cell lymphoma (ctcl) after at least 1 prior systemic therapy. approval url: https://www.ema.europa.eu/en/documents/product-information/adcetris-epar-product-information_en.pdf", "if a patient with invasive breast carcinoma has her2-negative, er positive, one recommended therapy is exemestane + everolimus. therapy type: hormone therapy + targeted therapy. therapy strategy: aromatase inhibition + pi3k/akt/mtor inhibition. indication: afinitor is indicated for the treatment of hormone receptor-positive, her2/neu negative advanced breast cancer, in combination with exemestane, in postmenopausal women without symptomatic visceral disease after recurrence or progression following a non-steroidal aromatase inhibitor. approval url: https://www.ema.europa.eu/en/documents/product-information/afinitor-epar-product-information_en.pdf", "if a patient with invasive breast carcinoma has pr positive, her2-negative, one recommended therapy is exemestane + everolimus. therapy type: hormone therapy + targeted therapy. therapy strategy: aromatase inhibition + pi3k/akt/mtor inhibition. indication: afinitor is indicated for the treatment of hormone receptor-positive, her2/neu negative advanced breast cancer, in combination with exemestane, in postmenopausal women without symptomatic visceral disease after recurrence or progression following a non-steroidal aromatase inhibitor. approval url: https://www.ema.europa.eu/en/documents/product-information/afinitor-epar-product-information_en.pdf", "if a patient with invasive breast carcinoma has pr positive, her2-negative, er positive, one recommended therapy is exemestane + everolimus. therapy type: hormone therapy + targeted therapy. therapy strategy: aromatase inhibition + pi3k/akt/mtor inhibition. indication: afinitor is indicated for the treatment of hormone receptor-positive, her2/neu negative advanced breast cancer, in combination with exemestane, in postmenopausal women without symptomatic visceral disease after recurrence or progression following a non-steroidal aromatase inhibitor. approval url: https://www.ema.europa.eu/en/documents/product-information/afinitor-epar-product-information_en.pdf", "if a patient with metastatic castration-resistant prostate adenocarcinoma has brca1 oncogenic variants, one recommended therapy is prednisolone + niraparib + abiraterone acetate. therapy type: chemotherapy + targeted therapy + hormone therapy. therapy strategy: corticosteroid + parp inhibition + antiandrogen. indication: akeega is indicated with prednisone or prednisolone for the treatment of adult patients with metastatic castration-resistant prostate cancer (mcrpc) and brca 1/2 mutations (germline and/or somatic) in whom chemotherapy is not clinically indicated. approval url: https://www.ema.europa.eu/en/documents/product-information/akeega-epar-product-information_en.pdf", "if a patient with metastatic castration-resistant prostate adenocarcinoma has brca2 oncogenic variants, one recommended therapy is prednisolone + niraparib + abiraterone acetate. therapy type: chemotherapy + targeted therapy + hormone therapy. therapy strategy: corticosteroid + parp inhibition + antiandrogen. indication: akeega is indicated with prednisone or prednisolone for the treatment of adult patients with metastatic castration-resistant prostate cancer (mcrpc) and brca 1/2 mutations (germline and/or somatic) in whom chemotherapy is not clinically indicated. approval url: https://www.ema.europa.eu/en/documents/product-information/akeega-epar-product-information_en.pdf", "if a patient with metastatic castration-resistant prostate adenocarcinoma has brca1 pathogenic variants, one recommended therapy is prednisolone + niraparib + abiraterone acetate. therapy type: chemotherapy + targeted therapy + hormone therapy. therapy strategy: corticosteroid + parp inhibition + antiandrogen. indication: akeega is indicated with prednisone or prednisolone for the treatment of adult patients with metastatic castration-resistant prostate cancer (mcrpc) and brca 1/2 mutations (germline and/or somatic) in whom chemotherapy is not clinically indicated. approval url: https://www.ema.europa.eu/en/documents/product-information/akeega-epar-product-information_en.pdf", "if a patient with metastatic castration-resistant prostate adenocarcinoma has brca2 pathogenic variants, one recommended therapy is prednisolone + niraparib + abiraterone acetate. therapy type: chemotherapy + targeted therapy + hormone therapy. therapy strategy: corticosteroid + parp inhibition + antiandrogen. indication: akeega is indicated with prednisone or prednisolone for the treatment of adult patients with metastatic castration-resistant prostate cancer (mcrpc) and brca 1/2 mutations (germline and/or somatic) in whom chemotherapy is not clinically indicated. approval url: https://www.ema.europa.eu/en/documents/product-information/akeega-epar-product-information_en.pdf", "if a patient with non-small cell lung cancer has v::alk, one recommended therapy is alectinib. therapy type: targeted therapy. therapy strategy: alk inhibition. indication: alecensa as monotherapy is indicated for the first-line treatment of adult patients with anaplastic lymphoma kinase (alk)-positive advanced non-small cell lung cancer (nsclc). approval url: https://www.ema.europa.eu/en/documents/product-information/alecensa-epar-product-information_en.pdf", "if a patient with non-small cell lung cancer has v::alk, one recommended therapy is alectinib. therapy type: targeted therapy. therapy strategy: alk inhibition. indication: alecensa as monotherapy is indicated for the treatment of adult patients with alk-positive advanced nsclc previously treated with crizotinib. approval url: https://www.ema.europa.eu/en/documents/product-information/alecensa-epar-product-information_en.pdf", "if a patient with non-small cell lung cancer has v::alk, one recommended therapy is alectinib. therapy type: targeted therapy. therapy strategy: alk inhibition. indication: alecensa as monotherapy is indicated as adjuvant treatment following complete tumour resection for adult patients with alk-positive non-small cell lung cancer (nsclc) at high risk of recurrence. approval url: https://www.ema.europa.eu/en/documents/product-information/alecensa-epar-product-information_en.pdf", "if a patient with non-small cell lung cancer has v::alk, one recommended therapy is brigatinib. therapy type: targeted therapy. therapy strategy: alk inhibition. indication: alunbrig is indicated as monotherapy for the treatment of adult patients with anaplastic lymphoma kinase (alk)-positive advanced non-small cell lung cancer (nsclc) previously not treated with an alk inhibitor. approval url: https://www.ema.europa.eu/en/documents/product-information/alunbrig-epar-product-information_en.pdf", "if a patient with non-small cell lung cancer has v::alk, one recommended therapy is brigatinib. therapy type: targeted therapy. therapy strategy: alk inhibition. indication: alunbrig is indicated as monotherapy for the treatment of adult patients with alk-positive advanced nsclc previously treated with crizotinib. approval url: https://www.ema.europa.eu/en/documents/product-information/alunbrig-epar-product-information_en.pdf", "if a patient with non-small cell lung cancer has egfr p.l858r, one recommended therapy is bevacizumab + erlotinib. therapy type: targeted therapy + targeted therapy. therapy strategy: vegf inhibition + egfr inhibition. indication: bevacizumab, in combination with erlotinib, is indicated for first-line treatment of adult patients with unresectable advanced, metastatic or recurrent non-squamous non-small cell lung cancer with epidermal growth factor receptor (egfr) activating mutations. approval url: https://www.ema.europa.eu/en/documents/product-information/avastin-epar-product-information_en.pdf", "if a patient with non-small cell lung cancer has egfr exon 19 (deletion), one recommended therapy is bevacizumab + erlotinib. therapy type: targeted therapy + targeted therapy. therapy strategy: vegf inhibition + egfr inhibition. indication: bevacizumab, in combination with erlotinib, is indicated for first-line treatment of adult patients with unresectable advanced, metastatic or recurrent non-squamous non-small cell lung cancer with epidermal growth factor receptor (egfr) activating mutations. approval url: https://www.ema.europa.eu/en/documents/product-information/avastin-epar-product-information_en.pdf", "if a patient with gastrointestinal stromal tumor has pdgfra p.d842v, one recommended therapy is avapritinib. therapy type: targeted therapy. therapy strategy: kit inhibition. indication: ayvakyt is indicated as monotherapy for the treatment of adult patients with unresectable or metastatic gastrointestinal stromal tumours (gist) harbouring the platelet-derived growth factor receptor alpha (pdgfra) d842v mutation. approval url: https://www.ema.europa.eu/en/documents/product-information/ayvakyt-epar-product-information_en.pdf", "if a patient with acute lymphoid leukemia has bcr::abl1, cd22 +, one recommended therapy is inotuzumab ozogamicin. therapy type: targeted therapy. therapy strategy: bcr-abl inhibition. indication: besponsa is indicated as monotherapy for the treatment of adults with relapsed or refractory cd22-positive b cell precursor acute lymphoblastic leukaemia (all). adult patients with philadelphia chromosome positive (ph+) relapsed or refractory b cell precursor all should have failed treatment with at least 1 tyrosine kinase inhibitor (tki). approval url: https://www.ema.europa.eu/en/documents/product-information/besponsa-epar-product-information_en.pdf", "if a patient with acute lymphoid leukemia has cd22 +, one recommended therapy is inotuzumab ozogamicin. therapy type: targeted therapy. therapy strategy: bcr-abl inhibition. indication: besponsa is indicated as monotherapy for the treatment of adults with relapsed or refractory cd22-positive b cell precursor acute lymphoblastic leukaemia (all). adult patients with philadelphia chromosome positive (ph+) relapsed or refractory b cell precursor all should have failed treatment with at least 1 tyrosine kinase inhibitor (tki). approval url: https://www.ema.europa.eu/en/documents/product-information/besponsa-epar-product-information_en.pdf", "if a patient with acute lymphoid leukemia has cd19 +, one recommended therapy is blinatumomab. therapy type: immunotherapy. therapy strategy: cd19 inhibition. indication: blincyto is indicated as monotherapy for the treatment of adults with cd19 positive relapsed or refractory b-cell precursor acute lymphoblastic leukaemia (all). patients with philadelphia chromosome-positive b-cell precursor all should have failed treatment with at least 2 tyrosine kinase inhibitors (tkis) and have no alternative treatment options. approval url: https://www.ema.europa.eu/en/documents/product-information/blincyto-epar-product-information_en.pdf", "if a patient with acute lymphoid leukemia has bcr::abl1, cd19 +, one recommended therapy is blinatumomab. therapy type: immunotherapy. therapy strategy: cd19 inhibition. indication: blincyto is indicated as monotherapy for the treatment of adults with cd19 positive relapsed or refractory b-cell precursor acute lymphoblastic leukaemia (all). patients with philadelphia chromosome-positive b-cell precursor all should have failed treatment with at least 2 tyrosine kinase inhibitors (tkis) and have no alternative treatment options. approval url: https://www.ema.europa.eu/en/documents/product-information/blincyto-epar-product-information_en.pdf", "if a patient with acute lymphoid leukemia has bcr::abl1, cd19 +, one recommended therapy is blinatumomab. therapy type: immunotherapy. therapy strategy: cd19 inhibition. indication: blincyto is indicated as monotherapy for the treatment of adults with philadelphia chromosome-negative cd19 positive b-cell precursor all in first or second complete remission with minimal residual disease (mrd) greater than or equal to 0.1%. approval url: https://www.ema.europa.eu/en/documents/product-information/blincyto-epar-product-information_en.pdf", "if a patient with acute lymphoid leukemia has bcr::abl1, cd19 +, one recommended therapy is blinatumomab. therapy type: immunotherapy. therapy strategy: cd19 inhibition. indication: blincyto is indicated as monotherapy for the treatment of paediatric patients aged 1 month or older with philadelphia chromosome-negative cd19 positive b-cell precursor all which is refractory or in relapse after receiving at least two prior therapies or in relapse after receiving prior allogeneic haematopoietic stem cell transplantation. approval url: https://www.ema.europa.eu/en/documents/product-information/blincyto-epar-product-information_en.pdf", "if a patient with acute lymphoid leukemia has bcr::abl1, cd19 +, one recommended therapy is blinatumomab. therapy type: immunotherapy. therapy strategy: cd19 inhibition. indication: blincyto is indicated as monotherapy for the treatment of paediatric patients aged 1 month or older with high-risk first relapsed philadelphia chromosome-negative cd19 positive b-cell precursor all as part of the consolidation therapy. approval url: https://www.ema.europa.eu/en/documents/product-information/blincyto-epar-product-information_en.pdf", "if a patient with chronic myelogenous leukemia has bcr::abl1, one recommended therapy is bosutinib. therapy type: targeted therapy. therapy strategy: bcr-abl inhibition. indication: bosulif is indicated for the treatment of adult and paediatric patients aged 6 years and older with newly-diagnosed chronic phase (cp) philadelphia chromosome-positive chronic myelogenous leukaemia (ph+ cml). approval url: https://www.ema.europa.eu/en/documents/product-information/bosulif-epar-product-information_en.pdf", "if a patient with chronic myelogenous leukemia has bcr::abl1, one recommended therapy is bosutinib. therapy type: targeted therapy. therapy strategy: bcr-abl inhibition. indication: bosulif is indicated for the treatment of adult patients with accelerated phase (ap), and blast phase (bp) ph+ cml previously treated with one or more tyrosine kinase inhibitor(s) [tki(s)] and for whom imatinib, nilotinib and dasatinib are not considered appropriate treatment options. approval url: https://www.ema.europa.eu/en/documents/product-information/bosulif-epar-product-information_en.pdf", "if a patient with melanoma has braf p.v600e, one recommended therapy is binimetinib + encorafenib. therapy type: targeted therapy + targeted therapy. therapy strategy: mek inhibition + b-raf inhibition. indication: encorafenib is indicated in combination with binimetinib for the treatment of adult patients with unresectable or metastatic melanoma with a braf v600 mutation. approval url: https://www.ema.europa.eu/en/documents/product-information/braftovi-epar-product-information_en.pdf", "if a patient with melanoma has braf p.v600k, one recommended therapy is binimetinib + encorafenib. therapy type: targeted therapy + targeted therapy. therapy strategy: mek inhibition + b-raf inhibition. indication: encorafenib is indicated in combination with binimetinib for the treatment of adult patients with unresectable or metastatic melanoma with a braf v600 mutation. approval url: https://www.ema.europa.eu/en/documents/product-information/braftovi-epar-product-information_en.pdf", "if a patient with colorectal adenocarcinoma has braf p.v600e, one recommended therapy is cetuximab + encorafenib. therapy type: targeted therapy + targeted therapy. therapy strategy: egfr inhibition + b-raf inhibition. indication: encorafenib is indicated in combination with cetuximab, for the treatment of adult patients with metastatic colorectal cancer (crc) with a braf v600e mutation, who have received prior systemic therapy. approval url: https://www.ema.europa.eu/en/documents/product-information/braftovi-epar-product-information_en.pdf", "if a patient with non-small cell lung cancer has braf p.v600e, one recommended therapy is binimetinib + encorafenib. therapy type: targeted therapy + targeted therapy. therapy strategy: mek inhibition + b-raf inhibition. indication: encorafenib in combination with binimetinib is indicated for the treatment of adult patients with advanced non-small cell lung cancer with a braf v600e mutation. approval url: https://www.ema.europa.eu/en/documents/product-information/braftovi-epar-product-information_en.pdf", "if a patient with medullary thyroid cancer has v::ret, one recommended therapy is vandetanib. therapy type: targeted therapy. therapy strategy: ret inhibition. indication: caprelsa is indicated for the treatment of aggressive and symptomatic rearranged during transfection (ret) mutant medullary thyroid cancer (mtc) in patients with unresectable locally advanced or metastatic disease. caprelsa is indicated in adults, children and adolescents aged 5 years and older. approval url: https://www.ema.europa.eu/en/documents/product-information/caprelsa-epar-product-information_en.pdf", "if a patient with melanoma has braf p.v600e, one recommended therapy is vemurafenib + cobimetinib. therapy type: targeted therapy + targeted therapy. therapy strategy: b-raf inhibition + mek inhibition. indication: cotellic is indicated for use in combination with vemurafenib for the treatment of adult patients with unresectable or metastatic melanoma with a braf v600 mutation. approval url: https://www.ema.europa.eu/en/documents/product-information/cotellic-epar-product-information_en.pdf", "if a patient with melanoma has braf p.v600k, one recommended therapy is vemurafenib + cobimetinib. therapy type: targeted therapy + targeted therapy. therapy strategy: b-raf inhibition + mek inhibition. indication: cotellic is indicated for use in combination with vemurafenib for the treatment of adult patients with unresectable or metastatic melanoma with a braf v600 mutation. approval url: https://www.ema.europa.eu/en/documents/product-information/cotellic-epar-product-information_en.pdf", "if a patient with non-small cell lung cancer has egfr oncogenic variants, one recommended therapy is erlotinib + ramucirumab. therapy type: targeted therapy + targeted therapy. therapy strategy: egfr inhibition + vegf/vegfr inhibition. indication: cyramza in combination with erlotinib is indicated for the first-line treatment of adult patients with metastatic non-small cell lung cancer with activating epidermal growth factor receptor (egfr) mutations. approval url: https://www.ema.europa.eu/en/documents/product-information/cyramza-epar-product-information_en.pdf", "if a patient with invasive breast carcinoma has her2-positive, one recommended therapy is trastuzumab + docetaxel. therapy type: targeted therapy + chemotherapy. therapy strategy: her2 inhibition + taxane-based chemotherapy. indication: taxotere in combination with trastuzumab is indicated for the treatment of patients with metastatic breast cancer whose tumours over express her2 and who previously have not received chemotherapy for metastatic disease. approval url: https://www.ema.europa.eu/en/documents/product-information/taxotere-epar-product-information_en.pdf", "if a patient with invasive breast carcinoma has erbb2 amplification, one recommended therapy is trastuzumab + docetaxel. therapy type: targeted therapy + chemotherapy. therapy strategy: her2 inhibition + taxane-based chemotherapy. indication: taxotere in combination with trastuzumab is indicated for the treatment of patients with metastatic breast cancer whose tumours over express her2 and who previously have not received chemotherapy for metastatic disease. approval url: https://www.ema.europa.eu/en/documents/product-information/taxotere-epar-product-information_en.pdf", "if a patient with invasive breast carcinoma has her2-positive, one recommended therapy is trastuzumab deruxtecan. therapy type: targeted therapy. therapy strategy: her2 inhibition. indication: enhertu as monotherapy is indicated for the treatment of adult patients with unresectable or metastatic her2-positive breast cancer who have received one or more prior anti-her2-based regimens. approval url: https://www.ema.europa.eu/en/documents/product-information/enhertu-epar-product-information_en.pdf", "if a patient with invasive breast carcinoma has erbb2 amplification, one recommended therapy is trastuzumab deruxtecan. therapy type: targeted therapy. therapy strategy: her2 inhibition. indication: enhertu as monotherapy is indicated for the treatment of adult patients with unresectable or metastatic her2-positive breast cancer who have received one or more prior anti-her2-based regimens. approval url: https://www.ema.europa.eu/en/documents/product-information/enhertu-epar-product-information_en.pdf", "if a patient with invasive breast carcinoma has her2-low, one recommended therapy is trastuzumab deruxtecan. therapy type: targeted therapy. therapy strategy: her2 inhibition. indication: enhertu as monotherapy is indicated for the treatment of adult patients with unresectable or metastatic her2-low breast cancer who have received prior chemotherapy in the metastatic setting or developed disease recurrence during or within 6 months of completing adjuvant chemotherapy. approval url: https://www.ema.europa.eu/en/documents/product-information/enhertu-epar-product-information_en.pdf", "if a patient with non-small cell lung cancer has erbb2 amplification, one recommended therapy is trastuzumab deruxtecan. therapy type: targeted therapy. therapy strategy: her2 inhibition. indication: enhertu as monotherapy is indicated for the treatment of adult patients with advanced nsclc whose tumours have an activating her2 (erbb2) mutation and who require systemic therapy following platinum-based chemotherapy with or without immunotherapy. approval url: https://www.ema.europa.eu/en/documents/product-information/enhertu-epar-product-information_en.pdf", "if a patient with non-small cell lung cancer has erbb2 oncogenic variants, one recommended therapy is trastuzumab deruxtecan. therapy type: targeted therapy. therapy strategy: her2 inhibition. indication: enhertu as monotherapy is indicated for the treatment of adult patients with advanced nsclc whose tumours have an activating her2 (erbb2) mutation and who require systemic therapy following platinum-based chemotherapy with or without immunotherapy. approval url: https://www.ema.europa.eu/en/documents/product-information/enhertu-epar-product-information_en.pdf", "if a patient with adenocarcinoma of the gastroesophageal junction has her2-positive, one recommended therapy is trastuzumab deruxtecan. therapy type: targeted therapy. therapy strategy: her2 inhibition. indication: enhertu as monotherapy is indicated for the treatment of adult patients with advanced her2-positive gastric or gastroesophageal junction (gej) adenocarcinoma who have received a prior trastuzumab-based regimen. approval url: https://www.ema.europa.eu/en/documents/product-information/enhertu-epar-product-information_en.pdf", "if a patient with adenocarcinoma of the gastroesophageal junction has erbb2 amplification, one recommended therapy is trastuzumab deruxtecan. therapy type: targeted therapy. therapy strategy: her2 inhibition. indication: enhertu as monotherapy is indicated for the treatment of adult patients with advanced her2-positive gastric or gastroesophageal junction (gej) adenocarcinoma who have received a prior trastuzumab-based regimen. approval url: https://www.ema.europa.eu/en/documents/product-information/enhertu-epar-product-information_en.pdf", "if a patient with colorectal adenocarcinoma has egfr positive, wild type kras, wild type hras, wild type nras, one recommended therapy is cetuximab. therapy type: targeted therapy. therapy strategy: egfr inhibition. indication: erbitux is indicated for the treatment of patients with epidermal growth factor receptor (egfr)-expressing, ras wild-type metastatic colorectal cancer as a single agent in patients who have failed oxaliplatin- and irinotecan-based therapy and who are intolerant to irinotecan. approval url: https://www.ema.europa.eu/en/documents/product-information/erbitux-epar-product-information_en.pdf", "if a patient with colorectal adenocarcinoma has egfr positive, wild type kras, wild type hras, wild type nras, one recommended therapy is irinotecan + cetuximab. therapy type: chemotherapy + targeted therapy. therapy strategy: topoisomerase i inhibition + egfr inhibition. indication: erbitux is indicated for the treatment of patients with epidermal growth factor receptor (egfr)-expressing, ras wild-type metastatic colorectal cancer in combination with irinotecan-based chemotherapy. approval url: https://www.ema.europa.eu/en/documents/product-information/erbitux-epar-product-information_en.pdf", "if a patient with colorectal adenocarcinoma has egfr positive, wild type kras, wild type hras, wild type nras, one recommended therapy is oxaliplatin + fluorouracil + cetuximab. therapy type: chemotherapy + chemotherapy + targeted therapy. therapy strategy: platinum-based chemotherapy + thymidylate synthase inhibition + egfr inhibition. indication: erbitux is indicated for the treatment of patients with epidermal growth factor receptor (egfr)-expressing, ras wild-type metastatic colorectal cancer in first-line in combination with folfox. approval url: https://www.ema.europa.eu/en/documents/product-information/erbitux-epar-product-information_en.pdf", "if a patient with locally advanced or metastatic invasive breast carcinoma has er positive, one recommended therapy is fulvestrant. therapy type: hormone therapy. therapy strategy: estrogen receptor inhibition. indication: faslodex is indicated as monotherapy for the treatment of estrogen receptor positive, locally advanced or metastatic breast cancer in postmenopausal women not previously treated with endocrine therapy, or with disease relapse on or after adjuvant antiestrogen therapy, or disease progression on antiestrogen therapy. approval url: https://www.ema.europa.eu/en/documents/product-information/faslodex-epar-product-information_en.pdf", "if a patient with locally advanced or metastatic invasive breast carcinoma has her2-negative, er positive, one recommended therapy is fulvestrant + palbociclib. therapy type: hormone therapy + targeted therapy. therapy strategy: estrogen receptor inhibition + cdk4/6 inhibition. indication: faslodex is indicated in combination with palbociclib for the treatment of hormone receptor (hr)-positive, human epidermal growth factor receptor 2 (her2)-negative locally advanced or metastatic breast cancer in women who have received prior endocrine therapy. approval url: https://www.ema.europa.eu/en/documents/product-information/faslodex-epar-product-information_en.pdf", "if a patient with locally advanced or metastatic invasive breast carcinoma has pr positive, her2-negative, one recommended therapy is fulvestrant + palbociclib. therapy type: hormone therapy + targeted therapy. therapy strategy: estrogen receptor inhibition + cdk4/6 inhibition. indication: faslodex is indicated in combination with palbociclib for the treatment of hormone receptor (hr)-positive, human epidermal growth factor receptor 2 (her2)-negative locally advanced or metastatic breast cancer in women who have received prior endocrine therapy. approval url: https://www.ema.europa.eu/en/documents/product-information/faslodex-epar-product-information_en.pdf", "if a patient with locally advanced or metastatic invasive breast carcinoma has pr positive, her2-negative, er positive, one recommended therapy is fulvestrant + palbociclib. therapy type: hormone therapy + targeted therapy. therapy strategy: estrogen receptor inhibition + cdk4/6 inhibition. indication: faslodex is indicated in combination with palbociclib for the treatment of hormone receptor (hr)-positive, human epidermal growth factor receptor 2 (her2)-negative locally advanced or metastatic breast cancer in women who have received prior endocrine therapy. approval url: https://www.ema.europa.eu/en/documents/product-information/faslodex-epar-product-information_en.pdf", "if a patient with non-small cell lung cancer has v::ret, one recommended therapy is pralsetinib. therapy type: targeted therapy. therapy strategy: ret inhibition. indication: gavreto is indicated as monotherapy for the treatment of adult patients with rearranged during transfection (ret) fusion-positive advanced non-small cell lung cancer (nsclc) not previously treated with a ret inhibitor. approval url: https://www.ema.europa.eu/en/documents/product-information/gavreto-epar-product-information_en.pdf", "if a patient with non-small cell lung cancer has egfr oncogenic variants, one recommended therapy is gefitinib. therapy type: targeted therapy. therapy strategy: egfr inhibition. indication: iressa is indicated as monotherapy for the treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (nsclc) with activating mutations of egfr-tk. approval url: https://www.ema.europa.eu/en/documents/product-information/iressa-epar-product-information_en.pdf", "if a patient with non-small cell lung cancer has egfr oncogenic variants, one recommended therapy is afatinib. therapy type: targeted therapy. therapy strategy: egfr inhibition. indication: giotrif as monotherapy is indicated for the treatment of epidermal growth factor receptor (egfr) tki-naive adult patients with locally advanced or metastatic non-small cell lung cancer (nsclc) with activating egfr mutation(s). approval url: https://www.ema.europa.eu/en/documents/product-information/giotrif-epar-product-information_en.pdf", "if a patient with metastatic invasive breast carcinoma has her2-positive, one recommended therapy is trastuzumab. therapy type: targeted therapy. therapy strategy: her2 inhibition. indication: herceptin is indicated for the treatment of adult patients with her2 positive metastatic breast cancer (mbc) as monotherapy for the treatment of those patients who have received at least two chemotherapy regimens for their metastatic disease. prior chemotherapy must have included at least an anthracycline and a taxane unless patients are unsuitable for these treatments. hormone receptor positive patients must also have failed hormonal therapy, unless patients are unsuitable for these treatments. approval url: https://www.ema.europa.eu/en/documents/product-information/herceptin-epar-product-information_en.pdf", "if a patient with metastatic invasive breast carcinoma has her2-positive, one recommended therapy is trastuzumab + paclitaxel. therapy type: targeted therapy + chemotherapy. therapy strategy: her2 inhibition + taxane-based chemotherapy. indication: herceptin is indicated for the treatment of adult patients with her2 positive metastatic breast cancer (mbc) in combination with paclitaxel for the treatment of those patients who have not received chemotherapy for their metastatic disease and for whom an anthracycline is not suitable. approval url: https://www.ema.europa.eu/en/documents/product-information/herceptin-epar-product-information_en.pdf", "if a patient with metastatic invasive breast carcinoma has her2-positive, one recommended therapy is trastuzumab + docetaxel. therapy type: targeted therapy + chemotherapy. therapy strategy: her2 inhibition + taxane-based chemotherapy. indication: herceptin is indicated for the treatment of adult patients with her2 positive metastatic breast cancer (mbc) in combination with docetaxel for the treatment of those patients who have not received chemotherapy for their metastatic disease. approval url: https://www.ema.europa.eu/en/documents/product-information/herceptin-epar-product-information_en.pdf", "if a patient with metastatic invasive breast carcinoma has her2-positive, one recommended therapy is trastuzumab + anastrozole. therapy type: targeted therapy + hormone therapy. therapy strategy: her2 inhibition + aromatase inhibition. indication: herceptin is indicated for the treatment of adult patients with her2 positive metastatic breast cancer (mbc) in combination with an aromatase inhibitor for the treatment of postmenopausal patients with hormone-receptor positive mbc, not previously treated with trastuzumab. approval url: https://www.ema.europa.eu/en/documents/product-information/herceptin-epar-product-information_en.pdf", "if a patient with invasive breast carcinoma has her2-positive, one recommended therapy is trastuzumab. therapy type: targeted therapy. therapy strategy: her2 inhibition. indication: herceptin is indicated for the treatment of adult patients with her2 positive early breast cancer (ebc) following surgery, chemotherapy (neoadjuvant or adjuvant) and radiotherapy (if applicable). approval url: https://www.ema.europa.eu/en/documents/product-information/herceptin-epar-product-information_en.pdf", "if a patient with invasive breast carcinoma has her2-positive, one recommended therapy is trastuzumab + paclitaxel. therapy type: targeted therapy + chemotherapy. therapy strategy: her2 inhibition + taxane-based chemotherapy. indication: herceptin is indicated for the treatment of adult patients with her2 positive early breast cancer (ebc) following adjuvant chemotherapy with doxorubicin and cyclophosphamide, in combination with paclitaxel or docetaxel. approval url: https://www.ema.europa.eu/en/documents/product-information/herceptin-epar-product-information_en.pdf", "if a patient with invasive breast carcinoma has her2-positive, one recommended therapy is trastuzumab + docetaxel. therapy type: targeted therapy + chemotherapy. therapy strategy: her2 inhibition + taxane-based chemotherapy. indication: herceptin is indicated for the treatment of adult patients with her2 positive early breast cancer (ebc) following adjuvant chemotherapy with doxorubicin and cyclophosphamide, in combination with paclitaxel or docetaxel. approval url: https://www.ema.europa.eu/en/documents/product-information/herceptin-epar-product-information_en.pdf", "if a patient with invasive breast carcinoma has her2-positive, one recommended therapy is trastuzumab + carboplatin + docetaxel. therapy type: targeted therapy + chemotherapy + chemotherapy. therapy strategy: her2 inhibition + platinum-based chemotherapy + taxane-based chemotherapy. indication: herceptin is indicated for the treatment of adult patients with her2 positive early breast cancer (ebc) in combination with adjuvant chemotherapy consisting of docetaxel and carboplatin. approval url: https://www.ema.europa.eu/en/documents/product-information/herceptin-epar-product-information_en.pdf", "if a patient with invasive breast carcinoma has her2-positive, one recommended therapy is trastuzumab + doxorubicin + paclitaxel. therapy type: targeted therapy + chemotherapy + chemotherapy. therapy strategy: her2 inhibition + topoisomerase inhibition + taxane-based chemotherapy. indication: herceptin is indicated for the treatment of adult patients with her2 positive early breast cancer (ebc) in combination with neoadjuvant chemotherapy followed by adjuvant herceptin therapy, for locally advanced (including inflammatory) disease or tumours > 2 cm in diameter. approval url: https://www.ema.europa.eu/en/documents/product-information/herceptin-epar-product-information_en.pdf", "if a patient with metastatic invasive breast carcinoma has erbb2 amplification, one recommended therapy is trastuzumab. therapy type: targeted therapy. therapy strategy: her2 inhibition. indication: herceptin is indicated for the treatment of adult patients with her2 positive metastatic breast cancer (mbc) as monotherapy for the treatment of those patients who have received at least two chemotherapy regimens for their metastatic disease. prior chemotherapy must have included at least an anthracycline and a taxane unless patients are unsuitable for these treatments. hormone receptor positive patients must also have failed hormonal therapy, unless patients are unsuitable for these treatments. approval url: https://www.ema.europa.eu/en/documents/product-information/herceptin-epar-product-information_en.pdf", "if a patient with metastatic invasive breast carcinoma has erbb2 amplification, one recommended therapy is trastuzumab + paclitaxel. therapy type: targeted therapy + chemotherapy. therapy strategy: her2 inhibition + taxane-based chemotherapy. indication: herceptin is indicated for the treatment of adult patients with her2 positive metastatic breast cancer (mbc) in combination with paclitaxel for the treatment of those patients who have not received chemotherapy for their metastatic disease and for whom an anthracycline is not suitable. approval url: https://www.ema.europa.eu/en/documents/product-information/herceptin-epar-product-information_en.pdf", "if a patient with metastatic invasive breast carcinoma has erbb2 amplification, one recommended therapy is trastuzumab + docetaxel. therapy type: targeted therapy + chemotherapy. therapy strategy: her2 inhibition + taxane-based chemotherapy. indication: herceptin is indicated for the treatment of adult patients with her2 positive metastatic breast cancer (mbc) in combination with docetaxel for the treatment of those patients who have not received chemotherapy for their metastatic disease. approval url: https://www.ema.europa.eu/en/documents/product-information/herceptin-epar-product-information_en.pdf", "if a patient with metastatic invasive breast carcinoma has erbb2 amplification, one recommended therapy is trastuzumab + anastrozole. therapy type: targeted therapy + hormone therapy. therapy strategy: her2 inhibition + aromatase inhibition. indication: herceptin is indicated for the treatment of adult patients with her2 positive metastatic breast cancer (mbc) in combination with an aromatase inhibitor for the treatment of postmenopausal patients with hormone-receptor positive mbc, not previously treated with trastuzumab. approval url: https://www.ema.europa.eu/en/documents/product-information/herceptin-epar-product-information_en.pdf", "if a patient with invasive breast carcinoma has erbb2 amplification, one recommended therapy is trastuzumab. therapy type: targeted therapy. therapy strategy: her2 inhibition. indication: herceptin is indicated for the treatment of adult patients with her2 positive early breast cancer (ebc) following surgery, chemotherapy (neoadjuvant or adjuvant) and radiotherapy (if applicable). approval url: https://www.ema.europa.eu/en/documents/product-information/herceptin-epar-product-information_en.pdf", "if a patient with invasive breast carcinoma has erbb2 amplification, one recommended therapy is trastuzumab + paclitaxel. therapy type: targeted therapy + chemotherapy. therapy strategy: her2 inhibition + taxane-based chemotherapy. indication: herceptin is indicated for the treatment of adult patients with her2 positive early breast cancer (ebc) following adjuvant chemotherapy with doxorubicin and cyclophosphamide, in combination with paclitaxel or docetaxel. approval url: https://www.ema.europa.eu/en/documents/product-information/herceptin-epar-product-information_en.pdf", "if a patient with invasive breast carcinoma has erbb2 amplification, one recommended therapy is trastuzumab + docetaxel. therapy type: targeted therapy + chemotherapy. therapy strategy: her2 inhibition + taxane-based chemotherapy. indication: herceptin is indicated for the treatment of adult patients with her2 positive early breast cancer (ebc) following adjuvant chemotherapy with doxorubicin and cyclophosphamide, in combination with paclitaxel or docetaxel. approval url: https://www.ema.europa.eu/en/documents/product-information/herceptin-epar-product-information_en.pdf", "if a patient with invasive breast carcinoma has erbb2 amplification, one recommended therapy is trastuzumab + carboplatin + docetaxel. therapy type: targeted therapy + chemotherapy + chemotherapy. therapy strategy: her2 inhibition + platinum-based chemotherapy + taxane-based chemotherapy. indication: herceptin is indicated for the treatment of adult patients with her2 positive early breast cancer (ebc) in combination with adjuvant chemotherapy consisting of docetaxel and carboplatin. approval url: https://www.ema.europa.eu/en/documents/product-information/herceptin-epar-product-information_en.pdf", "if a patient with invasive breast carcinoma has erbb2 amplification, one recommended therapy is trastuzumab + doxorubicin + paclitaxel. therapy type: targeted therapy + chemotherapy + chemotherapy. therapy strategy: her2 inhibition + topoisomerase inhibition + taxane-based chemotherapy. indication: herceptin is indicated for the treatment of adult patients with her2 positive early breast cancer (ebc) in combination with neoadjuvant chemotherapy followed by adjuvant herceptin therapy, for locally advanced (including inflammatory) disease or tumours > 2 cm in diameter. approval url: https://www.ema.europa.eu/en/documents/product-information/herceptin-epar-product-information_en.pdf", "if a patient with esophagogastric adenocarcinoma has her2-positive, one recommended therapy is trastuzumab + capecitabine + cisplatin. therapy type: targeted therapy + chemotherapy + chemotherapy. therapy strategy: her2 inhibition + thymidylate synthase inhibition + platinum-based chemotherapy. indication: herceptin in combination with capecitabine or 5-fluorouracil and cisplatin is indicated for the treatment of adult patients with her2 positive metastatic adenocarcinoma of the stomach or gastro-esophageal junction who have not received prior anti-cancer treatment for their metastatic disease. approval url: https://www.ema.europa.eu/en/documents/product-information/herceptin-epar-product-information_en.pdf", "if a patient with esophagogastric adenocarcinoma has her2-positive, one recommended therapy is trastuzumab + fluorouracil + cisplatin. therapy type: targeted therapy + chemotherapy + chemotherapy. therapy strategy: her2 inhibition + thymidylate synthase inhibition + platinum-based chemotherapy. indication: herceptin in combination with capecitabine or 5-fluorouracil and cisplatin is indicated for the treatment of adult patients with her2 positive metastatic adenocarcinoma of the stomach or gastro-esophageal junction who have not received prior anti-cancer treatment for their metastatic disease. approval url: https://www.ema.europa.eu/en/documents/product-information/herceptin-epar-product-information_en.pdf", "if a patient with esophagogastric adenocarcinoma has erbb2 amplification, one recommended therapy is trastuzumab + capecitabine + cisplatin. therapy type: targeted therapy + chemotherapy + chemotherapy. therapy strategy: her2 inhibition + thymidylate synthase inhibition + platinum-based chemotherapy. indication: herceptin in combination with capecitabine or 5-fluorouracil and cisplatin is indicated for the treatment of adult patients with her2 positive metastatic adenocarcinoma of the stomach or gastro-esophageal junction who have not received prior anti-cancer treatment for their metastatic disease. approval url: https://www.ema.europa.eu/en/documents/product-information/herceptin-epar-product-information_en.pdf", "if a patient with esophagogastric adenocarcinoma has erbb2 amplification, one recommended therapy is trastuzumab + fluorouracil + cisplatin. therapy type: targeted therapy + chemotherapy + chemotherapy. therapy strategy: her2 inhibition + thymidylate synthase inhibition + platinum-based chemotherapy. indication: herceptin in combination with capecitabine or 5-fluorouracil and cisplatin is indicated for the treatment of adult patients with her2 positive metastatic adenocarcinoma of the stomach or gastro-esophageal junction who have not received prior anti-cancer treatment for their metastatic disease. approval url: https://www.ema.europa.eu/en/documents/product-information/herceptin-epar-product-information_en.pdf", "if a patient with locally advanced or metastatic invasive breast carcinoma has her2-negative, er positive, one recommended therapy is palbociclib + letrozole. therapy type: targeted therapy + hormone therapy. therapy strategy: cdk4/6 inhibition + aromatase inhibition. indication: ibrance is indicated for the treatment of hormone receptor (hr)-positive, human epidermal growth factor receptor 2 (her2)-negative locally advanced or metastatic breast cancer in combination with an aromatase inhibitor. approval url: https://www.ema.europa.eu/en/documents/product-information/ibrance-epar-product-information_en.pdf", "if a patient with locally advanced or metastatic invasive breast carcinoma has pr positive, her2-negative, one recommended therapy is palbociclib + letrozole. therapy type: targeted therapy + hormone therapy. therapy strategy: cdk4/6 inhibition + aromatase inhibition. indication: ibrance is indicated for the treatment of hormone receptor (hr)-positive, human epidermal growth factor receptor 2 (her2)-negative locally advanced or metastatic breast cancer in combination with an aromatase inhibitor. approval url: https://www.ema.europa.eu/en/documents/product-information/ibrance-epar-product-information_en.pdf", "if a patient with locally advanced or metastatic invasive breast carcinoma has pr positive, her2-negative, er positive, one recommended therapy is palbociclib + letrozole. therapy type: targeted therapy + hormone therapy. therapy strategy: cdk4/6 inhibition + aromatase inhibition. indication: ibrance is indicated for the treatment of hormone receptor (hr)-positive, human epidermal growth factor receptor 2 (her2)-negative locally advanced or metastatic breast cancer in combination with an aromatase inhibitor. approval url: https://www.ema.europa.eu/en/documents/product-information/ibrance-epar-product-information_en.pdf", "if a patient with locally advanced or metastatic invasive breast carcinoma has her2-negative, er positive, one recommended therapy is fulvestrant + palbociclib. therapy type: hormone therapy + targeted therapy. therapy strategy: estrogen receptor inhibition + cdk4/6 inhibition. indication: ibrance is indicated for the treatment of hormone receptor (hr)-positive, human epidermal growth factor receptor 2 (her2)-negative locally advanced or metastatic breast cancer in combination with fulvestrant in women who have received prior endocrine therapy. approval url: https://www.ema.europa.eu/en/documents/product-information/ibrance-epar-product-information_en.pdf", "if a patient with locally advanced or metastatic invasive breast carcinoma has pr positive, her2-negative, one recommended therapy is fulvestrant + palbociclib. therapy type: hormone therapy + targeted therapy. therapy strategy: estrogen receptor inhibition + cdk4/6 inhibition. indication: ibrance is indicated for the treatment of hormone receptor (hr)-positive, human epidermal growth factor receptor 2 (her2)-negative locally advanced or metastatic breast cancer in combination with fulvestrant in women who have received prior endocrine therapy. approval url: https://www.ema.europa.eu/en/documents/product-information/ibrance-epar-product-information_en.pdf", "if a patient with locally advanced or metastatic invasive breast carcinoma has pr positive, her2-negative, er positive, one recommended therapy is fulvestrant + palbociclib. therapy type: hormone therapy + targeted therapy. therapy strategy: estrogen receptor inhibition + cdk4/6 inhibition. indication: ibrance is indicated for the treatment of hormone receptor (hr)-positive, human epidermal growth factor receptor 2 (her2)-negative locally advanced or metastatic breast cancer in combination with fulvestrant in women who have received prior endocrine therapy. approval url: https://www.ema.europa.eu/en/documents/product-information/ibrance-epar-product-information_en.pdf", "if a patient with chronic myelogenous leukemia has bcr::abl1, one recommended therapy is imatinib. therapy type: targeted therapy. therapy strategy: bcr-abl inhibition + c-kit inhibition + pdgf-r inhibition. indication: glivec is indicated for the treatment of adult and paediatric patients with newly diagnosed philadelphia chromosome (bcr-abl) positive (ph+) chronic myeloid leukaemia (cml) for whom bone marrow transplantation is not considered as the first line of treatment. approval url: https://www.ema.europa.eu/en/documents/product-information/glivec-epar-product-information_en.pdf", "if a patient with chronic myelogenous leukemia has bcr::abl1, one recommended therapy is imatinib. therapy type: targeted therapy. therapy strategy: bcr-abl inhibition + c-kit inhibition + pdgf-r inhibition. indication: glivec is indicated for the treatment of adult and paediatric patients with ph+ cml in chronic phase after failure of interferon-alpha therapy, or in accelerated phase or blast crisis. approval url: https://www.ema.europa.eu/en/documents/product-information/glivec-epar-product-information_en.pdf", "if a patient with acute lymphoid leukemia has bcr::abl1, one recommended therapy is imatinib. therapy type: targeted therapy. therapy strategy: bcr-abl inhibition + c-kit inhibition + pdgf-r inhibition. indication: glivec is indicated for the treatment of adult and paediatric patients with newly diagnosed philadelphia chromosome positive acute lymphoblastic leukaemia (ph+ all) integrated with chemotherapy. approval url: https://www.ema.europa.eu/en/documents/product-information/glivec-epar-product-information_en.pdf", "if a patient with acute lymphoid leukemia has bcr::abl1, one recommended therapy is imatinib. therapy type: targeted therapy. therapy strategy: bcr-abl inhibition + c-kit inhibition + pdgf-r inhibition. indication: glivec is indicated for the treatment of adult patients with relapsed or refractory ph+ all as monotherapy. approval url: https://www.ema.europa.eu/en/documents/product-information/glivec-epar-product-information_en.pdf", "if a patient with myelodysplastic syndromes has pdgfra rearrangements, one recommended therapy is imatinib. therapy type: targeted therapy. therapy strategy: bcr-abl inhibition + c-kit inhibition + pdgf-r inhibition. indication: glivec is indicated for the treatment of adult patients with myelodysplastic/myeloproliferative diseases (mds/mpd) associated with platelet-derived growth factor receptor (pdgfr) gene re-arrangements. approval url: https://www.ema.europa.eu/en/documents/product-information/glivec-epar-product-information_en.pdf", "if a patient with myelodysplastic syndromes has pdgfrb rearrangements, one recommended therapy is imatinib. therapy type: targeted therapy. therapy strategy: bcr-abl inhibition + c-kit inhibition + pdgf-r inhibition. indication: glivec is indicated for the treatment of adult patients with myelodysplastic/myeloproliferative diseases (mds/mpd) associated with platelet-derived growth factor receptor (pdgfr) gene re-arrangements. approval url: https://www.ema.europa.eu/en/documents/product-information/glivec-epar-product-information_en.pdf", "if a patient with myeloproliferative neoplasm has pdgfra rearrangements, one recommended therapy is imatinib. therapy type: targeted therapy. therapy strategy: bcr-abl inhibition + c-kit inhibition + pdgf-r inhibition. indication: glivec is indicated for the treatment of adult patients with myelodysplastic/myeloproliferative diseases (mds/mpd) associated with platelet-derived growth factor receptor (pdgfr) gene re-arrangements. approval url: https://www.ema.europa.eu/en/documents/product-information/glivec-epar-product-information_en.pdf", "if a patient with myeloproliferative neoplasm has pdgfrb rearrangements, one recommended therapy is imatinib. therapy type: targeted therapy. therapy strategy: bcr-abl inhibition + c-kit inhibition + pdgf-r inhibition. indication: glivec is indicated for the treatment of adult patients with myelodysplastic/myeloproliferative diseases (mds/mpd) associated with platelet-derived growth factor receptor (pdgfr) gene re-arrangements. approval url: https://www.ema.europa.eu/en/documents/product-information/glivec-epar-product-information_en.pdf", "if a patient with chronic eosinophilic leukemia, nos has fip1l1::pdgfra, one recommended therapy is imatinib. therapy type: targeted therapy. therapy strategy: bcr-abl inhibition + c-kit inhibition + pdgf-r inhibition. indication: glivec is indicated for the treatment of adult patients with advanced hypereosinophilic syndrome (hes) and/or chronic eosinophilic leukaemia (cel) with fip1l1-pdgfra rearrangement. approval url: https://www.ema.europa.eu/en/documents/product-information/glivec-epar-product-information_en.pdf", "if a patient with gastrointestinal stromal tumor has cd117 +, one recommended therapy is imatinib. therapy type: targeted therapy. therapy strategy: bcr-abl inhibition + c-kit inhibition + pdgf-r inhibition. indication: glivec is indicated for the treatment of the treatment of adult patients with kit (cd 117) positive unresectable and/or metastatic malignant gastrointestinal stromal tumours (gist). approval url: https://www.ema.europa.eu/en/documents/product-information/glivec-epar-product-information_en.pdf", "if a patient with gastrointestinal stromal tumor has cd117 +, one recommended therapy is imatinib. therapy type: targeted therapy. therapy strategy: bcr-abl inhibition + c-kit inhibition + pdgf-r inhibition. indication: glivec is indicated for the treatment of the adjuvant treatment of adult patients who are at significant risk of relapse following resection of kit (cd117)-positive gist. patients who have a low or very low risk of recurrence should not receive adjuvant treatment. approval url: https://www.ema.europa.eu/en/documents/product-information/glivec-epar-product-information_en.pdf", "if a patient with chronic myelogenous leukemia has abl1 p.t315i, one recommended therapy is ponatinib. therapy type: targeted therapy. therapy strategy: bcr-abl inhibition. indication: iclusig is indicated in adult patients with chronic phase, accelerated phase, or blast phase chronic myeloid leukaemia (cml) who are resistant to dasatinib or nilotinib; who are intolerant to dasatinib or nilotinib and for whom subsequent treatment with imatinib is not clinically appropriate; or who have the t315i mutation. approval url: https://www.ema.europa.eu/en/documents/product-information/iclusig-epar-product-information_en.pdf", "if a patient with acute lymphoid leukemia has bcr::abl1, one recommended therapy is ponatinib. therapy type: targeted therapy. therapy strategy: bcr-abl inhibition. indication: iclusig is indicated in adult patients with philadelphia chromosome positive acute lymphoblastic leukaemia (ph+ all) who are resistant to dasatinib; who are intolerant to dasatinib and for whom subsequent treatment with imatinib is not clinically appropriate; or who have the t315i mutation. approval url: https://www.ema.europa.eu/en/documents/product-information/iclusig-epar-product-information_en.pdf", "if a patient with acute lymphoid leukemia has bcr::abl1, abl1 p.t315i, one recommended therapy is ponatinib. therapy type: targeted therapy. therapy strategy: bcr-abl inhibition. indication: iclusig is indicated in adult patients with philadelphia chromosome positive acute lymphoblastic leukaemia (ph+ all) who are resistant to dasatinib; who are intolerant to dasatinib and for whom subsequent treatment with imatinib is not clinically appropriate; or who have the t315i mutation. approval url: https://www.ema.europa.eu/en/documents/product-information/iclusig-epar-product-information_en.pdf", "if a patient with non-small cell lung cancer has pd-l1 >= 1%, one recommended therapy is durvalumab. therapy type: immunotherapy. therapy strategy: pd-1/pd-l1 inhibition. indication: imfinzi as monotherapy is indicated for the treatment of locally advanced, unresectable non-small cell lung cancer (nsclc) in adults whose tumours express pd-l1 on >= 1% of tumour cells and whose disease has not progressed following platinum-based chemoradiation therapy. approval url: https://www.ema.europa.eu/en/documents/product-information/imfinzi-epar-product-information_en.pdf", "if a patient with non-small cell lung cancer has wild type egfr, wild type alk, one recommended therapy is tremelimumab + carboplatin + durvalumab. therapy type: immunotherapy + chemotherapy + immunotherapy. therapy strategy: ctla-4 inhibition + platinum-based chemotherapy + pd-1/pd-l1 inhibition. indication: imfinzi in combination with tremelimumab and platinum-based chemotherapy is indicated for the first-line treatment of adults with metastatic nsclc with no sensitising egfr mutations or alk positive mutations. approval url: https://www.ema.europa.eu/en/documents/product-information/imfinzi-epar-product-information_en.pdf", "if a patient with endometrial carcinoma has dmmr, one recommended therapy is carboplatin + paclitaxel + durvalumab. therapy type: chemotherapy + chemotherapy + immunotherapy. therapy strategy: platinum-based chemotherapy + taxane-based chemotherapy + pd-1/pd-l1 inhibition. indication: imfinzi in combination with carboplatin and paclitaxel is indicated for the first-line treatment of adults with primary advanced or recurrent endometrial cancer who are candidates for systemic therapy, followed by maintenance treatment with imfinzi as monotherapy in endometrial cancer that is mismatch repair deficient (dmmr) or imfinzi in combination with olaparib in endometrial cancer that is mismatch repair proficient (pmmr). approval url: https://www.ema.europa.eu/en/documents/product-information/imfinzi-epar-product-information_en.pdf", "if a patient with endometrial carcinoma has pmmr, one recommended therapy is carboplatin + paclitaxel + durvalumab + olaparib. therapy type: chemotherapy + chemotherapy + immunotherapy + targeted therapy. therapy strategy: platinum-based chemotherapy + taxane-based chemotherapy + pd-1/pd-l1 inhibition + parp inhibition. indication: imfinzi in combination with carboplatin and paclitaxel is indicated for the first-line treatment of adults with primary advanced or recurrent endometrial cancer who are candidates for systemic therapy, followed by maintenance treatment with imfinzi as monotherapy in endometrial cancer that is mismatch repair deficient (dmmr) or imfinzi in combination with olaparib in endometrial cancer that is mismatch repair proficient (pmmr). approval url: https://www.ema.europa.eu/en/documents/product-information/imfinzi-epar-product-information_en.pdf", "if a patient with non-small cell lung cancer has wild type egfr, wild type alk, one recommended therapy is tremelimumab + carboplatin + durvalumab. therapy type: immunotherapy + chemotherapy + immunotherapy. therapy strategy: ctla-4 inhibition + platinum-based chemotherapy + pd-1/pd-l1 inhibition. indication: imjudo in combination with durvalumab and platinum-based chemotherapy is indicated for the first-line treatment of adults with metastatic non-small cell lung cancer (nsclc) with no sensitising egfr mutations or alk positive mutations. approval url: https://www.ema.europa.eu/en/documents/product-information/imjudo-epar-product-information_en.pdf", "if a patient with endometrial carcinoma has msi-h, one recommended therapy is carboplatin + dostarlimab + paclitaxel. therapy type: chemotherapy + immunotherapy + chemotherapy. therapy strategy: platinum-based chemotherapy + pd-1/pd-l1 inhibition + taxane-based chemotherapy. indication: jemperli is indicated in combination with carboplatin and paclitaxel for the treatment of adult patients with mismatch repair deficient (dmmr)/ microsatellite instability-high (msi-h) primary advanced or recurrent endometrial cancer (ec) and who are candidates for systemic therapy. approval url: https://www.ema.europa.eu/en/documents/product-information/jemperli-epar-product-information_en.pdf", "if a patient with endometrial carcinoma has dmmr, one recommended therapy is carboplatin + dostarlimab + paclitaxel. therapy type: chemotherapy + immunotherapy + chemotherapy. therapy strategy: platinum-based chemotherapy + pd-1/pd-l1 inhibition + taxane-based chemotherapy. indication: jemperli is indicated in combination with carboplatin and paclitaxel for the treatment of adult patients with mismatch repair deficient (dmmr)/ microsatellite instability-high (msi-h) primary advanced or recurrent endometrial cancer (ec) and who are candidates for systemic therapy. approval url: https://www.ema.europa.eu/en/documents/product-information/jemperli-epar-product-information_en.pdf", "if a patient with endometrial carcinoma has msi-h, one recommended therapy is dostarlimab. therapy type: immunotherapy. therapy strategy: pd-1/pd-l1 inhibition. indication: jemperli is indicated as monotherapy for the treatment of adult patients with dmmr/msi-h recurrent or advanced ec that has progressed on or following prior treatment with a platinum-containing regimen. approval url: https://www.ema.europa.eu/en/documents/product-information/jemperli-epar-product-information_en.pdf", "if a patient with endometrial carcinoma has dmmr, one recommended therapy is dostarlimab. therapy type: immunotherapy. therapy strategy: pd-1/pd-l1 inhibition. indication: jemperli is indicated as monotherapy for the treatment of adult patients with dmmr/msi-h recurrent or advanced ec that has progressed on or following prior treatment with a platinum-containing regimen. approval url: https://www.ema.europa.eu/en/documents/product-information/jemperli-epar-product-information_en.pdf", "if a patient with non-small cell lung cancer has wild type egfr, wild type alk, pd-l1 >= 50%, one recommended therapy is pembrolizumab. therapy type: immunotherapy. therapy strategy: pd-1/pd-l1 inhibition. indication: keytruda as monotherapy is indicated for the first-line treatment of metastatic non-small cell lung carcinoma in adults whose tumours express pd-l1 with a >= 50% tumour proportion score (tps) with no egfr or alk positive tumour mutations. approval url: https://www.ema.europa.eu/en/documents/product-information/keytruda-epar-product-information_en.pdf", "if a patient with non-small cell lung cancer has wild type egfr, wild type alk, cd274 amplification, one recommended therapy is pembrolizumab. therapy type: immunotherapy. therapy strategy: pd-1/pd-l1 inhibition. indication: keytruda as monotherapy is indicated for the first-line treatment of metastatic non-small cell lung carcinoma in adults whose tumours express pd-l1 with a >= 50% tumour proportion score (tps) with no egfr or alk positive tumour mutations. approval url: https://www.ema.europa.eu/en/documents/product-information/keytruda-epar-product-information_en.pdf", "if a patient with non-small cell lung cancer has wild type egfr, wild type alk, one recommended therapy is carboplatin + pemetrexed + pembrolizumab. therapy type: chemotherapy + chemotherapy + immunotherapy. therapy strategy: platinum-based chemotherapy + antifolate + pd-1/pd-l1 inhibition. indication: keytruda, in combination with pemetrexed and platinum chemotherapy, is indicated for the first-line treatment of metastatic non-squamous non-small cell lung carcinoma in adults whose tumours have no egfr or alk positive mutations. approval url: https://www.ema.europa.eu/en/documents/product-information/keytruda-epar-product-information_en.pdf", "if a patient with non-small cell lung cancer has wild type egfr, wild type alk, one recommended therapy is pemetrexed + cisplatin + pembrolizumab. therapy type: chemotherapy + chemotherapy + immunotherapy. therapy strategy: antifolate + platinum-based chemotherapy + pd-1/pd-l1 inhibition. indication: keytruda, in combination with pemetrexed and platinum chemotherapy, is indicated for the first-line treatment of metastatic non-squamous non-small cell lung carcinoma in adults whose tumours have no egfr or alk positive mutations. approval url: https://www.ema.europa.eu/en/documents/product-information/keytruda-epar-product-information_en.pdf", "if a patient with non-small cell lung cancer has wild type egfr, wild type alk, one recommended therapy is gemcitabine + cisplatin + pembrolizumab. therapy type: chemotherapy + chemotherapy + immunotherapy. therapy strategy: antimetabolite + platinum-based chemotherapy + pd-1/pd-l1 inhibition. indication: keytruda, in combination with pemetrexed and platinum chemotherapy, is indicated for the first-line treatment of metastatic non-squamous non-small cell lung carcinoma in adults whose tumours have no egfr or alk positive mutations. approval url: https://www.ema.europa.eu/en/documents/product-information/keytruda-epar-product-information_en.pdf", "if a patient with non-small cell lung cancer has wild type egfr, wild type alk, one recommended therapy is carboplatin + gemcitabine + pembrolizumab. therapy type: chemotherapy + chemotherapy + immunotherapy. therapy strategy: platinum-based chemotherapy + antimetabolite + pd-1/pd-l1 inhibition. indication: keytruda, in combination with pemetrexed and platinum chemotherapy, is indicated for the first-line treatment of metastatic non-squamous non-small cell lung carcinoma in adults whose tumours have no egfr or alk positive mutations. approval url: https://www.ema.europa.eu/en/documents/product-information/keytruda-epar-product-information_en.pdf", "if a patient with non-small cell lung cancer has wild type egfr, wild type alk, one recommended therapy is carboplatin + paclitaxel + pembrolizumab. therapy type: chemotherapy + chemotherapy + immunotherapy. therapy strategy: platinum-based chemotherapy + taxane-based chemotherapy + pd-1/pd-l1 inhibition. indication: keytruda, in combination with pemetrexed and platinum chemotherapy, is indicated for the first-line treatment of metastatic non-squamous non-small cell lung carcinoma in adults whose tumours have no egfr or alk positive mutations. approval url: https://www.ema.europa.eu/en/documents/product-information/keytruda-epar-product-information_en.pdf", "if a patient with non-small cell lung cancer has pd-l1 >= 1%, one recommended therapy is pembrolizumab. therapy type: immunotherapy. therapy strategy: pd-1/pd-l1 inhibition. indication: keytruda as monotherapy is indicated for the treatment of locally advanced or metastatic non-small cell lung carcinoma in adults whose tumours express pd-l1 with a >= 1% tps and who have received at least one prior chemotherapy regimen. patients with egfr or alk positive tumour mutations should also have received targeted therapy before receiving keytruda. approval url: https://www.ema.europa.eu/en/documents/product-information/keytruda-epar-product-information_en.pdf", "if a patient with bladder urothelial carcinoma has pd-l1 (cps) >= 10, one recommended therapy is pembrolizumab. therapy type: immunotherapy. therapy strategy: pd-1/pd-l1 inhibition. indication: keytruda as monotherapy is indicated for the treatment of locally advanced or metastatic urothelial carcinoma in adults who are not eligible for cisplatin-containing chemotherapy and whose tumours express pd-l1 with a combined positive score (cps) >= 10. approval url: https://www.ema.europa.eu/en/documents/product-information/keytruda-epar-product-information_en.pdf", "if a patient with head and neck squamous cell carcinoma has pd-l1 (cps) >= 1, one recommended therapy is pembrolizumab. therapy type: immunotherapy. therapy strategy: pd-1/pd-l1 inhibition. indication: keytruda, as monotherapy or in combination with platinum and 5-fluorouracil (5-fu) chemotherapy, is indicated for the first-line treatment of metastatic or unresectable recurrent head and neck squamous cell carcinoma in adults whose tumours express pd-l1 with a cps >= 1. approval url: https://www.ema.europa.eu/en/documents/product-information/keytruda-epar-product-information_en.pdf", "if a patient with head and neck squamous cell carcinoma has pd-l1 (cps) >= 1, one recommended therapy is carboplatin + fluorouracil + pembrolizumab. therapy type: chemotherapy + chemotherapy + immunotherapy. therapy strategy: platinum-based chemotherapy + thymidylate synthase inhibition + pd-1/pd-l1 inhibition. indication: keytruda, as monotherapy or in combination with platinum and 5-fluorouracil (5-fu) chemotherapy, is indicated for the first-line treatment of metastatic or unresectable recurrent head and neck squamous cell carcinoma in adults whose tumours express pd-l1 with a cps >= 1. approval url: https://www.ema.europa.eu/en/documents/product-information/keytruda-epar-product-information_en.pdf", "if a patient with head and neck squamous cell carcinoma has pd-l1 (cps) >= 1, one recommended therapy is fluorouracil + cisplatin + pembrolizumab. therapy type: chemotherapy + chemotherapy + immunotherapy. therapy strategy: thymidylate synthase inhibition + platinum-based chemotherapy + pd-1/pd-l1 inhibition. indication: keytruda, as monotherapy or in combination with platinum and 5-fluorouracil (5-fu) chemotherapy, is indicated for the first-line treatment of metastatic or unresectable recurrent head and neck squamous cell carcinoma in adults whose tumours express pd-l1 with a cps >= 1. approval url: https://www.ema.europa.eu/en/documents/product-information/keytruda-epar-product-information_en.pdf", "if a patient with head and neck squamous cell carcinoma has pd-l1 >= 50%, one recommended therapy is pembrolizumab. therapy type: immunotherapy. therapy strategy: pd-1/pd-l1 inhibition. indication: keytruda as monotherapy is indicated for the treatment of recurrent or metastatic head and neck squamous cell carcinoma in adults whose tumours express pd-l1 with a >= 50% tps and progressing on or after platinum -containing chemotherapy. approval url: https://www.ema.europa.eu/en/documents/product-information/keytruda-epar-product-information_en.pdf", "if a patient with colorectal adenocarcinoma has msi-h, one recommended therapy is pembrolizumab. therapy type: immunotherapy. therapy strategy: pd-1/pd-l1 inhibition. indication: keytruda as monotherapy is indicated for adults with msi-h or dmmr colorectal cancer in the following settings: first-line treatment of metastatic colorectal cancer; treatment of unresectable or metastatic colorectal cancer after previous fluoropyrimidine -based combination therapy. approval url: https://www.ema.europa.eu/en/documents/product-information/keytruda-epar-product-information_en.pdf", "if a patient with colorectal adenocarcinoma has dmmr, one recommended therapy is pembrolizumab. therapy type: immunotherapy. therapy strategy: pd-1/pd-l1 inhibition. indication: keytruda as monotherapy is indicated for adults with msi-h or dmmr colorectal cancer in the following settings: first-line treatment of metastatic colorectal cancer; treatment of unresectable or metastatic colorectal cancer after previous fluoropyrimidine -based combination therapy. approval url: https://www.ema.europa.eu/en/documents/product-information/keytruda-epar-product-information_en.pdf", "if a patient with endometrial carcinoma has msi-h, one recommended therapy is pembrolizumab. therapy type: immunotherapy. therapy strategy: pd-1/pd-l1 inhibition. indication: keytruda as monotherapy is indicated for the treatment of the following msi-h or dmmr tumours in adults with advanced or recurrent endometrial carcinoma, who have disease progression on or following prior treatment with a platinum-containing therapy in any setting and who are not candidates for curative surgery or radiation. approval url: https://www.ema.europa.eu/en/documents/product-information/keytruda-epar-product-information_en.pdf", "if a patient with endometrial carcinoma has dmmr, one recommended therapy is pembrolizumab. therapy type: immunotherapy. therapy strategy: pd-1/pd-l1 inhibition. indication: keytruda as monotherapy is indicated for the treatment of the following msi-h or dmmr tumours in adults with advanced or recurrent endometrial carcinoma, who have disease progression on or following prior treatment with a platinum-containing therapy in any setting and who are not candidates for curative surgery or radiation. approval url: https://www.ema.europa.eu/en/documents/product-information/keytruda-epar-product-information_en.pdf", "if a patient with esophagogastric adenocarcinoma has msi-h, one recommended therapy is pembrolizumab. therapy type: immunotherapy. therapy strategy: pd-1/pd-l1 inhibition. indication: keytruda as monotherapy is indicated for the treatment of the following msi-h or dmmr tumours in adults with unresectable or metastatic gastric, small intestine, or biliary cancer, who have disease progression on or following at least one prior therapy. approval url: https://www.ema.europa.eu/en/documents/product-information/keytruda-epar-product-information_en.pdf", "if a patient with esophagogastric adenocarcinoma has dmmr, one recommended therapy is pembrolizumab. therapy type: immunotherapy. therapy strategy: pd-1/pd-l1 inhibition. indication: keytruda as monotherapy is indicated for the treatment of the following msi-h or dmmr tumours in adults with unresectable or metastatic gastric, small intestine, or biliary cancer, who have disease progression on or following at least one prior therapy. approval url: https://www.ema.europa.eu/en/documents/product-information/keytruda-epar-product-information_en.pdf", "if a patient with gastrointestinal stromal tumor has msi-h, one recommended therapy is pembrolizumab. therapy type: immunotherapy. therapy strategy: pd-1/pd-l1 inhibition. indication: keytruda as monotherapy is indicated for the treatment of the following msi-h or dmmr tumours in adults with unresectable or metastatic gastric, small intestine, or biliary cancer, who have disease progression on or following at least one prior therapy. approval url: https://www.ema.europa.eu/en/documents/product-information/keytruda-epar-product-information_en.pdf", "if a patient with gastrointestinal stromal tumor has dmmr, one recommended therapy is pembrolizumab. therapy type: immunotherapy. therapy strategy: pd-1/pd-l1 inhibition. indication: keytruda as monotherapy is indicated for the treatment of the following msi-h or dmmr tumours in adults with unresectable or metastatic gastric, small intestine, or biliary cancer, who have disease progression on or following at least one prior therapy. approval url: https://www.ema.europa.eu/en/documents/product-information/keytruda-epar-product-information_en.pdf", "if a patient with cholangiocarcinoma has msi-h, one recommended therapy is pembrolizumab. therapy type: immunotherapy. therapy strategy: pd-1/pd-l1 inhibition. indication: keytruda as monotherapy is indicated for the treatment of the following msi-h or dmmr tumours in adults with unresectable or metastatic gastric, small intestine, or biliary cancer, who have disease progression on or following at least one prior therapy. approval url: https://www.ema.europa.eu/en/documents/product-information/keytruda-epar-product-information_en.pdf", "if a patient with cholangiocarcinoma has dmmr, one recommended therapy is pembrolizumab. therapy type: immunotherapy. therapy strategy: pd-1/pd-l1 inhibition. indication: keytruda as monotherapy is indicated for the treatment of the following msi-h or dmmr tumours in adults with unresectable or metastatic gastric, small intestine, or biliary cancer, who have disease progression on or following at least one prior therapy. approval url: https://www.ema.europa.eu/en/documents/product-information/keytruda-epar-product-information_en.pdf", "if a patient with esophageal adenocarcinoma has pd-l1 (cps) >= 10, one recommended therapy is fluorouracil + cisplatin + pembrolizumab. therapy type: chemotherapy + chemotherapy + immunotherapy. therapy strategy: thymidylate synthase inhibition + platinum-based chemotherapy + pd-1/pd-l1 inhibition. indication: keytruda, in combination with platinum and fluoropyrimidine -based chemotherapy, is indicated for the first-line treatment of locally advanced unresectable or metastatic carcinoma of the oesophagus in adults whose tumours express pd-l1 with a cps >= 10. approval url: https://www.ema.europa.eu/en/documents/product-information/keytruda-epar-product-information_en.pdf", "if a patient with esophageal adenocarcinoma has pd-l1 (cps) >= 10, one recommended therapy is carboplatin + fluorouracil + pembrolizumab. therapy type: chemotherapy + chemotherapy + immunotherapy. therapy strategy: platinum-based chemotherapy + thymidylate synthase inhibition + pd-1/pd-l1 inhibition. indication: keytruda, in combination with platinum and fluoropyrimidine -based chemotherapy, is indicated for the first-line treatment of locally advanced unresectable or metastatic carcinoma of the oesophagus in adults whose tumours express pd-l1 with a cps >= 10. approval url: https://www.ema.europa.eu/en/documents/product-information/keytruda-epar-product-information_en.pdf", "if a patient with invasive breast carcinoma has er negative, pr negative, her2-negative, one recommended therapy is pembrolizumab. therapy type: immunotherapy. therapy strategy: pd-1/pd-l1 inhibition. indication: keytruda, in combination with chemotherapy as neoadjuvant treatment, and then continued as monotherapy as adjuvant treatment after surgery, is indicated for the treatment of adults with locally advanced, or early-stage triple-negative breast cancer at high risk of recurrence. approval url: https://www.ema.europa.eu/en/documents/product-information/keytruda-epar-product-information_en.pdf", "if a patient with invasive breast carcinoma has er negative, pr negative, her2-negative, pd-l1 (cps) >= 10, one recommended therapy is paclitaxel + pembrolizumab. therapy type: chemotherapy + immunotherapy. therapy strategy: taxane-based chemotherapy + pd-1/pd-l1 inhibition. indication: keytruda, in combination with chemotherapy, is indicated for the treatment of locally recurrent unresectable or metastatic triple-negative breast cancer in adults whose tumours express pd-l1 with a cps >= 10 and who have not received prior chemotherapy for metastatic disease. approval url: https://www.ema.europa.eu/en/documents/product-information/keytruda-epar-product-information_en.pdf", "if a patient with invasive breast carcinoma has er negative, pr negative, her2-negative, pd-l1 (cps) >= 10, one recommended therapy is nab-paclitaxel + pembrolizumab. therapy type: chemotherapy + immunotherapy. therapy strategy: taxane-based chemotherapy + pd-1/pd-l1 inhibition. indication: keytruda, in combination with chemotherapy, is indicated for the treatment of locally recurrent unresectable or metastatic triple-negative breast cancer in adults whose tumours express pd-l1 with a cps >= 10 and who have not received prior chemotherapy for metastatic disease. approval url: https://www.ema.europa.eu/en/documents/product-information/keytruda-epar-product-information_en.pdf", "if a patient with invasive breast carcinoma has er negative, pr negative, her2-negative, pd-l1 (cps) >= 10, one recommended therapy is carboplatin + gemcitabine + pembrolizumab. therapy type: chemotherapy + chemotherapy + immunotherapy. therapy strategy: platinum-based chemotherapy + antimetabolite + pd-1/pd-l1 inhibition. indication: keytruda, in combination with chemotherapy, is indicated for the treatment of locally recurrent unresectable or metastatic triple-negative breast cancer in adults whose tumours express pd-l1 with a cps >= 10 and who have not received prior chemotherapy for metastatic disease. approval url: https://www.ema.europa.eu/en/documents/product-information/keytruda-epar-product-information_en.pdf", "if a patient with cervical adenocarcinoma has pd-l1 (cps) >= 1, one recommended therapy is carboplatin + paclitaxel + pembrolizumab. therapy type: chemotherapy + chemotherapy + immunotherapy. therapy strategy: platinum-based chemotherapy + taxane-based chemotherapy + pd-1/pd-l1 inhibition. indication: keytruda, in combination with chemotherapy with or without bevacizumab, is indicated for the treatment of persistent, recurrent, or metastatic cervical cancer in adults whose tumours express pd-l1 with a cps >= 1. approval url: https://www.ema.europa.eu/en/documents/product-information/keytruda-epar-product-information_en.pdf", "if a patient with cervical adenocarcinoma has pd-l1 (cps) >= 1, one recommended therapy is carboplatin + paclitaxel + bevacizumab + pembrolizumab. therapy type: chemotherapy + chemotherapy + targeted therapy + immunotherapy. therapy strategy: platinum-based chemotherapy + taxane-based chemotherapy + vegf inhibition + pd-1/pd-l1 inhibition. indication: keytruda, in combination with chemotherapy with or without bevacizumab, is indicated for the treatment of persistent, recurrent, or metastatic cervical cancer in adults whose tumours express pd-l1 with a cps >= 1. approval url: https://www.ema.europa.eu/en/documents/product-information/keytruda-epar-product-information_en.pdf", "if a patient with adenocarcinoma of the gastroesophageal junction has her2-positive, pd-l1 (cps) >= 1, one recommended therapy is trastuzumab + fluorouracil + cisplatin + pembrolizumab. therapy type: targeted therapy + chemotherapy + chemotherapy + immunotherapy. therapy strategy: her2 inhibition + thymidylate synthase inhibition + platinum-based chemotherapy + pd-1/pd-l1 inhibition. indication: keytruda, in combination with trastuzumab, fluoropyrimidine and platinum-containing chemotherapy, is indicated for the first-line treatment of locally advanced unresectable or metastatic her2-positive gastric or gastro -oesophageal junction adenocarcinoma in adults whose tumours express pd-l1 with a cps >= 1. approval url: https://www.ema.europa.eu/en/documents/product-information/keytruda-epar-product-information_en.pdf", "if a patient with adenocarcinoma of the gastroesophageal junction has her2-positive, pd-l1 (cps) >= 1, one recommended therapy is trastuzumab + carboplatin + fluorouracil + pembrolizumab. therapy type: targeted therapy + chemotherapy + chemotherapy + immunotherapy. therapy strategy: her2 inhibition + platinum-based chemotherapy + thymidylate synthase inhibition + pd-1/pd-l1 inhibition. indication: keytruda, in combination with trastuzumab, fluoropyrimidine and platinum-containing chemotherapy, is indicated for the first-line treatment of locally advanced unresectable or metastatic her2-positive gastric or gastro -oesophageal junction adenocarcinoma in adults whose tumours express pd-l1 with a cps >= 1. approval url: https://www.ema.europa.eu/en/documents/product-information/keytruda-epar-product-information_en.pdf", "if a patient with adenocarcinoma of the gastroesophageal junction has pd-l1 (cps) >= 1, her2-negative, one recommended therapy is fluorouracil + cisplatin + pembrolizumab. therapy type: chemotherapy + chemotherapy + immunotherapy. therapy strategy: thymidylate synthase inhibition + platinum-based chemotherapy + pd-1/pd-l1 inhibition. indication: keytruda, in combination with fluoropyrimidine and platinum -containing chemotherapy, is indicated for the first-line treatment of locally advanced unresectable or metastatic her2-negative gastric or gastro -oesophageal junction adenocarcinoma in adults whose tumours express pd-l1 with a cps >= 1. approval url: https://www.ema.europa.eu/en/documents/product-information/keytruda-epar-product-information_en.pdf", "if a patient with adenocarcinoma of the gastroesophageal junction has pd-l1 (cps) >= 1, her2-negative, one recommended therapy is carboplatin + fluorouracil + pembrolizumab. therapy type: chemotherapy + chemotherapy + immunotherapy. therapy strategy: platinum-based chemotherapy + thymidylate synthase inhibition + pd-1/pd-l1 inhibition. indication: keytruda, in combination with fluoropyrimidine and platinum -containing chemotherapy, is indicated for the first-line treatment of locally advanced unresectable or metastatic her2-negative gastric or gastro -oesophageal junction adenocarcinoma in adults whose tumours express pd-l1 with a cps >= 1. approval url: https://www.ema.europa.eu/en/documents/product-information/keytruda-epar-product-information_en.pdf", "if a patient with invasive breast carcinoma has her2-positive, one recommended therapy is trastuzumab emtansine. therapy type: targeted therapy. therapy strategy: her2 inhibition. indication: kadcyla, as a single agent, is indicated for the adjuvant treatment of adult patients with her2-positive early breast cancer who have residual invasive disease, in the breast and/or lymph nodes, after neoadjuvant taxane-based and her2-targeted therapy. approval url: https://www.ema.europa.eu/en/documents/product-information/kadcyla-epar-product-information_en.pdf", "if a patient with invasive breast carcinoma has erbb2 amplification, one recommended therapy is trastuzumab emtansine. therapy type: targeted therapy. therapy strategy: her2 inhibition. indication: kadcyla, as a single agent, is indicated for the adjuvant treatment of adult patients with her2-positive early breast cancer who have residual invasive disease, in the breast and/or lymph nodes, after neoadjuvant taxane-based and her2-targeted therapy. approval url: https://www.ema.europa.eu/en/documents/product-information/kadcyla-epar-product-information_en.pdf", "if a patient with locally advanced or metastatic invasive breast carcinoma has her2-positive, one recommended therapy is trastuzumab emtansine. therapy type: targeted therapy. therapy strategy: her2 inhibition. indication: kadcyla, as a single agent, is indicated for the treatment of adult patients with her2-positive, unresectable locally advanced or metastatic breast cancer who previously received trastuzumab and a taxane, separately or in combination. patients should have either: received prior therapy for locally advanced or metastatic disease, or developed disease recurrence during or within six months of completing adjuvant therapy. approval url: https://www.ema.europa.eu/en/documents/product-information/kadcyla-epar-product-information_en.pdf", "if a patient with locally advanced or metastatic invasive breast carcinoma has erbb2 amplification, one recommended therapy is trastuzumab emtansine. therapy type: targeted therapy. therapy strategy: her2 inhibition. indication: kadcyla, as a single agent, is indicated for the treatment of adult patients with her2-positive, unresectable locally advanced or metastatic breast cancer who previously received trastuzumab and a taxane, separately or in combination. patients should have either: received prior therapy for locally advanced or metastatic disease, or developed disease recurrence during or within six months of completing adjuvant therapy. approval url: https://www.ema.europa.eu/en/documents/product-information/kadcyla-epar-product-information_en.pdf", "if a patient with locally advanced or metastatic invasive breast carcinoma has her2-negative, er positive, one recommended therapy is ribociclib + letrozole. therapy type: targeted therapy + hormone therapy. therapy strategy: cdk4/6 inhibition + aromatase inhibition. indication: kisqali is indicated for the treatment of women with hormone receptor (hr)-positive, human epidermal growth factor receptor 2 (her2)-negative locally advanced or metastatic breast cancer in combination with an aromatase inhibitor or fulvestrant as initial endocrine-based therapy, or in women who have received prior endocrine therapy. approval url: https://www.ema.europa.eu/en/documents/product-information/kisqali-epar-product-information_en.pdf", "if a patient with locally advanced or metastatic invasive breast carcinoma has pr positive, her2-negative, one recommended therapy is ribociclib + letrozole. therapy type: targeted therapy + hormone therapy. therapy strategy: cdk4/6 inhibition + aromatase inhibition. indication: kisqali is indicated for the treatment of women with hormone receptor (hr)-positive, human epidermal growth factor receptor 2 (her2)-negative locally advanced or metastatic breast cancer in combination with an aromatase inhibitor or fulvestrant as initial endocrine-based therapy, or in women who have received prior endocrine therapy. approval url: https://www.ema.europa.eu/en/documents/product-information/kisqali-epar-product-information_en.pdf", "if a patient with locally advanced or metastatic invasive breast carcinoma has pr positive, her2-negative, er positive, one recommended therapy is ribociclib + letrozole. therapy type: targeted therapy + hormone therapy. therapy strategy: cdk4/6 inhibition + aromatase inhibition. indication: kisqali is indicated for the treatment of women with hormone receptor (hr)-positive, human epidermal growth factor receptor 2 (her2)-negative locally advanced or metastatic breast cancer in combination with an aromatase inhibitor or fulvestrant as initial endocrine-based therapy, or in women who have received prior endocrine therapy. approval url: https://www.ema.europa.eu/en/documents/product-information/kisqali-epar-product-information_en.pdf", "if a patient with locally advanced or metastatic invasive breast carcinoma has her2-negative, er positive, one recommended therapy is fulvestrant + ribociclib. therapy type: hormone therapy + targeted therapy. therapy strategy: estrogen receptor inhibition + cdk4/6 inhibition. indication: kisqali is indicated for the treatment of women with hormone receptor (hr)-positive, human epidermal growth factor receptor 2 (her2)-negative locally advanced or metastatic breast cancer in combination with an aromatase inhibitor or fulvestrant as initial endocrine-based therapy, or in women who have received prior endocrine therapy. approval url: https://www.ema.europa.eu/en/documents/product-information/kisqali-epar-product-information_en.pdf", "if a patient with locally advanced or metastatic invasive breast carcinoma has pr positive, her2-negative, one recommended therapy is fulvestrant + ribociclib. therapy type: hormone therapy + targeted therapy. therapy strategy: estrogen receptor inhibition + cdk4/6 inhibition. indication: kisqali is indicated for the treatment of women with hormone receptor (hr)-positive, human epidermal growth factor receptor 2 (her2)-negative locally advanced or metastatic breast cancer in combination with an aromatase inhibitor or fulvestrant as initial endocrine-based therapy, or in women who have received prior endocrine therapy. approval url: https://www.ema.europa.eu/en/documents/product-information/kisqali-epar-product-information_en.pdf", "if a patient with locally advanced or metastatic invasive breast carcinoma has pr positive, her2-negative, er positive, one recommended therapy is fulvestrant + ribociclib. therapy type: hormone therapy + targeted therapy. therapy strategy: estrogen receptor inhibition + cdk4/6 inhibition. indication: kisqali is indicated for the treatment of women with hormone receptor (hr)-positive, human epidermal growth factor receptor 2 (her2)-negative locally advanced or metastatic breast cancer in combination with an aromatase inhibitor or fulvestrant as initial endocrine-based therapy, or in women who have received prior endocrine therapy. approval url: https://www.ema.europa.eu/en/documents/product-information/kisqali-epar-product-information_en.pdf", "if a patient with non-small cell lung cancer has kras p.g12c, one recommended therapy is adagrasib. therapy type: targeted therapy. therapy strategy: ras inhibition. indication: krazati as monotherapy is indicated for the treatment of adult patients with advanced non-small cell lung cancer (nsclc) with kras g12c mutation and disease progression after at least one prior systemic therapy. approval url: https://www.ema.europa.eu/en/documents/product-information/krazati-epar-product-information_en.pdf", "if a patient with non-small cell lung cancer has wild type egfr, wild type alk, pd-l1 >= 50%, wild type ros1, one recommended therapy is cemiplimab. therapy type: immunotherapy. therapy strategy: pd-1/pd-l1 inhibition. indication: libtayo as monotherapy is indicated for the first-line treatment of adult patients with non-small cell lung cancer (nsclc) expressing pd-l1 (in >= 50% tumour cells), with no egfr, alk or ros1 aberrations, who have locally advanced nsclc who are not candidates for definitive chemoradiation, or metastatic nsclc. approval url: https://www.ema.europa.eu/en/documents/product-information/libtayo-epar-product-information_en.pdf", "if a patient with non-small cell lung cancer has wild type egfr, wild type alk, pd-l1 >= 1%, wild type ros1, one recommended therapy is carboplatin + cemiplimab + pemetrexed. therapy type: chemotherapy + immunotherapy + chemotherapy. therapy strategy: platinum-based chemotherapy + pd-1/pd-l1 inhibition + antifolate. indication: libtayo in combination with platinum_based chemotherapy is indicated for the first_line treatment of adult patients with nsclc expressing pd-l1 (in >= 1% of tumour cells), with no egfr, alk or ros1 aberrations, who have locally advanced nsclc who are not candidates for definitive chemoradiation, or metastatic nsclc. approval url: https://www.ema.europa.eu/en/documents/product-information/libtayo-epar-product-information_en.pdf", "if a patient with non-small cell lung cancer has v::alk, one recommended therapy is lorlatinib. therapy type: targeted therapy. therapy strategy: alk inhibition. indication: lorviqua as monotherapy is indicated for the treatment of adult patients with anaplastic lymphoma kinase (alk)-positive advanced non-small cell lung cancer (nsclc) previously not treated with an alk inhibitor. approval url: https://www.ema.europa.eu/en/documents/product-information/lorviqua-epar-product-information_en.pdf", "if a patient with non-small cell lung cancer has v::alk, one recommended therapy is lorlatinib. therapy type: targeted therapy. therapy strategy: alk inhibition. indication: lorviqua as monotherapy is indicated for the treatment of adult patients with alk-positive advanced nsclc whose disease has progressed after alectinib or ceritinib as the first alk tyrosine kinase inhibitor (tki) therapy; or crizotinib and at least one other alk tki. approval url: https://www.ema.europa.eu/en/documents/product-information/lorviqua-epar-product-information_en.pdf", "if a patient with non-small cell lung cancer has kras p.g12c, one recommended therapy is sotorasib. therapy type: targeted therapy. therapy strategy: ras inhibition. indication: lumykras as monotherapy is indicated for the treatment of adults with advanced non-small cell lung cancer (nsclc) with kras g12c mutation and who have progressed after at least one prior line of systemic therapy. approval url: https://www.ema.europa.eu/en/documents/product-information/lumykras-epar-product-information_en.pdf", "if a patient with ovarian epithelial tumor has brca1 oncogenic variants, one recommended therapy is olaparib. therapy type: targeted therapy. therapy strategy: parp inhibition. indication: lynparza is indicated as monotherapy for the maintenance treatment of adult patients with advanced (figo stages iii and iv) brca1/2-mutated (germline and/or somatic) high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer who are in response (complete or partial) following completion of first-line platinum-based chemotherapy. approval url: https://www.ema.europa.eu/en/documents/product-information/lynparza-epar-product-information_en.pdf", "if a patient with high-grade serous fallopian tube cancer has brca1 oncogenic variants, one recommended therapy is olaparib. therapy type: targeted therapy. therapy strategy: parp inhibition. indication: lynparza is indicated as monotherapy for the maintenance treatment of adult patients with advanced (figo stages iii and iv) brca1/2-mutated (germline and/or somatic) high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer who are in response (complete or partial) following completion of first-line platinum-based chemotherapy. approval url: https://www.ema.europa.eu/en/documents/product-information/lynparza-epar-product-information_en.pdf", "if a patient with peritoneal serous carcinoma has brca1 oncogenic variants, one recommended therapy is olaparib. therapy type: targeted therapy. therapy strategy: parp inhibition. indication: lynparza is indicated as monotherapy for the maintenance treatment of adult patients with advanced (figo stages iii and iv) brca1/2-mutated (germline and/or somatic) high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer who are in response (complete or partial) following completion of first-line platinum-based chemotherapy. approval url: https://www.ema.europa.eu/en/documents/product-information/lynparza-epar-product-information_en.pdf", "if a patient with ovarian epithelial tumor has brca1 pathogenic variants, one recommended therapy is olaparib. therapy type: targeted therapy. therapy strategy: parp inhibition. indication: lynparza is indicated as monotherapy for the maintenance treatment of adult patients with advanced (figo stages iii and iv) brca1/2-mutated (germline and/or somatic) high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer who are in response (complete or partial) following completion of first-line platinum-based chemotherapy. approval url: https://www.ema.europa.eu/en/documents/product-information/lynparza-epar-product-information_en.pdf", "if a patient with high-grade serous fallopian tube cancer has brca1 pathogenic variants, one recommended therapy is olaparib. therapy type: targeted therapy. therapy strategy: parp inhibition. indication: lynparza is indicated as monotherapy for the maintenance treatment of adult patients with advanced (figo stages iii and iv) brca1/2-mutated (germline and/or somatic) high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer who are in response (complete or partial) following completion of first-line platinum-based chemotherapy. approval url: https://www.ema.europa.eu/en/documents/product-information/lynparza-epar-product-information_en.pdf", "if a patient with peritoneal serous carcinoma has brca1 pathogenic variants, one recommended therapy is olaparib. therapy type: targeted therapy. therapy strategy: parp inhibition. indication: lynparza is indicated as monotherapy for the maintenance treatment of adult patients with advanced (figo stages iii and iv) brca1/2-mutated (germline and/or somatic) high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer who are in response (complete or partial) following completion of first-line platinum-based chemotherapy. approval url: https://www.ema.europa.eu/en/documents/product-information/lynparza-epar-product-information_en.pdf", "if a patient with ovarian epithelial tumor has brca2 oncogenic variants, one recommended therapy is olaparib. therapy type: targeted therapy. therapy strategy: parp inhibition. indication: lynparza is indicated as monotherapy for the maintenance treatment of adult patients with advanced (figo stages iii and iv) brca1/2-mutated (germline and/or somatic) high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer who are in response (complete or partial) following completion of first-line platinum-based chemotherapy. approval url: https://www.ema.europa.eu/en/documents/product-information/lynparza-epar-product-information_en.pdf", "if a patient with high-grade serous fallopian tube cancer has brca2 oncogenic variants, one recommended therapy is olaparib. therapy type: targeted therapy. therapy strategy: parp inhibition. indication: lynparza is indicated as monotherapy for the maintenance treatment of adult patients with advanced (figo stages iii and iv) brca1/2-mutated (germline and/or somatic) high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer who are in response (complete or partial) following completion of first-line platinum-based chemotherapy. approval url: https://www.ema.europa.eu/en/documents/product-information/lynparza-epar-product-information_en.pdf", "if a patient with peritoneal serous carcinoma has brca2 oncogenic variants, one recommended therapy is olaparib. therapy type: targeted therapy. therapy strategy: parp inhibition. indication: lynparza is indicated as monotherapy for the maintenance treatment of adult patients with advanced (figo stages iii and iv) brca1/2-mutated (germline and/or somatic) high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer who are in response (complete or partial) following completion of first-line platinum-based chemotherapy. approval url: https://www.ema.europa.eu/en/documents/product-information/lynparza-epar-product-information_en.pdf", "if a patient with ovarian epithelial tumor has brca2 pathogenic variants, one recommended therapy is olaparib. therapy type: targeted therapy. therapy strategy: parp inhibition. indication: lynparza is indicated as monotherapy for the maintenance treatment of adult patients with advanced (figo stages iii and iv) brca1/2-mutated (germline and/or somatic) high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer who are in response (complete or partial) following completion of first-line platinum-based chemotherapy. approval url: https://www.ema.europa.eu/en/documents/product-information/lynparza-epar-product-information_en.pdf", "if a patient with high-grade serous fallopian tube cancer has brca2 pathogenic variants, one recommended therapy is olaparib. therapy type: targeted therapy. therapy strategy: parp inhibition. indication: lynparza is indicated as monotherapy for the maintenance treatment of adult patients with advanced (figo stages iii and iv) brca1/2-mutated (germline and/or somatic) high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer who are in response (complete or partial) following completion of first-line platinum-based chemotherapy. approval url: https://www.ema.europa.eu/en/documents/product-information/lynparza-epar-product-information_en.pdf", "if a patient with peritoneal serous carcinoma has brca2 pathogenic variants, one recommended therapy is olaparib. therapy type: targeted therapy. therapy strategy: parp inhibition. indication: lynparza is indicated as monotherapy for the maintenance treatment of adult patients with advanced (figo stages iii and iv) brca1/2-mutated (germline and/or somatic) high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer who are in response (complete or partial) following completion of first-line platinum-based chemotherapy. approval url: https://www.ema.europa.eu/en/documents/product-information/lynparza-epar-product-information_en.pdf", "if a patient with ovarian epithelial tumor has brca1 oncogenic variants, one recommended therapy is olaparib + bevacizumab. therapy type: targeted therapy + targeted therapy. therapy strategy: parp inhibition + vegf inhibition. indication: lynparza in combination with bevacizumab is indicated for the maintenance treatment of adult patients with advanced (figo stages iii and iv) high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer who are in response (complete or partial) following completion of first-line platinum-based chemotherapy in combination with bevacizumab and whose cancer is associated with homologous recombination deficiency (hrd) positive status defined by either a brca1/2 mutation and/or genomic instability. approval url: https://www.ema.europa.eu/en/documents/product-information/lynparza-epar-product-information_en.pdf", "if a patient with high-grade serous fallopian tube cancer has brca1 oncogenic variants, one recommended therapy is olaparib + bevacizumab. therapy type: targeted therapy + targeted therapy. therapy strategy: parp inhibition + vegf inhibition. indication: lynparza in combination with bevacizumab is indicated for the maintenance treatment of adult patients with advanced (figo stages iii and iv) high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer who are in response (complete or partial) following completion of first-line platinum-based chemotherapy in combination with bevacizumab and whose cancer is associated with homologous recombination deficiency (hrd) positive status defined by either a brca1/2 mutation and/or genomic instability. approval url: https://www.ema.europa.eu/en/documents/product-information/lynparza-epar-product-information_en.pdf", "if a patient with peritoneal serous carcinoma has brca1 oncogenic variants, one recommended therapy is olaparib + bevacizumab. therapy type: targeted therapy + targeted therapy. therapy strategy: parp inhibition + vegf inhibition. indication: lynparza in combination with bevacizumab is indicated for the maintenance treatment of adult patients with advanced (figo stages iii and iv) high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer who are in response (complete or partial) following completion of first-line platinum-based chemotherapy in combination with bevacizumab and whose cancer is associated with homologous recombination deficiency (hrd) positive status defined by either a brca1/2 mutation and/or genomic instability. approval url: https://www.ema.europa.eu/en/documents/product-information/lynparza-epar-product-information_en.pdf", "if a patient with ovarian epithelial tumor has brca1 pathogenic variants, one recommended therapy is olaparib + bevacizumab. therapy type: targeted therapy + targeted therapy. therapy strategy: parp inhibition + vegf inhibition. indication: lynparza in combination with bevacizumab is indicated for the maintenance treatment of adult patients with advanced (figo stages iii and iv) high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer who are in response (complete or partial) following completion of first-line platinum-based chemotherapy in combination with bevacizumab and whose cancer is associated with homologous recombination deficiency (hrd) positive status defined by either a brca1/2 mutation and/or genomic instability. approval url: https://www.ema.europa.eu/en/documents/product-information/lynparza-epar-product-information_en.pdf", "if a patient with high-grade serous fallopian tube cancer has brca1 pathogenic variants, one recommended therapy is olaparib + bevacizumab. therapy type: targeted therapy + targeted therapy. therapy strategy: parp inhibition + vegf inhibition. indication: lynparza in combination with bevacizumab is indicated for the maintenance treatment of adult patients with advanced (figo stages iii and iv) high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer who are in response (complete or partial) following completion of first-line platinum-based chemotherapy in combination with bevacizumab and whose cancer is associated with homologous recombination deficiency (hrd) positive status defined by either a brca1/2 mutation and/or genomic instability. approval url: https://www.ema.europa.eu/en/documents/product-information/lynparza-epar-product-information_en.pdf", "if a patient with peritoneal serous carcinoma has brca1 pathogenic variants, one recommended therapy is olaparib + bevacizumab. therapy type: targeted therapy + targeted therapy. therapy strategy: parp inhibition + vegf inhibition. indication: lynparza in combination with bevacizumab is indicated for the maintenance treatment of adult patients with advanced (figo stages iii and iv) high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer who are in response (complete or partial) following completion of first-line platinum-based chemotherapy in combination with bevacizumab and whose cancer is associated with homologous recombination deficiency (hrd) positive status defined by either a brca1/2 mutation and/or genomic instability. approval url: https://www.ema.europa.eu/en/documents/product-information/lynparza-epar-product-information_en.pdf", "if a patient with ovarian epithelial tumor has brca2 oncogenic variants, one recommended therapy is olaparib + bevacizumab. therapy type: targeted therapy + targeted therapy. therapy strategy: parp inhibition + vegf inhibition. indication: lynparza in combination with bevacizumab is indicated for the maintenance treatment of adult patients with advanced (figo stages iii and iv) high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer who are in response (complete or partial) following completion of first-line platinum-based chemotherapy in combination with bevacizumab and whose cancer is associated with homologous recombination deficiency (hrd) positive status defined by either a brca1/2 mutation and/or genomic instability. approval url: https://www.ema.europa.eu/en/documents/product-information/lynparza-epar-product-information_en.pdf", "if a patient with high-grade serous fallopian tube cancer has brca2 oncogenic variants, one recommended therapy is olaparib + bevacizumab. therapy type: targeted therapy + targeted therapy. therapy strategy: parp inhibition + vegf inhibition. indication: lynparza in combination with bevacizumab is indicated for the maintenance treatment of adult patients with advanced (figo stages iii and iv) high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer who are in response (complete or partial) following completion of first-line platinum-based chemotherapy in combination with bevacizumab and whose cancer is associated with homologous recombination deficiency (hrd) positive status defined by either a brca1/2 mutation and/or genomic instability. approval url: https://www.ema.europa.eu/en/documents/product-information/lynparza-epar-product-information_en.pdf", "if a patient with peritoneal serous carcinoma has brca2 oncogenic variants, one recommended therapy is olaparib + bevacizumab. therapy type: targeted therapy + targeted therapy. therapy strategy: parp inhibition + vegf inhibition. indication: lynparza in combination with bevacizumab is indicated for the maintenance treatment of adult patients with advanced (figo stages iii and iv) high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer who are in response (complete or partial) following completion of first-line platinum-based chemotherapy in combination with bevacizumab and whose cancer is associated with homologous recombination deficiency (hrd) positive status defined by either a brca1/2 mutation and/or genomic instability. approval url: https://www.ema.europa.eu/en/documents/product-information/lynparza-epar-product-information_en.pdf", "if a patient with ovarian epithelial tumor has brca2 pathogenic variants, one recommended therapy is olaparib + bevacizumab. therapy type: targeted therapy + targeted therapy. therapy strategy: parp inhibition + vegf inhibition. indication: lynparza in combination with bevacizumab is indicated for the maintenance treatment of adult patients with advanced (figo stages iii and iv) high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer who are in response (complete or partial) following completion of first-line platinum-based chemotherapy in combination with bevacizumab and whose cancer is associated with homologous recombination deficiency (hrd) positive status defined by either a brca1/2 mutation and/or genomic instability. approval url: https://www.ema.europa.eu/en/documents/product-information/lynparza-epar-product-information_en.pdf", "if a patient with high-grade serous fallopian tube cancer has brca2 pathogenic variants, one recommended therapy is olaparib + bevacizumab. therapy type: targeted therapy + targeted therapy. therapy strategy: parp inhibition + vegf inhibition. indication: lynparza in combination with bevacizumab is indicated for the maintenance treatment of adult patients with advanced (figo stages iii and iv) high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer who are in response (complete or partial) following completion of first-line platinum-based chemotherapy in combination with bevacizumab and whose cancer is associated with homologous recombination deficiency (hrd) positive status defined by either a brca1/2 mutation and/or genomic instability. approval url: https://www.ema.europa.eu/en/documents/product-information/lynparza-epar-product-information_en.pdf", "if a patient with peritoneal serous carcinoma has brca2 pathogenic variants, one recommended therapy is olaparib + bevacizumab. therapy type: targeted therapy + targeted therapy. therapy strategy: parp inhibition + vegf inhibition. indication: lynparza in combination with bevacizumab is indicated for the maintenance treatment of adult patients with advanced (figo stages iii and iv) high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer who are in response (complete or partial) following completion of first-line platinum-based chemotherapy in combination with bevacizumab and whose cancer is associated with homologous recombination deficiency (hrd) positive status defined by either a brca1/2 mutation and/or genomic instability. approval url: https://www.ema.europa.eu/en/documents/product-information/lynparza-epar-product-information_en.pdf", "if a patient with ovarian epithelial tumor has hrd, one recommended therapy is olaparib + bevacizumab. therapy type: targeted therapy + targeted therapy. therapy strategy: parp inhibition + vegf inhibition. indication: lynparza in combination with bevacizumab is indicated for the maintenance treatment of adult patients with advanced (figo stages iii and iv) high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer who are in response (complete or partial) following completion of first-line platinum-based chemotherapy in combination with bevacizumab and whose cancer is associated with homologous recombination deficiency (hrd) positive status defined by either a brca1/2 mutation and/or genomic instability. approval url: https://www.ema.europa.eu/en/documents/product-information/lynparza-epar-product-information_en.pdf", "if a patient with high-grade serous fallopian tube cancer has hrd, one recommended therapy is olaparib + bevacizumab. therapy type: targeted therapy + targeted therapy. therapy strategy: parp inhibition + vegf inhibition. indication: lynparza in combination with bevacizumab is indicated for the maintenance treatment of adult patients with advanced (figo stages iii and iv) high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer who are in response (complete or partial) following completion of first-line platinum-based chemotherapy in combination with bevacizumab and whose cancer is associated with homologous recombination deficiency (hrd) positive status defined by either a brca1/2 mutation and/or genomic instability. approval url: https://www.ema.europa.eu/en/documents/product-information/lynparza-epar-product-information_en.pdf", "if a patient with peritoneal serous carcinoma has hrd, one recommended therapy is olaparib + bevacizumab. therapy type: targeted therapy + targeted therapy. therapy strategy: parp inhibition + vegf inhibition. indication: lynparza in combination with bevacizumab is indicated for the maintenance treatment of adult patients with advanced (figo stages iii and iv) high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer who are in response (complete or partial) following completion of first-line platinum-based chemotherapy in combination with bevacizumab and whose cancer is associated with homologous recombination deficiency (hrd) positive status defined by either a brca1/2 mutation and/or genomic instability. approval url: https://www.ema.europa.eu/en/documents/product-information/lynparza-epar-product-information_en.pdf", "if a patient with locally advanced or metastatic invasive breast carcinoma has her2-negative, brca1 pathogenic variants, one recommended therapy is olaparib. therapy type: targeted therapy. therapy strategy: parp inhibition. indication: lynparza is indicated as monotherapy for the treatment of adult patients with germline brca1/2-mutations, who have her2 negative locally advanced or metastatic breast cancer. patients should have previously been treated with an anthracycline and a taxane in the (neo)adjuvant or metastatic setting unless patients were not suitable for these treatments. patients with hormone receptor (hr)-positive breast cancer should also have progressed on or after prior endocrine therapy, or be considered unsuitable for endocrine therapy. approval url: https://www.ema.europa.eu/en/documents/product-information/lynparza-epar-product-information_en.pdf", "if a patient with early invasive breast carcinoma has her2-negative, brca1 pathogenic variants, one recommended therapy is olaparib. therapy type: targeted therapy. therapy strategy: parp inhibition. indication: lynparza is indicated as monotherapy or in combination with endocrine therapy for the adjuvant treatment of adult patients with germline brca1/2-mutations who have her2-negative, high risk early breast cancer previously treated with neoadjuvant or adjuvant chemotherapy. approval url: https://www.ema.europa.eu/en/documents/product-information/lynparza-epar-product-information_en.pdf", "if a patient with locally advanced or metastatic invasive breast carcinoma has her2-negative, brca2 pathogenic variants, one recommended therapy is olaparib. therapy type: targeted therapy. therapy strategy: parp inhibition. indication: lynparza is indicated as monotherapy for the treatment of adult patients with germline brca1/2-mutations, who have her2 negative locally advanced or metastatic breast cancer. patients should have previously been treated with an anthracycline and a taxane in the (neo)adjuvant or metastatic setting unless patients were not suitable for these treatments. patients with hormone receptor (hr)-positive breast cancer should also have progressed on or after prior endocrine therapy, or be considered unsuitable for endocrine therapy. approval url: https://www.ema.europa.eu/en/documents/product-information/lynparza-epar-product-information_en.pdf", "if a patient with early invasive breast carcinoma has her2-negative, brca2 pathogenic variants, one recommended therapy is olaparib. therapy type: targeted therapy. therapy strategy: parp inhibition. indication: lynparza is indicated as monotherapy or in combination with endocrine therapy for the adjuvant treatment of adult patients with germline brca1/2-mutations who have her2-negative, high risk early breast cancer previously treated with neoadjuvant or adjuvant chemotherapy. approval url: https://www.ema.europa.eu/en/documents/product-information/lynparza-epar-product-information_en.pdf", "if a patient with pancreatic adenocarcinoma has brca1 pathogenic variants, one recommended therapy is olaparib. therapy type: targeted therapy. therapy strategy: parp inhibition. indication: lynparza is indicated as monotherapy for the maintenance treatment of adult patients with germline brca1/2-mutations who have metastatic adenocarcinoma of the pancreas and have not progressed after a minimum of 16 weeks of platinum treatment within a first-line chemotherapy regimen. approval url: https://www.ema.europa.eu/en/documents/product-information/lynparza-epar-product-information_en.pdf", "if a patient with pancreatic adenocarcinoma has brca2 pathogenic variants, one recommended therapy is olaparib. therapy type: targeted therapy. therapy strategy: parp inhibition. indication: lynparza is indicated as monotherapy for the maintenance treatment of adult patients with germline brca1/2-mutations who have metastatic adenocarcinoma of the pancreas and have not progressed after a minimum of 16 weeks of platinum treatment within a first-line chemotherapy regimen. approval url: https://www.ema.europa.eu/en/documents/product-information/lynparza-epar-product-information_en.pdf", "if a patient with prostate adenocarcinoma has brca1 oncogenic variants, one recommended therapy is olaparib. therapy type: targeted therapy. therapy strategy: parp inhibition. indication: lynparza is indicated as monotherapy for the treatment of adult patients with metastatic castration-resistant prostate cancer (mcrpc) and brca1/2-mutations (germline and/or somatic) who have progressed following prior therapy that included a new hormonal agent. approval url: https://www.ema.europa.eu/en/documents/product-information/lynparza-epar-product-information_en.pdf", "if a patient with prostate adenocarcinoma has brca2 oncogenic variants, one recommended therapy is olaparib. therapy type: targeted therapy. therapy strategy: parp inhibition. indication: lynparza is indicated as monotherapy for the treatment of adult patients with metastatic castration-resistant prostate cancer (mcrpc) and brca1/2-mutations (germline and/or somatic) who have progressed following prior therapy that included a new hormonal agent. approval url: https://www.ema.europa.eu/en/documents/product-information/lynparza-epar-product-information_en.pdf", "if a patient with prostate adenocarcinoma has brca1 pathogenic variants, one recommended therapy is olaparib. therapy type: targeted therapy. therapy strategy: parp inhibition. indication: lynparza is indicated as monotherapy for the treatment of adult patients with metastatic castration-resistant prostate cancer (mcrpc) and brca1/2-mutations (germline and/or somatic) who have progressed following prior therapy that included a new hormonal agent. approval url: https://www.ema.europa.eu/en/documents/product-information/lynparza-epar-product-information_en.pdf", "if a patient with prostate adenocarcinoma has brca2 pathogenic variants, one recommended therapy is olaparib. therapy type: targeted therapy. therapy strategy: parp inhibition. indication: lynparza is indicated as monotherapy for the treatment of adult patients with metastatic castration-resistant prostate cancer (mcrpc) and brca1/2-mutations (germline and/or somatic) who have progressed following prior therapy that included a new hormonal agent. approval url: https://www.ema.europa.eu/en/documents/product-information/lynparza-epar-product-information_en.pdf", "if a patient with endometrial carcinoma has pmmr, one recommended therapy is durvalumab + olaparib. therapy type: immunotherapy + targeted therapy. therapy strategy: pd-1/pd-l1 inhibition + parp inhibition. indication: lynparza in combination with durvalumab is indicated for the maintenance treatment of adult patients with primary advanced or recurrent endometrial cancer that is mismatch repair proficient (pmmr) whose disease has not progressed on first-line treatment with durvalumab in combination with carboplatin and paclitaxel. approval url: https://www.ema.europa.eu/en/documents/product-information/lynparza-epar-product-information_en.pdf", "if a patient with intrahepatic cholangiocarcinoma has fgfr2::v, one recommended therapy is futibatinib. therapy type: targeted therapy. therapy strategy: fgfr inhibition. indication: lytgobi monotherapy is indicated for the treatment of adult patients with locally advanced or metastatic cholangiocarcinoma with a fibroblast growth factor receptor 2 (fgfr2) fusion or rearrangement that have progressed after at least one prior line of systemic therapy. approval url: https://www.ema.europa.eu/en/documents/product-information/lytgobi-epar-product-information_en.pdf", "if a patient with intrahepatic cholangiocarcinoma has fgfr2 rearrangements, one recommended therapy is futibatinib. therapy type: targeted therapy. therapy strategy: fgfr inhibition. indication: lytgobi monotherapy is indicated for the treatment of adult patients with locally advanced or metastatic cholangiocarcinoma with a fibroblast growth factor receptor 2 (fgfr2) fusion or rearrangement that have progressed after at least one prior line of systemic therapy. approval url: https://www.ema.europa.eu/en/documents/product-information/lytgobi-epar-product-information_en.pdf", "if a patient with diffuse large b-cell lymphoma has cd20 +, one recommended therapy is doxorubicin + prednisolone + vincristine + rituximab + cyclophosphamide. therapy type: chemotherapy + chemotherapy + chemotherapy + immunotherapy + chemotherapy. therapy strategy: topoisomerase inhibition + corticosteroid + vinca alkaloid chemotherapy + cd20 inhibition + alkylating chemotherapy. indication: mabthera is indicated for the treatment of adult patients with cd20 positive diffuse large b cell non-hodgkin's lymphoma in combination with chop (cyclophosphamide, doxorubicin, vincristine,prednisolone) chemotherapy. approval url: https://www.ema.europa.eu/en/documents/product-information/mabthera-epar-product-information_en.pdf", "if a patient with non-hodgkin lymphoma has cd20 +, one recommended therapy is doxorubicin + prednisolone + vincristine + rituximab + cyclophosphamide. therapy type: chemotherapy + chemotherapy + chemotherapy + immunotherapy + chemotherapy. therapy strategy: topoisomerase inhibition + corticosteroid + vinca alkaloid chemotherapy + cd20 inhibition + alkylating chemotherapy. indication: mabthera is indicated for the treatment of adult patients with cd20 positive diffuse large b cell non-hodgkin's lymphoma in combination with chop (cyclophosphamide, doxorubicin, vincristine,prednisolone) chemotherapy. approval url: https://www.ema.europa.eu/en/documents/product-information/mabthera-epar-product-information_en.pdf", "if a patient with mature b-cell diffuse large b-cell lymphoma has cd20 +, one recommended therapy is doxorubicin + vincristine + methotrexate + rituximab + corticosteroid + etoposide + cytarabine + cyclophosphamide. therapy type: chemotherapy + chemotherapy + chemotherapy + immunotherapy + hormone therapy + chemotherapy + chemotherapy + chemotherapy. therapy strategy: topoisomerase inhibition + vinca alkaloid chemotherapy + antifolate + cd20 inhibition + anti-inflammatory + topoisomerase inhibition + dna polymerase inhibition + alkylating chemotherapy. indication: mabthera in combination with chemotherapy is indicated for the treatment of paediatric patients (aged >= 6 months to < 18 years old) with previously untreated advanced stage cd20 positive diffuse large b-cell lymphoma (dlbcl), burkitt lymphoma (bl)/burkitt leukaemia (mature b-cell acute leukaemia) (bal) or burkitt-like lymphoma (bll). approval url: https://www.ema.europa.eu/en/documents/product-information/mabthera-epar-product-information_en.pdf", "if a patient with diffuse large b-cell non-hodgkin lymphoma has cd20 +, one recommended therapy is doxorubicin + vincristine + methotrexate + rituximab + corticosteroid + etoposide + cytarabine + cyclophosphamide. therapy type: chemotherapy + chemotherapy + chemotherapy + immunotherapy + hormone therapy + chemotherapy + chemotherapy + chemotherapy. therapy strategy: topoisomerase inhibition + vinca alkaloid chemotherapy + antifolate + cd20 inhibition + anti-inflammatory + topoisomerase inhibition + dna polymerase inhibition + alkylating chemotherapy. indication: mabthera in combination with chemotherapy is indicated for the treatment of paediatric patients (aged >= 6 months to < 18 years old) with previously untreated advanced stage cd20 positive diffuse large b-cell lymphoma (dlbcl), burkitt lymphoma (bl)/burkitt leukaemia (mature b-cell acute leukaemia) (bal) or burkitt-like lymphoma (bll). approval url: https://www.ema.europa.eu/en/documents/product-information/mabthera-epar-product-information_en.pdf", "if a patient with diffuse large b-cell burkitt lymphoma has cd20 +, one recommended therapy is doxorubicin + vincristine + methotrexate + rituximab + corticosteroid + etoposide + cytarabine + cyclophosphamide. therapy type: chemotherapy + chemotherapy + chemotherapy + immunotherapy + hormone therapy + chemotherapy + chemotherapy + chemotherapy. therapy strategy: topoisomerase inhibition + vinca alkaloid chemotherapy + antifolate + cd20 inhibition + anti-inflammatory + topoisomerase inhibition + dna polymerase inhibition + alkylating chemotherapy. indication: mabthera in combination with chemotherapy is indicated for the treatment of paediatric patients (aged >= 6 months to < 18 years old) with previously untreated advanced stage cd20 positive diffuse large b-cell lymphoma (dlbcl), burkitt lymphoma (bl)/burkitt leukaemia (mature b-cell acute leukaemia) (bal) or burkitt-like lymphoma (bll). approval url: https://www.ema.europa.eu/en/documents/product-information/mabthera-epar-product-information_en.pdf", "if a patient with melanoma has braf p.v600e, one recommended therapy is trametinib. therapy type: targeted therapy. therapy strategy: mek inhibition. indication: trametinib as monotherapy or in combination with dabrafenib is indicated for the treatment of adult patients with unresectable or metastatic melanoma with a braf v600 mutation. approval url: https://www.ema.europa.eu/en/documents/product-information/mekinist-epar-product-information_en.pdf", "if a patient with melanoma has braf p.v600k, one recommended therapy is trametinib. therapy type: targeted therapy. therapy strategy: mek inhibition. indication: trametinib as monotherapy or in combination with dabrafenib is indicated for the treatment of adult patients with unresectable or metastatic melanoma with a braf v600 mutation. approval url: https://www.ema.europa.eu/en/documents/product-information/mekinist-epar-product-information_en.pdf", "if a patient with melanoma has braf p.v600e, one recommended therapy is trametinib + dabrafenib. therapy type: targeted therapy + targeted therapy. therapy strategy: mek inhibition + b-raf inhibition. indication: trametinib as monotherapy or in combination with dabrafenib is indicated for the treatment of adult patients with unresectable or metastatic melanoma with a braf v600 mutation. approval url: https://www.ema.europa.eu/en/documents/product-information/mekinist-epar-product-information_en.pdf", "if a patient with melanoma has braf p.v600e, one recommended therapy is trametinib + dabrafenib. therapy type: targeted therapy + targeted therapy. therapy strategy: mek inhibition + b-raf inhibition. indication: trametinib in combination with dabrafenib is indicated for the adjuvant treatment of adult patients with stage iii melanoma with a braf v600 mutation, following complete resection. approval url: https://www.ema.europa.eu/en/documents/product-information/mekinist-epar-product-information_en.pdf", "if a patient with melanoma has braf p.v600k, one recommended therapy is trametinib + dabrafenib. therapy type: targeted therapy + targeted therapy. therapy strategy: mek inhibition + b-raf inhibition. indication: trametinib as monotherapy or in combination with dabrafenib is indicated for the treatment of adult patients with unresectable or metastatic melanoma with a braf v600 mutation. approval url: https://www.ema.europa.eu/en/documents/product-information/mekinist-epar-product-information_en.pdf", "if a patient with melanoma has braf p.v600k, one recommended therapy is trametinib + dabrafenib. therapy type: targeted therapy + targeted therapy. therapy strategy: mek inhibition + b-raf inhibition. indication: trametinib in combination with dabrafenib is indicated for the adjuvant treatment of adult patients with stage iii melanoma with a braf v600 mutation, following complete resection. approval url: https://www.ema.europa.eu/en/documents/product-information/mekinist-epar-product-information_en.pdf", "if a patient with non-small cell lung cancer has braf p.v600e, one recommended therapy is trametinib + dabrafenib. therapy type: targeted therapy + targeted therapy. therapy strategy: mek inhibition + b-raf inhibition. indication: trametinib in combination with dabrafenib is indicated for the treatment of adult patients with advanced non-small cell lung cancer with a braf v600 mutation. approval url: https://www.ema.europa.eu/en/documents/product-information/mekinist-epar-product-information_en.pdf", "if a patient with non-small cell lung cancer has braf p.v600k, one recommended therapy is trametinib + dabrafenib. therapy type: targeted therapy + targeted therapy. therapy strategy: mek inhibition + b-raf inhibition. indication: trametinib in combination with dabrafenib is indicated for the treatment of adult patients with advanced non-small cell lung cancer with a braf v600 mutation. approval url: https://www.ema.europa.eu/en/documents/product-information/mekinist-epar-product-information_en.pdf", "if a patient with melanoma has braf p.v600e, one recommended therapy is binimetinib + encorafenib. therapy type: targeted therapy + targeted therapy. therapy strategy: mek inhibition + b-raf inhibition. indication: binimetinib in combination with encorafenib is indicated for the treatment of adult patients with unresectable or metastatic melanoma with a braf v600 mutation. approval url: https://www.ema.europa.eu/en/documents/product-information/mektovi-epar-product-information_en.pdf", "if a patient with melanoma has braf p.v600k, one recommended therapy is binimetinib + encorafenib. therapy type: targeted therapy + targeted therapy. therapy strategy: mek inhibition + b-raf inhibition. indication: binimetinib in combination with encorafenib is indicated for the treatment of adult patients with unresectable or metastatic melanoma with a braf v600 mutation. approval url: https://www.ema.europa.eu/en/documents/product-information/mektovi-epar-product-information_en.pdf", "if a patient with non-small cell lung cancer has braf p.v600e, one recommended therapy is binimetinib + encorafenib. therapy type: targeted therapy + targeted therapy. therapy strategy: mek inhibition + b-raf inhibition. indication: binimetinib in combination with encorafenib is indicated for the treatment of adult patients with advanced non-small cell lung cancer with a braf v600e mutation. approval url: https://www.ema.europa.eu/en/documents/product-information/mektovi-epar-product-information_en.pdf", "if a patient with acute myeloid leukemia has cd33 +, one recommended therapy is daunorubicin + cytarabine + gemtuzumab ozogamicin. therapy type: chemotherapy + chemotherapy + immunotherapy. therapy strategy: dna polymerase inhibition + dna polymerase inhibition + cd33 inhibition. indication: mylotarg is indicated for combination therapy with daunorubicin (dnr) and cytarabine (arac) for the treatment of patients aged 15 years and above with previously untreated, de novo cd33-positive acute myeloid leukaemia (aml), except acute promyelocytic leukaemia (apl). approval url: https://www.ema.europa.eu/en/documents/product-information/mylotarg-epar-product-information_en.pdf", "if a patient with invasive breast carcinoma has her2-positive, pr positive, er positive, one recommended therapy is neratinib. therapy type: targeted therapy. therapy strategy: her2 inhibition. indication: nerlynx is indicated for the extended adjuvant treatment of adult patients with early-stage hormone receptor positive her2-overexpressed/amplified breast cancer and who completed adjuvant trastuzumab-based therapy less than one year ago. approval url: https://www.ema.europa.eu/en/documents/product-information/nerlynx-epar-product-information_en.pdf", "if a patient with invasive breast carcinoma has her2-positive, er positive, one recommended therapy is neratinib. therapy type: targeted therapy. therapy strategy: her2 inhibition. indication: nerlynx is indicated for the extended adjuvant treatment of adult patients with early-stage hormone receptor positive her2-overexpressed/amplified breast cancer and who completed adjuvant trastuzumab-based therapy less than one year ago. approval url: https://www.ema.europa.eu/en/documents/product-information/nerlynx-epar-product-information_en.pdf", "if a patient with invasive breast carcinoma has her2-positive, pr positive, one recommended therapy is neratinib. therapy type: targeted therapy. therapy strategy: her2 inhibition. indication: nerlynx is indicated for the extended adjuvant treatment of adult patients with early-stage hormone receptor positive her2-overexpressed/amplified breast cancer and who completed adjuvant trastuzumab-based therapy less than one year ago. approval url: https://www.ema.europa.eu/en/documents/product-information/nerlynx-epar-product-information_en.pdf", "if a patient with invasive breast carcinoma has pr positive, er positive, erbb2 amplification, one recommended therapy is neratinib. therapy type: targeted therapy. therapy strategy: her2 inhibition. indication: nerlynx is indicated for the extended adjuvant treatment of adult patients with early-stage hormone receptor positive her2-overexpressed/amplified breast cancer and who completed adjuvant trastuzumab-based therapy less than one year ago. approval url: https://www.ema.europa.eu/en/documents/product-information/nerlynx-epar-product-information_en.pdf", "if a patient with invasive breast carcinoma has er positive, erbb2 amplification, one recommended therapy is neratinib. therapy type: targeted therapy. therapy strategy: her2 inhibition. indication: nerlynx is indicated for the extended adjuvant treatment of adult patients with early-stage hormone receptor positive her2-overexpressed/amplified breast cancer and who completed adjuvant trastuzumab-based therapy less than one year ago. approval url: https://www.ema.europa.eu/en/documents/product-information/nerlynx-epar-product-information_en.pdf", "if a patient with invasive breast carcinoma has pr positive, erbb2 amplification, one recommended therapy is neratinib. therapy type: targeted therapy. therapy strategy: her2 inhibition. indication: nerlynx is indicated for the extended adjuvant treatment of adult patients with early-stage hormone receptor positive her2-overexpressed/amplified breast cancer and who completed adjuvant trastuzumab-based therapy less than one year ago. approval url: https://www.ema.europa.eu/en/documents/product-information/nerlynx-epar-product-information_en.pdf", "if a patient with non-small cell lung cancer has wild type egfr, wild type alk, one recommended therapy is carboplatin + nivolumab + ipilimumab + pemetrexed. therapy type: chemotherapy + immunotherapy + immunotherapy + chemotherapy. therapy strategy: platinum-based chemotherapy + pd-1/pd-l1 inhibition + ctla-4 inhibition + antifolate. indication: opdivo in combination with ipilimumab and 2 cycles of platinum-based chemotherapy is indicated for the first-line treatment of metastatic non-small cell lung cancer in adults whose tumours have no sensitising egfr mutation or alk translocation. approval url: https://www.ema.europa.eu/en/documents/product-information/opdivo-epar-product-information_en.pdf", "if a patient with non-small cell lung cancer has wild type egfr, wild type alk, one recommended therapy is nivolumab + ipilimumab + pemetrexed + cisplatin. therapy type: immunotherapy + immunotherapy + chemotherapy + chemotherapy. therapy strategy: pd-1/pd-l1 inhibition + ctla-4 inhibition + antifolate + platinum-based chemotherapy. indication: opdivo in combination with ipilimumab and 2 cycles of platinum-based chemotherapy is indicated for the first-line treatment of metastatic non-small cell lung cancer in adults whose tumours have no sensitising egfr mutation or alk translocation. approval url: https://www.ema.europa.eu/en/documents/product-information/opdivo-epar-product-information_en.pdf", "if a patient with non-small cell lung cancer has wild type egfr, wild type alk, one recommended therapy is carboplatin + paclitaxel + nivolumab + ipilimumab. therapy type: chemotherapy + chemotherapy + immunotherapy + immunotherapy. therapy strategy: platinum-based chemotherapy + taxane-based chemotherapy + pd-1/pd-l1 inhibition + ctla-4 inhibition. indication: opdivo in combination with ipilimumab and 2 cycles of platinum-based chemotherapy is indicated for the first-line treatment of metastatic non-small cell lung cancer in adults whose tumours have no sensitising egfr mutation or alk translocation. approval url: https://www.ema.europa.eu/en/documents/product-information/opdivo-epar-product-information_en.pdf", "if a patient with non-small cell lung cancer has pd-l1 >= 1%, one recommended therapy is carboplatin + paclitaxel + nivolumab. therapy type: chemotherapy + chemotherapy + immunotherapy. therapy strategy: platinum-based chemotherapy + taxane-based chemotherapy + pd-1/pd-l1 inhibition. indication: opdivo in combination with platinum-based chemotherapy is indicated for the neoadjuvant treatment of resectable non-small cell lung cancer at high risk of recurrence in adult patients whose tumours have pd-l1 expression >= 1%. approval url: https://www.ema.europa.eu/en/documents/product-information/opdivo-epar-product-information_en.pdf", "if a patient with non-small cell lung cancer has pd-l1 >= 1%, one recommended therapy is carboplatin + nivolumab + pemetrexed. therapy type: chemotherapy + immunotherapy + chemotherapy. therapy strategy: platinum-based chemotherapy + pd-1/pd-l1 inhibition + antifolate. indication: opdivo in combination with platinum-based chemotherapy is indicated for the neoadjuvant treatment of resectable non-small cell lung cancer at high risk of recurrence in adult patients whose tumours have pd-l1 expression >= 1%. approval url: https://www.ema.europa.eu/en/documents/product-information/opdivo-epar-product-information_en.pdf", "if a patient with non-small cell lung cancer has pd-l1 >= 1%, one recommended therapy is nivolumab + gemcitabine + cisplatin. therapy type: immunotherapy + chemotherapy + chemotherapy. therapy strategy: pd-1/pd-l1 inhibition + antimetabolite + platinum-based chemotherapy. indication: opdivo in combination with platinum-based chemotherapy is indicated for the neoadjuvant treatment of resectable non-small cell lung cancer at high risk of recurrence in adult patients whose tumours have pd-l1 expression >= 1%. approval url: https://www.ema.europa.eu/en/documents/product-information/opdivo-epar-product-information_en.pdf", "if a patient with bladder urothelial carcinoma has pd-l1 >= 1%, one recommended therapy is nivolumab. therapy type: immunotherapy. therapy strategy: pd-1/pd-l1 inhibition. indication: opdivo as monotherapy is indicated for the adjuvant treatment of adults with muscle invasive urothelial carcinoma (miuc) with tumour cell pd-l1 expression >= 1%, who are at high risk of recurrence after undergoing radical resection of miuc. approval url: https://www.ema.europa.eu/en/documents/product-information/opdivo-epar-product-information_en.pdf", "if a patient with colorectal adenocarcinoma has msi-h, one recommended therapy is nivolumab + ipilimumab. therapy type: immunotherapy + immunotherapy. therapy strategy: pd-1/pd-l1 inhibition + ctla-4 inhibition. indication: opdivo in combination with ipilimumab is indicated for the treatment of adult patients with mismatch repair deficient or microsatellite instability-high metastatic colorectal cancer after prior fluoropyrimidine-based combination chemotherapy. approval url: https://www.ema.europa.eu/en/documents/product-information/opdivo-epar-product-information_en.pdf", "if a patient with colorectal adenocarcinoma has dmmr, one recommended therapy is nivolumab + ipilimumab. therapy type: immunotherapy + immunotherapy. therapy strategy: pd-1/pd-l1 inhibition + ctla-4 inhibition. indication: opdivo in combination with ipilimumab is indicated for the treatment of adult patients with mismatch repair deficient or microsatellite instability-high metastatic colorectal cancer after prior fluoropyrimidine-based combination chemotherapy. approval url: https://www.ema.europa.eu/en/documents/product-information/opdivo-epar-product-information_en.pdf", "if a patient with esophageal squamous cell carcinoma has pd-l1 >= 1%, one recommended therapy is nivolumab + ipilimumab. therapy type: immunotherapy + immunotherapy. therapy strategy: pd-1/pd-l1 inhibition + ctla-4 inhibition. indication: opdivo in combination with ipilimumab is indicated for the first-line treatment of adult patients with unresectable advanced, recurrent or metastatic oesophageal squamous cell carcinoma with tumour cell pd-l1 expression >= 1%. approval url: https://www.ema.europa.eu/en/documents/product-information/opdivo-epar-product-information_en.pdf", "if a patient with esophageal squamous cell carcinoma has pd-l1 >= 1%, one recommended therapy is fluorouracil + nivolumab + cisplatin. therapy type: chemotherapy + immunotherapy + chemotherapy. therapy strategy: thymidylate synthase inhibition + pd-1/pd-l1 inhibition + platinum-based chemotherapy. indication: opdivo in combination with fluoropyrimidine- and platinum-based combination chemotherapy is indicated for the first-line treatment of adult patients with unresectable advanced, recurrent or metastatic oesophageal squamous cell carcinoma with tumour cell pd-l1 expression >= 1% approval url: https://www.ema.europa.eu/en/documents/product-information/opdivo-epar-product-information_en.pdf", "if a patient with esophageal adenocarcinoma has pd-l1 (cps) >= 5, her2-negative, one recommended therapy is oxaliplatin + fluorouracil + nivolumab. therapy type: chemotherapy + chemotherapy + immunotherapy. therapy strategy: platinum-based chemotherapy + thymidylate synthase inhibition + pd-1/pd-l1 inhibition. indication: opdivo in combination with fluoropyrimidine- and platinum-based combination chemotherapy is indicated for the first-line treatment of adult patients with her2-negative advanced or metastatic gastric, gastro-oesophageal junction or oesophageal adenocarcinoma whose tumours express pd-l1 with a combined positive score (cps) >= 5. approval url: https://www.ema.europa.eu/en/documents/product-information/opdivo-epar-product-information_en.pdf", "if a patient with esophageal adenocarcinoma has pd-l1 (cps) >= 5, her2-negative, one recommended therapy is oxaliplatin + nivolumab. therapy type: chemotherapy + immunotherapy. therapy strategy: platinum-based chemotherapy + pd-1/pd-l1 inhibition. indication: opdivo in combination with fluoropyrimidine- and platinum-based combination chemotherapy is indicated for the first-line treatment of adult patients with her2-negative advanced or metastatic gastric, gastro-oesophageal junction or oesophageal adenocarcinoma whose tumours express pd-l1 with a combined positive score (cps) >= 5. approval url: https://www.ema.europa.eu/en/documents/product-information/opdivo-epar-product-information_en.pdf", "if a patient with esophagogastric adenocarcinoma has pd-l1 (cps) >= 5, her2-negative, one recommended therapy is oxaliplatin + fluorouracil + nivolumab. therapy type: chemotherapy + chemotherapy + immunotherapy. therapy strategy: platinum-based chemotherapy + thymidylate synthase inhibition + pd-1/pd-l1 inhibition. indication: opdivo in combination with fluoropyrimidine- and platinum-based combination chemotherapy is indicated for the first-line treatment of adult patients with her2-negative advanced or metastatic gastric, gastro-oesophageal junction or oesophageal adenocarcinoma whose tumours express pd-l1 with a combined positive score (cps) >= 5. approval url: https://www.ema.europa.eu/en/documents/product-information/opdivo-epar-product-information_en.pdf", "if a patient with esophagogastric adenocarcinoma has pd-l1 (cps) >= 5, her2-negative, one recommended therapy is oxaliplatin + nivolumab. therapy type: chemotherapy + immunotherapy. therapy strategy: platinum-based chemotherapy + pd-1/pd-l1 inhibition. indication: opdivo in combination with fluoropyrimidine- and platinum-based combination chemotherapy is indicated for the first-line treatment of adult patients with her2-negative advanced or metastatic gastric, gastro-oesophageal junction or oesophageal adenocarcinoma whose tumours express pd-l1 with a combined positive score (cps) >= 5. approval url: https://www.ema.europa.eu/en/documents/product-information/opdivo-epar-product-information_en.pdf", "if a patient with adenocarcinoma of the gastroesophageal junction has pd-l1 (cps) >= 5, her2-negative, one recommended therapy is oxaliplatin + fluorouracil + nivolumab. therapy type: chemotherapy + chemotherapy + immunotherapy. therapy strategy: platinum-based chemotherapy + thymidylate synthase inhibition + pd-1/pd-l1 inhibition. indication: opdivo in combination with fluoropyrimidine- and platinum-based combination chemotherapy is indicated for the first-line treatment of adult patients with her2-negative advanced or metastatic gastric, gastro-oesophageal junction or oesophageal adenocarcinoma whose tumours express pd-l1 with a combined positive score (cps) >= 5. approval url: https://www.ema.europa.eu/en/documents/product-information/opdivo-epar-product-information_en.pdf", "if a patient with adenocarcinoma of the gastroesophageal junction has pd-l1 (cps) >= 5, her2-negative, one recommended therapy is oxaliplatin + nivolumab. therapy type: chemotherapy + immunotherapy. therapy strategy: platinum-based chemotherapy + pd-1/pd-l1 inhibition. indication: opdivo in combination with fluoropyrimidine- and platinum-based combination chemotherapy is indicated for the first-line treatment of adult patients with her2-negative advanced or metastatic gastric, gastro-oesophageal junction or oesophageal adenocarcinoma whose tumours express pd-l1 with a combined positive score (cps) >= 5. approval url: https://www.ema.europa.eu/en/documents/product-information/opdivo-epar-product-information_en.pdf", "if a patient with melanoma has pd-l1 < 1%, one recommended therapy is nivolumab + relatlimab. therapy type: immunotherapy + immunotherapy. therapy strategy: pd-1/pd-l1 inhibition + lag-3 inhibition. indication: opdualag is indicated for the first-line treatment of advanced (unresectable or metastatic) melanoma in adults and adolescents 12 years of age and older with tumour cell pd-l1 expression < 1%. approval url: https://www.ema.europa.eu/en/documents/product-information/opdualag-epar-product-information_en.pdf", "if a patient with locally advanced or metastatic invasive breast carcinoma has esr1 oncogenic variants, her2-negative, er positive, one recommended therapy is elacestrant. therapy type: hormone therapy. therapy strategy: er signaling inhibition. indication: orserdu monotherapy is indicated for the treatment of postmenopausal women, and men, with estrogen receptor (er)-positive, her2-negative, locally advanced or metastatic breast cancer with an activating esr1 mutation who have disease progression following at least one line of endocrine therapy including a cdk 4/6 inhibitor. approval url: https://www.ema.europa.eu/en/documents/product-information/orserdu-epar-product-information_en.pdf", "if a patient with intrahepatic cholangiocarcinoma has fgfr2::v, one recommended therapy is elacestrant. therapy type: hormone therapy. therapy strategy: er signaling inhibition. indication: pemazyre monotherapy is indicated for the treatment of adults with locally advanced or metastatic cholangiocarcinoma with a fibroblast growth factor receptor 2 (fgfr2) fusion or rearrangement that have progressed after at least one prior line of systemic therapy. approval url: https://www.ema.europa.eu/en/documents/product-information/pemazyre-epar-product-information_en.pdf", "if a patient with intrahepatic cholangiocarcinoma has fgfr2 rearrangements, one recommended therapy is elacestrant. therapy type: hormone therapy. therapy strategy: er signaling inhibition. indication: pemazyre monotherapy is indicated for the treatment of adults with locally advanced or metastatic cholangiocarcinoma with a fibroblast growth factor receptor 2 (fgfr2) fusion or rearrangement that have progressed after at least one prior line of systemic therapy. approval url: https://www.ema.europa.eu/en/documents/product-information/pemazyre-epar-product-information_en.pdf", "if a patient with invasive breast carcinoma has her2-positive, one recommended therapy is trastuzumab + doxorubicin + paclitaxel + pertuzumab + cyclophosphamide. therapy type: targeted therapy + chemotherapy + chemotherapy + targeted therapy + chemotherapy. therapy strategy: her2 inhibition + topoisomerase inhibition + taxane-based chemotherapy + her2 inhibition + alkylating chemotherapy. indication: perjeta is indicated for use in combination with trastuzumab and chemotherapy in the neoadjuvant treatment of adult patients with her2-positive, locally advanced, inflammatory, or early stage breast cancer at high risk of recurrence. approval url: https://www.ema.europa.eu/en/documents/product-information/perjeta-epar-product-information_en.pdf", "if a patient with invasive breast carcinoma has her2-positive, one recommended therapy is trastuzumab + docetaxel + pertuzumab. therapy type: targeted therapy + chemotherapy + targeted therapy. therapy strategy: her2 inhibition + taxane-based chemotherapy + her2 inhibition. indication: perjeta is indicated for use in combination with trastuzumab and chemotherapy in the neoadjuvant treatment of adult patients with her2-positive, locally advanced, inflammatory, or early stage breast cancer at high risk of recurrence. approval url: https://www.ema.europa.eu/en/documents/product-information/perjeta-epar-product-information_en.pdf", "if a patient with invasive breast carcinoma has her2-positive, one recommended therapy is trastuzumab + doxorubicin + fluorouracil + docetaxel + pertuzumab + cyclophosphamide. therapy type: targeted therapy + chemotherapy + chemotherapy + chemotherapy + targeted therapy + chemotherapy. therapy strategy: her2 inhibition + topoisomerase inhibition + thymidylate synthase inhibition + taxane-based chemotherapy + her2 inhibition + alkylating chemotherapy. indication: perjeta is indicated for use in combination with trastuzumab and chemotherapy in the adjuvant treatment of adult patients with her2-positive early breast cancer at high risk of recurrence. approval url: https://www.ema.europa.eu/en/documents/product-information/perjeta-epar-product-information_en.pdf", "if a patient with invasive breast carcinoma has her2-positive, one recommended therapy is trastuzumab + doxorubicin + fluorouracil + paclitaxel + pertuzumab + cyclophosphamide. therapy type: targeted therapy + chemotherapy + chemotherapy + chemotherapy + targeted therapy + chemotherapy. therapy strategy: her2 inhibition + topoisomerase inhibition + thymidylate synthase inhibition + taxane-based chemotherapy + her2 inhibition + alkylating chemotherapy. indication: perjeta is indicated for use in combination with trastuzumab and chemotherapy in the adjuvant treatment of adult patients with her2-positive early breast cancer at high risk of recurrence. approval url: https://www.ema.europa.eu/en/documents/product-information/perjeta-epar-product-information_en.pdf", "if a patient with invasive breast carcinoma has her2-positive, one recommended therapy is trastuzumab + docetaxel + pertuzumab + epirubicin + cyclophosphamide. therapy type: targeted therapy + chemotherapy + targeted therapy + chemotherapy + chemotherapy. therapy strategy: her2 inhibition + taxane-based chemotherapy + her2 inhibition + topoisomerase inhibition + alkylating chemotherapy. indication: perjeta is indicated for use in combination with trastuzumab and chemotherapy in the adjuvant treatment of adult patients with her2-positive early breast cancer at high risk of recurrence. approval url: https://www.ema.europa.eu/en/documents/product-information/perjeta-epar-product-information_en.pdf", "if a patient with invasive breast carcinoma has her2-positive, one recommended therapy is trastuzumab + paclitaxel + pertuzumab + epirubicin + cyclophosphamide. therapy type: targeted therapy + chemotherapy + targeted therapy + chemotherapy + chemotherapy. therapy strategy: her2 inhibition + taxane-based chemotherapy + her2 inhibition + topoisomerase inhibition + alkylating chemotherapy. indication: perjeta is indicated for use in combination with trastuzumab and chemotherapy in the adjuvant treatment of adult patients with her2-positive early breast cancer at high risk of recurrence. approval url: https://www.ema.europa.eu/en/documents/product-information/perjeta-epar-product-information_en.pdf", "if a patient with invasive breast carcinoma has her2-positive, one recommended therapy is trastuzumab + carboplatin + docetaxel + pertuzumab. therapy type: targeted therapy + chemotherapy + chemotherapy + targeted therapy. therapy strategy: her2 inhibition + platinum-based chemotherapy + taxane-based chemotherapy + her2 inhibition. indication: perjeta is indicated for use in combination with trastuzumab and chemotherapy in the adjuvant treatment of adult patients with her2-positive early breast cancer at high risk of recurrence. approval url: https://www.ema.europa.eu/en/documents/product-information/perjeta-epar-product-information_en.pdf", "if a patient with invasive breast carcinoma has her2-positive, one recommended therapy is trastuzumab + docetaxel + pertuzumab. therapy type: targeted therapy + chemotherapy + targeted therapy. therapy strategy: her2 inhibition + taxane-based chemotherapy + her2 inhibition. indication: perjeta is indicated for use in combination with trastuzumab and docetaxel in adult patients with her2-positive metastatic or locally recurrent unresectable breast cancer, who have not received previous anti-her2 therapy or chemotherapy for their metastatic disease. approval url: https://www.ema.europa.eu/en/documents/product-information/perjeta-epar-product-information_en.pdf", "if a patient with invasive breast carcinoma has her2-positive, one recommended therapy is trastuzumab + doxorubicin + paclitaxel + pertuzumab + cyclophosphamide. therapy type: targeted therapy + chemotherapy + chemotherapy + targeted therapy + chemotherapy. therapy strategy: her2 inhibition + topoisomerase inhibition + taxane-based chemotherapy + her2 inhibition + alkylating chemotherapy. indication: phesgo is indicated for use in combination with chemotherapy in the neoadjuvant treatment of adult patients with her2-positive, locally advanced, inflammatory, or early stage breast cancer at high risk of recurrence. approval url: https://www.ema.europa.eu/en/documents/product-information/phesgo-epar-product-information_en.pdf", "if a patient with invasive breast carcinoma has her2-positive, one recommended therapy is trastuzumab + docetaxel + pertuzumab. therapy type: targeted therapy + chemotherapy + targeted therapy. therapy strategy: her2 inhibition + taxane-based chemotherapy + her2 inhibition. indication: phesgo is indicated for use in combination with chemotherapy in the neoadjuvant treatment of adult patients with her2-positive, locally advanced, inflammatory, or early stage breast cancer at high risk of recurrence. approval url: https://www.ema.europa.eu/en/documents/product-information/phesgo-epar-product-information_en.pdf", "if a patient with invasive breast carcinoma has her2-positive, one recommended therapy is trastuzumab + fluorouracil + docetaxel + pertuzumab + epirubicin + cyclophosphamide. therapy type: targeted therapy + chemotherapy + chemotherapy + targeted therapy + chemotherapy + chemotherapy. therapy strategy: her2 inhibition + thymidylate synthase inhibition + taxane-based chemotherapy + her2 inhibition + topoisomerase inhibition + alkylating chemotherapy. indication: phesgo is indicated for use in combination with chemotherapy in the adjuvant treatment of adult patients with her2-positive early breast cancer at high risk of recurrence. approval url: https://www.ema.europa.eu/en/documents/product-information/phesgo-epar-product-information_en.pdf", "if a patient with invasive breast carcinoma has her2-positive, one recommended therapy is trastuzumab + fluorouracil + paclitaxel + pertuzumab + epirubicin + cyclophosphamide. therapy type: targeted therapy + chemotherapy + chemotherapy + targeted therapy + chemotherapy + chemotherapy. therapy strategy: her2 inhibition + thymidylate synthase inhibition + taxane-based chemotherapy + her2 inhibition + topoisomerase inhibition + alkylating chemotherapy. indication: phesgo is indicated for use in combination with chemotherapy in the adjuvant treatment of adult patients with her2-positive early breast cancer at high risk of recurrence. approval url: https://www.ema.europa.eu/en/documents/product-information/phesgo-epar-product-information_en.pdf", "if a patient with invasive breast carcinoma has her2-positive, one recommended therapy is trastuzumab + doxorubicin + fluorouracil + docetaxel + pertuzumab + cyclophosphamide. therapy type: targeted therapy + chemotherapy + chemotherapy + chemotherapy + targeted therapy + chemotherapy. therapy strategy: her2 inhibition + topoisomerase inhibition + thymidylate synthase inhibition + taxane-based chemotherapy + her2 inhibition + alkylating chemotherapy. indication: phesgo is indicated for use in combination with chemotherapy in the adjuvant treatment of adult patients with her2-positive early breast cancer at high risk of recurrence. approval url: https://www.ema.europa.eu/en/documents/product-information/phesgo-epar-product-information_en.pdf", "if a patient with invasive breast carcinoma has her2-positive, one recommended therapy is trastuzumab + doxorubicin + fluorouracil + paclitaxel + pertuzumab + cyclophosphamide. therapy type: targeted therapy + chemotherapy + chemotherapy + chemotherapy + targeted therapy + chemotherapy. therapy strategy: her2 inhibition + topoisomerase inhibition + thymidylate synthase inhibition + taxane-based chemotherapy + her2 inhibition + alkylating chemotherapy. indication: phesgo is indicated for use in combination with chemotherapy in the adjuvant treatment of adult patients with her2-positive early breast cancer at high risk of recurrence. approval url: https://www.ema.europa.eu/en/documents/product-information/phesgo-epar-product-information_en.pdf", "if a patient with invasive breast carcinoma has her2-positive, one recommended therapy is trastuzumab + docetaxel + pertuzumab + epirubicin + cyclophosphamide. therapy type: targeted therapy + chemotherapy + targeted therapy + chemotherapy + chemotherapy. therapy strategy: her2 inhibition + taxane-based chemotherapy + her2 inhibition + topoisomerase inhibition + alkylating chemotherapy. indication: phesgo is indicated for use in combination with chemotherapy in the adjuvant treatment of adult patients with her2-positive early breast cancer at high risk of recurrence. approval url: https://www.ema.europa.eu/en/documents/product-information/phesgo-epar-product-information_en.pdf", "if a patient with invasive breast carcinoma has her2-positive, one recommended therapy is trastuzumab + paclitaxel + pertuzumab + epirubicin + cyclophosphamide. therapy type: targeted therapy + chemotherapy + targeted therapy + chemotherapy + chemotherapy. therapy strategy: her2 inhibition + taxane-based chemotherapy + her2 inhibition + topoisomerase inhibition + alkylating chemotherapy. indication: phesgo is indicated for use in combination with chemotherapy in the adjuvant treatment of adult patients with her2-positive early breast cancer at high risk of recurrence. approval url: https://www.ema.europa.eu/en/documents/product-information/phesgo-epar-product-information_en.pdf", "if a patient with invasive breast carcinoma has her2-positive, one recommended therapy is trastuzumab + carboplatin + docetaxel + pertuzumab. therapy type: targeted therapy + chemotherapy + chemotherapy + targeted therapy. therapy strategy: her2 inhibition + platinum-based chemotherapy + taxane-based chemotherapy + her2 inhibition. indication: phesgo is indicated for use in combination with chemotherapy in the adjuvant treatment of adult patients with her2-positive early breast cancer at high risk of recurrence. approval url: https://www.ema.europa.eu/en/documents/product-information/phesgo-epar-product-information_en.pdf", "if a patient with invasive breast carcinoma has her2-positive, one recommended therapy is trastuzumab + docetaxel + pertuzumab. therapy type: targeted therapy + chemotherapy + targeted therapy. therapy strategy: her2 inhibition + taxane-based chemotherapy + her2 inhibition. indication: phesgo is indicated for use in combination with docetaxel in adult patients with her2-positive metastatic or locally recurrent unresectable breast cancer, who have not received previous anti-her2 therapy or chemotherapy for their metastatic disease. approval url: https://www.ema.europa.eu/en/documents/product-information/phesgo-epar-product-information_en.pdf", "if a patient with locally advanced or metastatic invasive breast carcinoma has her2-negative, er positive, pik3ca somatic variants, one recommended therapy is fulvestrant + alpelisib. therapy type: hormone therapy + targeted therapy. therapy strategy: estrogen receptor inhibition + pi3k/akt/mtor inhibition. indication: piqray is indicated in combination with fulvestrant for the treatment of postmenopausal women, and men, with hormone receptor (hr)-positive, human epidermal growth factor receptor 2 (her2)-negative, locally advanced or metastatic breast cancer with a pik3ca mutation after disease progression following endocrine therapy as monotherapy. approval url: https://www.ema.europa.eu/en/documents/product-information/piqray-epar-product-information_en.pdf", "if a patient with locally advanced or metastatic invasive breast carcinoma has pr positive, her2-negative, pik3ca somatic variants, one recommended therapy is fulvestrant + alpelisib. therapy type: hormone therapy + targeted therapy. therapy strategy: estrogen receptor inhibition + pi3k/akt/mtor inhibition. indication: piqray is indicated in combination with fulvestrant for the treatment of postmenopausal women, and men, with hormone receptor (hr)-positive, human epidermal growth factor receptor 2 (her2)-negative, locally advanced or metastatic breast cancer with a pik3ca mutation after disease progression following endocrine therapy as monotherapy. approval url: https://www.ema.europa.eu/en/documents/product-information/piqray-epar-product-information_en.pdf", "if a patient with locally advanced or metastatic invasive breast carcinoma has pr positive, her2-negative, er positive, pik3ca somatic variants, one recommended therapy is fulvestrant + alpelisib. therapy type: hormone therapy + targeted therapy. therapy strategy: estrogen receptor inhibition + pi3k/akt/mtor inhibition. indication: piqray is indicated in combination with fulvestrant for the treatment of postmenopausal women, and men, with hormone receptor (hr)-positive, human epidermal growth factor receptor 2 (her2)-negative, locally advanced or metastatic breast cancer with a pik3ca mutation after disease progression following endocrine therapy as monotherapy. approval url: https://www.ema.europa.eu/en/documents/product-information/piqray-epar-product-information_en.pdf", "if a patient with non-small cell lung cancer has v::ret, one recommended therapy is selpercatinib. therapy type: targeted therapy. therapy strategy: ret inhibition. indication: retsevmo as monotherapy is indicated for the treatment of adults with advanced ret fusion-positive non-small cell lung cancer (nsclc) not previously treated with a ret inhibitor. approval url: https://www.ema.europa.eu/en/documents/product-information/retsevmo-epar-product-information_en.pdf", "if a patient with papillary thyroid cancer has v::ret, one recommended therapy is selpercatinib. therapy type: targeted therapy. therapy strategy: ret inhibition. indication: retsevmo as monotherapy is indicated for the treatment of adults and adolescents 12 years and older with advanced ret fusion-positive thyroid cancer who are radioactive iodine-refractory (if radioactive iodine is appropriate). approval url: https://www.ema.europa.eu/en/documents/product-information/retsevmo-epar-product-information_en.pdf", "if a patient with medullary thyroid cancer has ret p.m918t, one recommended therapy is selpercatinib. therapy type: targeted therapy. therapy strategy: ret inhibition. indication: retsevmo as monotherapy is indicated for the treatment of adults and adolescents 12 years and older with advanced ret-mutant medullary thyroid cancer (mtc). approval url: https://www.ema.europa.eu/en/documents/product-information/retsevmo-epar-product-information_en.pdf", "if a patient with any solid tumor has v::ret, one recommended therapy is selpercatinib. therapy type: targeted therapy. therapy strategy: ret inhibition. indication: retsevmo as monotherapy is indicated for the treatment of adults with advanced ret fusion-positive solid tumours, when treatment options not targeting ret provide limited clinical benefit, or have been exhausted. approval url: https://www.ema.europa.eu/en/documents/product-information/retsevmo-epar-product-information_en.pdf", "if a patient with myeloproliferative neoplasm has 5q deletion, one recommended therapy is lenalidomide. therapy type: chemotherapy. therapy strategy: angiogenesis inhibition. indication: revlimid as monotherapy is indicated for the treatment of adult patients with transfusion-dependent anaemia due to low- or intermediate-1-risk myelodysplastic syndromes associated with an isolated deletion 5q cytogenetic abnormality when other therapeutic options are insufficient or inadequate. approval url: https://www.ema.europa.eu/en/documents/product-information/revlimid-epar-product-information_en.pdf", "if a patient with non-small cell lung cancer has v::ros1, one recommended therapy is entrectinib. therapy type: targeted therapy. therapy strategy: alk inhibition + ros1 inhibition + ntrk inhibition. indication: rozlytrek as monotherapy is indicated for the treatment of adult patients with ros1-positive, advanced non-small cell lung cancer (nsclc) not previously treated with ros1 inhibitors. approval url: https://www.ema.europa.eu/en/documents/product-information/rozlytrek-epar-product-information_en.pdf", "if a patient with any solid tumor has v::ntrk1, one recommended therapy is entrectinib. therapy type: targeted therapy. therapy strategy: alk inhibition + ros1 inhibition + ntrk inhibition. indication: rozlytrek as monotherapy is indicated for the treatment of adult and paediatric patients older than one month with solid tumours expressing a neurotrophic tyrosine receptor kinase (ntrk) gene fusion (i) who have a disease that is locally advanced, metastatic or where surgical resection is likely to result in severe morbidity, and (ii) who have not received a prior ntrk inhibitor, (iii) who have no satisfactory treatment options. approval url: https://www.ema.europa.eu/en/documents/product-information/rozlytrek-epar-product-information_en.pdf", "if a patient with any solid tumor has v::ntrk2, one recommended therapy is entrectinib. therapy type: targeted therapy. therapy strategy: alk inhibition + ros1 inhibition + ntrk inhibition. indication: rozlytrek as monotherapy is indicated for the treatment of adult and paediatric patients older than one month with solid tumours expressing a neurotrophic tyrosine receptor kinase (ntrk) gene fusion (i) who have a disease that is locally advanced, metastatic or where surgical resection is likely to result in severe morbidity, and (ii) who have not received a prior ntrk inhibitor, (iii) who have no satisfactory treatment options. approval url: https://www.ema.europa.eu/en/documents/product-information/rozlytrek-epar-product-information_en.pdf", "if a patient with any solid tumor has v::ntrk3, one recommended therapy is entrectinib. therapy type: targeted therapy. therapy strategy: alk inhibition + ros1 inhibition + ntrk inhibition. indication: rozlytrek as monotherapy is indicated for the treatment of adult and paediatric patients older than one month with solid tumours expressing a neurotrophic tyrosine receptor kinase (ntrk) gene fusion (i) who have a disease that is locally advanced, metastatic or where surgical resection is likely to result in severe morbidity, and (ii) who have not received a prior ntrk inhibitor, (iii) who have no satisfactory treatment options. approval url: https://www.ema.europa.eu/en/documents/product-information/rozlytrek-epar-product-information_en.pdf", "if a patient with acute myeloid leukemia has flt3-itd, one recommended therapy is midostaurin + daunorubicin + cytarabine. therapy type: targeted therapy + chemotherapy + chemotherapy. therapy strategy: flt3 inhibition + dna polymerase inhibition + dna polymerase inhibition. indication: rydapt is indicated in combination with standard daunorubicin and cytarabine induction and high-dose cytarabine consolidation chemotherapy, and for patients in complete response followed by rydapt single agent maintenance therapy, for adult patients with newly diagnosed acute myeloid leukaemia (aml) who are flt3 mutation-positive. approval url: https://www.ema.europa.eu/en/documents/product-information/rydapt-epar-product-information_en.pdf", "if a patient with chronic myelogenous leukemia has bcr::abl1, one recommended therapy is asciminib. therapy type: targeted therapy. therapy strategy: bcr-abl inhibition. indication: scemblix is indicated for the treatment of adult patients with philadelphia chromosome-positive chronic myeloid leukaemia in chronic phase (ph+ cml-cp) previously treated with two or more tyrosine kinase inhibitors. approval url: https://www.ema.europa.eu/en/documents/product-information/scemblix-epar-product-information_en.pdf", "if a patient with low-grade glioma, nos has braf p.v600e, one recommended therapy is trametinib + dabrafenib. therapy type: targeted therapy + targeted therapy. therapy strategy: mek inhibition + b-raf inhibition. indication: spexotras in combination with dabrafenib is indicated for the treatment of paediatric patients aged 1 year and older with low-grade glioma (lgg) with a braf v600e mutation who require systemic therapy. approval url: https://www.ema.europa.eu/en/documents/product-information/spexotras-epar-product-information_en.pdf", "if a patient with high-grade glioma, nos has braf p.v600e, one recommended therapy is trametinib + dabrafenib. therapy type: targeted therapy + targeted therapy. therapy strategy: mek inhibition + b-raf inhibition. indication: spexotras in combination with dabrafenib is indicated for the treatment of paediatric patients aged 1 year and older with high-grade glioma (hgg) with a braf v600e mutation who have received at least one prior radiation and/or chemotherapy treatment. approval url: https://www.ema.europa.eu/en/documents/product-information/spexotras-epar-product-information_en.pdf", "if a patient with chronic myelogenous leukemia has bcr::abl1, one recommended therapy is dasatinib. therapy type: targeted therapy. therapy strategy: bcr-abl inhibition. indication: sprycel is indicated for the treatment of adult patients with newly diagnosed philadelphia chromosome positive (ph+) chronic myelogenous leukaemia (cml) in the chronic phase. approval url: https://www.ema.europa.eu/en/documents/product-information/sprycel-epar-product-information_en.pdf", "if a patient with acute lymphoid leukemia has bcr::abl1, one recommended therapy is dasatinib. therapy type: targeted therapy. therapy strategy: bcr-abl inhibition. indication: sprycel is indicated for the treatment of adult patients with ph+ acute lymphoblastic leukaemia (all) and lymphoid blast cml with resistance or intolerance to prior therapy. approval url: https://www.ema.europa.eu/en/documents/product-information/sprycel-epar-product-information_en.pdf", "if a patient with chronic myelogenous leukemia has bcr::abl1, one recommended therapy is dasatinib. therapy type: targeted therapy. therapy strategy: bcr-abl inhibition. indication: sprycel is indicated for the treatment of adult patients with ph+ acute lymphoblastic leukaemia (all) and lymphoid blast cml with resistance or intolerance to prior therapy. approval url: https://www.ema.europa.eu/en/documents/product-information/sprycel-epar-product-information_en.pdf", "if a patient with chronic myelogenous leukemia has bcr::abl1, one recommended therapy is dasatinib. therapy type: targeted therapy. therapy strategy: bcr-abl inhibition. indication: sprycel is indicated for the treatment of paediatric patients with newly diagnosed ph+ cml in chronic phase (ph+ cml-cp) or ph+ cml-cp resistant or intolerant to prior therapy including imatinib. approval url: https://www.ema.europa.eu/en/documents/product-information/sprycel-epar-product-information_en.pdf", "if a patient with acute lymphoid leukemia has bcr::abl1, one recommended therapy is dasatinib. therapy type: targeted therapy. therapy strategy: bcr-abl inhibition. indication: sprycel is indicated for the treatment of paediatric patients with newly diagnosed ph+ all in combination with chemotherapy. approval url: https://www.ema.europa.eu/en/documents/product-information/sprycel-epar-product-information_en.pdf", "if a patient with non-small cell lung cancer has met exon 14 (splice site), one recommended therapy is capmatinib. therapy type: targeted therapy. therapy strategy: met inhibition. indication: tabrecta as monotherapy is indicated for the treatment of adult patients with advanced non-small cell lung cancer (nsclc) harbouring alterations leading to mesenchymal-epithelial transition factor gene exon 14 (metex14) skipping, who require systemic therapy following prior treatment with immunotherapy and/or platinum-based chemotherapy. approval url: https://www.ema.europa.eu/en/documents/product-information/tabrecta-epar-product-information_en.pdf", "if a patient with non-small cell lung cancer has met exon 14 (deletion), one recommended therapy is capmatinib. therapy type: targeted therapy. therapy strategy: met inhibition. indication: tabrecta as monotherapy is indicated for the treatment of adult patients with advanced non-small cell lung cancer (nsclc) harbouring alterations leading to mesenchymal-epithelial transition factor gene exon 14 (metex14) skipping, who require systemic therapy following prior treatment with immunotherapy and/or platinum-based chemotherapy. approval url: https://www.ema.europa.eu/en/documents/product-information/tabrecta-epar-product-information_en.pdf", "if a patient with melanoma has braf p.v600e, one recommended therapy is dabrafenib. therapy type: targeted therapy. therapy strategy: b-raf inhibition. indication: dabrafenib as monotherapy or in combination with trametinib is indicated for the treatment of adult patients with unresectable or metastatic melanoma with a braf v600 mutation. approval url: https://www.ema.europa.eu/en/documents/product-information/tafinlar-epar-product-information_en.pdf", "if a patient with melanoma has braf p.v600k, one recommended therapy is dabrafenib. therapy type: targeted therapy. therapy strategy: b-raf inhibition. indication: dabrafenib as monotherapy or in combination with trametinib is indicated for the treatment of adult patients with unresectable or metastatic melanoma with a braf v600 mutation. approval url: https://www.ema.europa.eu/en/documents/product-information/tafinlar-epar-product-information_en.pdf", "if a patient with melanoma has braf p.v600e, one recommended therapy is trametinib + dabrafenib. therapy type: targeted therapy + targeted therapy. therapy strategy: mek inhibition + b-raf inhibition. indication: dabrafenib as monotherapy or in combination with trametinib is indicated for the treatment of adult patients with unresectable or metastatic melanoma with a braf v600 mutation. approval url: https://www.ema.europa.eu/en/documents/product-information/tafinlar-epar-product-information_en.pdf", "if a patient with melanoma has braf p.v600k, one recommended therapy is trametinib + dabrafenib. therapy type: targeted therapy + targeted therapy. therapy strategy: mek inhibition + b-raf inhibition. indication: dabrafenib as monotherapy or in combination with trametinib is indicated for the treatment of adult patients with unresectable or metastatic melanoma with a braf v600 mutation. approval url: https://www.ema.europa.eu/en/documents/product-information/tafinlar-epar-product-information_en.pdf", "if a patient with melanoma has braf p.v600e, one recommended therapy is trametinib + dabrafenib. therapy type: targeted therapy + targeted therapy. therapy strategy: mek inhibition + b-raf inhibition. indication: dabrafenib in combination with trametinib is indicated for the adjuvant treatment of adult patients with stage iii melanoma with a braf v600 mutation, following complete resection. approval url: https://www.ema.europa.eu/en/documents/product-information/tafinlar-epar-product-information_en.pdf", "if a patient with melanoma has braf p.v600k, one recommended therapy is trametinib + dabrafenib. therapy type: targeted therapy + targeted therapy. therapy strategy: mek inhibition + b-raf inhibition. indication: dabrafenib in combination with trametinib is indicated for the adjuvant treatment of adult patients with stage iii melanoma with a braf v600 mutation, following complete resection. approval url: https://www.ema.europa.eu/en/documents/product-information/tafinlar-epar-product-information_en.pdf", "if a patient with non-small cell lung cancer has braf p.v600e, one recommended therapy is trametinib + dabrafenib. therapy type: targeted therapy + targeted therapy. therapy strategy: mek inhibition + b-raf inhibition. indication: dabrafenib in combination with trametinib is indicated for the treatment of adult patients with advanced non-small cell lung cancer with a braf v600 mutation. approval url: https://www.ema.europa.eu/en/documents/product-information/tafinlar-epar-product-information_en.pdf", "if a patient with non-small cell lung cancer has braf p.v600k, one recommended therapy is trametinib + dabrafenib. therapy type: targeted therapy + targeted therapy. therapy strategy: mek inhibition + b-raf inhibition. indication: dabrafenib in combination with trametinib is indicated for the treatment of adult patients with advanced non-small cell lung cancer with a braf v600 mutation. approval url: https://www.ema.europa.eu/en/documents/product-information/tafinlar-epar-product-information_en.pdf", "if a patient with non-small cell lung cancer has egfr exon 19 (deletion), one recommended therapy is osimertinib. therapy type: targeted therapy. therapy strategy: egfr inhibition. indication: tagrisso as monotherapy is indicated for the adjuvant treatment after complete tumour resection in adult patients with stage ib-iiia non-small cell lung cancer (nsclc) whose tumours have epidermal growth factor receptor (egfr) exon 19 deletions or exon 21 (l858r) substitution mutations. approval url: https://www.ema.europa.eu/en/documents/product-information/tagrisso-epar-product-information_en.pdf", "if a patient with non-small cell lung cancer has egfr p.l858r, one recommended therapy is osimertinib. therapy type: targeted therapy. therapy strategy: egfr inhibition. indication: tagrisso as monotherapy is indicated for the adjuvant treatment after complete tumour resection in adult patients with stage ib-iiia non-small cell lung cancer (nsclc) whose tumours have epidermal growth factor receptor (egfr) exon 19 deletions or exon 21 (l858r) substitution mutations. approval url: https://www.ema.europa.eu/en/documents/product-information/tagrisso-epar-product-information_en.pdf", "if a patient with non-small cell lung cancer has egfr oncogenic variants, one recommended therapy is osimertinib. therapy type: targeted therapy. therapy strategy: egfr inhibition. indication: tagrisso as monotherapy is indicated for the first-line treatment of adult patients with locally advanced or metastatic nsclc with activating egfr mutations. approval url: https://www.ema.europa.eu/en/documents/product-information/tagrisso-epar-product-information_en.pdf", "if a patient with non-small cell lung cancer has egfr p.t790m, one recommended therapy is osimertinib. therapy type: targeted therapy. therapy strategy: egfr inhibition. indication: tagrisso as monotherapy is indicated for the treatment of adult patients with locally advanced or metastatic egfr t790m mutation-positive nsclc. approval url: https://www.ema.europa.eu/en/documents/product-information/tagrisso-epar-product-information_en.pdf", "if a patient with non-small cell lung cancer has egfr exon 19 (deletion), one recommended therapy is osimertinib + cisplatin. therapy type: targeted therapy + chemotherapy. therapy strategy: egfr inhibition + platinum-based chemotherapy. indication: tagrisso is indicated in combination with pemetrexed and platinum-based chemotherapy for the first-line treatment of adult patients with advanced nsclc whose tumours have egfr exon 19 deletions or exon 21 (l858r) substitution mutations. approval url: https://www.ema.europa.eu/en/documents/product-information/tagrisso-epar-product-information_en.pdf", "if a patient with non-small cell lung cancer has egfr exon 19 (deletion), one recommended therapy is carboplatin + osimertinib. therapy type: chemotherapy + targeted therapy. therapy strategy: platinum-based chemotherapy + egfr inhibition. indication: tagrisso is indicated in combination with pemetrexed and platinum-based chemotherapy for the first-line treatment of adult patients with advanced nsclc whose tumours have egfr exon 19 deletions or exon 21 (l858r) substitution mutations. approval url: https://www.ema.europa.eu/en/documents/product-information/tagrisso-epar-product-information_en.pdf", "if a patient with non-small cell lung cancer has egfr p.l858r, one recommended therapy is osimertinib + cisplatin. therapy type: targeted therapy + chemotherapy. therapy strategy: egfr inhibition + platinum-based chemotherapy. indication: tagrisso is indicated in combination with pemetrexed and platinum-based chemotherapy for the first-line treatment of adult patients with advanced nsclc whose tumours have egfr exon 19 deletions or exon 21 (l858r) substitution mutations. approval url: https://www.ema.europa.eu/en/documents/product-information/tagrisso-epar-product-information_en.pdf", "if a patient with non-small cell lung cancer has egfr p.l858r, one recommended therapy is carboplatin + osimertinib. therapy type: chemotherapy + targeted therapy. therapy strategy: platinum-based chemotherapy + egfr inhibition. indication: tagrisso is indicated in combination with pemetrexed and platinum-based chemotherapy for the first-line treatment of adult patients with advanced nsclc whose tumours have egfr exon 19 deletions or exon 21 (l858r) substitution mutations. approval url: https://www.ema.europa.eu/en/documents/product-information/tagrisso-epar-product-information_en.pdf", "if a patient with locally advanced or metastatic invasive breast carcinoma has her2-negative, brca1 pathogenic variants, one recommended therapy is talazoparib. therapy type: targeted therapy. therapy strategy: parp inhibition. indication: talzenna is indicated as monotherapy for the treatment of adult patients with germline brca1/2-mutations, who have her2-negative locally advanced or metastatic breast cancer. patients should have been previously treated with an anthracycline and/or a taxane in the (neo)adjuvant, locally advanced or metastatic setting unless patients were not suitable for these treatments. patients with hormone receptor (hr)-positive breast cancer should have been treated with a prior endocrine-based therapy, or be considered unsuitable for endocrine-based therapy. approval url: https://www.ema.europa.eu/en/documents/product-information/talzenna-epar-product-information_en.pdf", "if a patient with locally advanced or metastatic invasive breast carcinoma has her2-negative, brca2 pathogenic variants, one recommended therapy is talazoparib. therapy type: targeted therapy. therapy strategy: parp inhibition. indication: talzenna is indicated as monotherapy for the treatment of adult patients with germline brca1/2-mutations, who have her2-negative locally advanced or metastatic breast cancer. patients should have been previously treated with an anthracycline and/or a taxane in the (neo)adjuvant, locally advanced or metastatic setting unless patients were not suitable for these treatments. patients with hormone receptor (hr)-positive breast cancer should have been treated with a prior endocrine-based therapy, or be considered unsuitable for endocrine-based therapy. approval url: https://www.ema.europa.eu/en/documents/product-information/talzenna-epar-product-information_en.pdf", "if a patient with non-small cell lung cancer has egfr oncogenic variants, one recommended therapy is erlotinib. therapy type: targeted therapy. therapy strategy: egfr inhibition. indication: tarceva is indicated for the first-line treatment of patients with locally advanced or metastatic non-small cell lung cancer (nsclc) with egfr activating mutations. approval url: https://www.ema.europa.eu/en/documents/product-information/tarceva-epar-product-information_en.pdf", "if a patient with non-small cell lung cancer has egfr oncogenic variants, one recommended therapy is erlotinib. therapy type: targeted therapy. therapy strategy: egfr inhibition. indication: tarceva is also indicated for switch maintenance treatment in patients with locally advanced or metastatic nsclc with egfr activating mutations and stable disease after first-line chemotherapy approval url: https://www.ema.europa.eu/en/documents/product-information/tarceva-epar-product-information_en.pdf", "if a patient with chronic myelogenous leukemia has bcr::abl1, one recommended therapy is nilotinib. therapy type: targeted therapy. therapy strategy: bcr-abl inhibition. indication: tasigna is indicated for the treatment of adult and paediatric patients with newly diagnosed philadelphia chromosome positive chronic myelogenous leukaemia (cml) in the chronic phase. approval url: https://www.ema.europa.eu/en/documents/product-information/tasigna-epar-product-information_en.pdf", "if a patient with chronic myelogenous leukemia has bcr::abl1, one recommended therapy is nilotinib. therapy type: targeted therapy. therapy strategy: bcr-abl inhibition. indication: tasigna is indicated for the treatment of adult patients with chronic phase and accelerated phase philadelphia chromosome positive cml with resistance or intolerance to prior therapy including imatinib. efficacy data in patients with cml in blast crisis are not available. approval url: https://www.ema.europa.eu/en/documents/product-information/tasigna-epar-product-information_en.pdf", "if a patient with chronic myelogenous leukemia has bcr::abl1, one recommended therapy is nilotinib. therapy type: targeted therapy. therapy strategy: bcr-abl inhibition. indication: tasigna is indicated for the treatment of paediatric patients with chronic phase philadelphia chromosome positive cml with resistance or intolerance to prior therapy including imatinib. approval url: https://www.ema.europa.eu/en/documents/product-information/tasigna-epar-product-information_en.pdf", "if a patient with bladder urothelial carcinoma has pd-l1 >= 5%, one recommended therapy is atezolizumab. therapy type: immunotherapy. therapy strategy: pd-1/pd-l1 inhibition. indication: tecentriq as monotherapy is indicated for the treatment of adult patients with locally advanced or metastatic uc (i) after prior platinum-containing chemotherapy, or (ii) who are considered cisplatin ineligible, and whose tumours have a pd-l1 expression >= 5%. approval url: https://www.ema.europa.eu/en/documents/product-information/tecentriq-epar-product-information_en.pdf", "if a patient with non-small cell lung cancer has wild type egfr, wild type alk, pd-l1 >= 50%, one recommended therapy is atezolizumab. therapy type: immunotherapy. therapy strategy: pd-1/pd-l1 inhibition. indication: tecentriq as monotherapy is indicated as adjuvant treatment following complete resection and platinum-based chemotherapy for adult patients with nsclc with a high risk of recurrence whose tumours have pd-l1 expression on >= 50% of tumour cells (tc) and who do not have egfr mutant or alk-positive nsclc. approval url: https://www.ema.europa.eu/en/documents/product-information/tecentriq-epar-product-information_en.pdf", "if a patient with non-small cell lung cancer has egfr somatic variants, one recommended therapy is carboplatin + paclitaxel + bevacizumab + atezolizumab. therapy type: chemotherapy + chemotherapy + targeted therapy + immunotherapy. therapy strategy: platinum-based chemotherapy + taxane-based chemotherapy + vegf inhibition + pd-1/pd-l1 inhibition. indication: tecentriq, in combination with bevacizumab, paclitaxel and carboplatin, is indicated for the first-line treatment of adult patients with metastatic non-squamous nsclc. in patients with egfr mutant or alk-positive nsclc, tecentriq, in combination with bevacizumab, paclitaxel and carboplatin, is indicated only after failure of appropriate targeted therapies. approval url: https://www.ema.europa.eu/en/documents/product-information/tecentriq-epar-product-information_en.pdf", "if a patient with non-small cell lung cancer has v::alk, one recommended therapy is carboplatin + paclitaxel + bevacizumab + atezolizumab. therapy type: chemotherapy + chemotherapy + targeted therapy + immunotherapy. therapy strategy: platinum-based chemotherapy + taxane-based chemotherapy + vegf inhibition + pd-1/pd-l1 inhibition. indication: tecentriq, in combination with bevacizumab, paclitaxel and carboplatin, is indicated for the first-line treatment of adult patients with metastatic non-squamous nsclc. in patients with egfr mutant or alk-positive nsclc, tecentriq, in combination with bevacizumab, paclitaxel and carboplatin, is indicated only after failure of appropriate targeted therapies. approval url: https://www.ema.europa.eu/en/documents/product-information/tecentriq-epar-product-information_en.pdf", "if a patient with non-small cell lung cancer has wild type egfr, one recommended therapy is carboplatin + nab-paclitaxel + atezolizumab. therapy type: chemotherapy + chemotherapy + immunotherapy. therapy strategy: platinum-based chemotherapy + taxane-based chemotherapy + pd-1/pd-l1 inhibition. indication: tecentriq, in combination with nab-paclitaxel and carboplatin, is indicated for the first-line treatment of adult patients with metastatic non-squamous nsclc who do not have egfr mutant or alk-positive nsclc. approval url: https://www.ema.europa.eu/en/documents/product-information/tecentriq-epar-product-information_en.pdf", "if a patient with non-small cell lung cancer has wild type alk, one recommended therapy is carboplatin + nab-paclitaxel + atezolizumab. therapy type: chemotherapy + chemotherapy + immunotherapy. therapy strategy: platinum-based chemotherapy + taxane-based chemotherapy + pd-1/pd-l1 inhibition. indication: tecentriq, in combination with nab-paclitaxel and carboplatin, is indicated for the first-line treatment of adult patients with metastatic non-squamous nsclc who do not have egfr mutant or alk-positive nsclc. approval url: https://www.ema.europa.eu/en/documents/product-information/tecentriq-epar-product-information_en.pdf", "if a patient with non-small cell lung cancer has wild type egfr, wild type alk, one recommended therapy is carboplatin + nab-paclitaxel + atezolizumab. therapy type: chemotherapy + chemotherapy + immunotherapy. therapy strategy: platinum-based chemotherapy + taxane-based chemotherapy + pd-1/pd-l1 inhibition. indication: tecentriq, in combination with nab-paclitaxel and carboplatin, is indicated for the first-line treatment of adult patients with metastatic non-squamous nsclc who do not have egfr mutant or alk-positive nsclc. approval url: https://www.ema.europa.eu/en/documents/product-information/tecentriq-epar-product-information_en.pdf", "if a patient with non-small cell lung cancer has wild type egfr, wild type alk, pd-l1 >= 50%, one recommended therapy is atezolizumab. therapy type: immunotherapy. therapy strategy: pd-1/pd-l1 inhibition. indication: tecentriq as monotherapy is indicated for the first-line treatment of adult patients with metastatic nsclc whose tumours have a pd-l1 expression >= 50% tc or >= 10% tumour-infiltrating immune cells (ic) and who do not have egfr mutant or alk-positive nsclc. approval url: https://www.ema.europa.eu/en/documents/product-information/tecentriq-epar-product-information_en.pdf", "if a patient with non-small cell lung cancer has wild type egfr, wild type alk, pd-l1 >= 10% tiic, one recommended therapy is atezolizumab. therapy type: immunotherapy. therapy strategy: pd-1/pd-l1 inhibition. indication: tecentriq as monotherapy is indicated for the first-line treatment of adult patients with metastatic nsclc whose tumours have a pd-l1 expression >= 50% tc or >= 10% tumour-infiltrating immune cells (ic) and who do not have egfr mutant or alk-positive nsclc. approval url: https://www.ema.europa.eu/en/documents/product-information/tecentriq-epar-product-information_en.pdf", "if a patient with non-small cell lung cancer has egfr somatic variants, one recommended therapy is atezolizumab. therapy type: immunotherapy. therapy strategy: pd-1/pd-l1 inhibition. indication: tecentriq as monotherapy is indicated for the treatment of adult patients with locally advanced or metastatic nsclc after prior chemotherapy. patients with egfr mutant or alk-positive nsclc should also have received targeted therapies before receiving tecentriq. approval url: https://www.ema.europa.eu/en/documents/product-information/tecentriq-epar-product-information_en.pdf", "if a patient with non-small cell lung cancer has v::alk, one recommended therapy is atezolizumab. therapy type: immunotherapy. therapy strategy: pd-1/pd-l1 inhibition. indication: tecentriq as monotherapy is indicated for the treatment of adult patients with locally advanced or metastatic nsclc after prior chemotherapy. patients with egfr mutant or alk-positive nsclc should also have received targeted therapies before receiving tecentriq. approval url: https://www.ema.europa.eu/en/documents/product-information/tecentriq-epar-product-information_en.pdf", "if a patient with invasive breast carcinoma has er negative, pr negative, pd-l1 >= 1%, her2-negative, one recommended therapy is nab-paclitaxel + atezolizumab. therapy type: chemotherapy + immunotherapy. therapy strategy: taxane-based chemotherapy + pd-1/pd-l1 inhibition. indication: tecentriq in combination with nab-paclitaxel is indicated for the treatment of adult patients with unresectable locally advanced or metastatic tnbc whose tumours have pd-l1 expression >= 1% and who have not received prior chemotherapy for metastatic disease. approval url: https://www.ema.europa.eu/en/documents/product-information/tecentriq-epar-product-information_en.pdf", "if a patient with non-small cell lung cancer has met exon 14 (splice site), one recommended therapy is tepotinib. therapy type: targeted therapy. therapy strategy: met inhibition. indication: tepmetko as monotherapy is indicated for the treatment of adult patients with advanced non-small cell lung cancer (nsclc) harbouring alterations leading to mesenchymal-epithelial transition factor gene exon 14 (metex14) skipping, who require systemic therapy following prior treatment with immunotherapy and/or platinum-based chemotherapy. approval url: https://www.ema.europa.eu/en/documents/product-information/tepmetko-epar-product-information_en.pdf", "if a patient with non-small cell lung cancer has met exon 14 (deletion), one recommended therapy is tepotinib. therapy type: targeted therapy. therapy strategy: met inhibition. indication: tepmetko as monotherapy is indicated for the treatment of adult patients with advanced non-small cell lung cancer (nsclc) harbouring alterations leading to mesenchymal-epithelial transition factor gene exon 14 (metex14) skipping, who require systemic therapy following prior treatment with immunotherapy and/or platinum-based chemotherapy. approval url: https://www.ema.europa.eu/en/documents/product-information/tepmetko-epar-product-information_en.pdf", "if a patient with acute myeloid leukemia has idh1 p.r132c, one recommended therapy is ivosidenib + azacitidine. therapy type: targeted therapy + chemotherapy. therapy strategy: idh1 inhibition + hypomethylating agent chemotherapy. indication: tibsovo in combination with azacitidine is indicated for the treatment of adult patients with newly diagnosed acute myeloid leukaemia (aml) with an isocitrate dehydrogenase-1 (idh1) r132 mutation who are not eligible to receive standard induction chemotherapy. approval url: https://www.ema.europa.eu/en/documents/product-information/tibsovo-epar-product-information_en.pdf", "if a patient with acute myeloid leukemia has idh1 p.r132g, one recommended therapy is ivosidenib + azacitidine. therapy type: targeted therapy + chemotherapy. therapy strategy: idh1 inhibition + hypomethylating agent chemotherapy. indication: tibsovo in combination with azacitidine is indicated for the treatment of adult patients with newly diagnosed acute myeloid leukaemia (aml) with an isocitrate dehydrogenase-1 (idh1) r132 mutation who are not eligible to receive standard induction chemotherapy. approval url: https://www.ema.europa.eu/en/documents/product-information/tibsovo-epar-product-information_en.pdf", "if a patient with acute myeloid leukemia has idh1 p.r132h, one recommended therapy is ivosidenib + azacitidine. therapy type: targeted therapy + chemotherapy. therapy strategy: idh1 inhibition + hypomethylating agent chemotherapy. indication: tibsovo in combination with azacitidine is indicated for the treatment of adult patients with newly diagnosed acute myeloid leukaemia (aml) with an isocitrate dehydrogenase-1 (idh1) r132 mutation who are not eligible to receive standard induction chemotherapy. approval url: https://www.ema.europa.eu/en/documents/product-information/tibsovo-epar-product-information_en.pdf", "if a patient with acute myeloid leukemia has idh1 p.r132l, one recommended therapy is ivosidenib + azacitidine. therapy type: targeted therapy + chemotherapy. therapy strategy: idh1 inhibition + hypomethylating agent chemotherapy. indication: tibsovo in combination with azacitidine is indicated for the treatment of adult patients with newly diagnosed acute myeloid leukaemia (aml) with an isocitrate dehydrogenase-1 (idh1) r132 mutation who are not eligible to receive standard induction chemotherapy. approval url: https://www.ema.europa.eu/en/documents/product-information/tibsovo-epar-product-information_en.pdf", "if a patient with acute myeloid leukemia has idh1 p.r132s, one recommended therapy is ivosidenib + azacitidine. therapy type: targeted therapy + chemotherapy. therapy strategy: idh1 inhibition + hypomethylating agent chemotherapy. indication: tibsovo in combination with azacitidine is indicated for the treatment of adult patients with newly diagnosed acute myeloid leukaemia (aml) with an isocitrate dehydrogenase-1 (idh1) r132 mutation who are not eligible to receive standard induction chemotherapy. approval url: https://www.ema.europa.eu/en/documents/product-information/tibsovo-epar-product-information_en.pdf", "if a patient with cholangiocarcinoma has idh1 p.r132c, one recommended therapy is ivosidenib. therapy type: targeted therapy. therapy strategy: idh1 inhibition. indication: tibsovo monotherapy is indicated for the treatment of adult patients with locally advanced or metastatic cholangiocarcinoma with an idh1 r132 mutation who were previously treated by at least one prior line of systemic therapy. approval url: https://www.ema.europa.eu/en/documents/product-information/tibsovo-epar-product-information_en.pdf", "if a patient with cholangiocarcinoma has idh1 p.r132g, one recommended therapy is ivosidenib. therapy type: targeted therapy. therapy strategy: idh1 inhibition. indication: tibsovo monotherapy is indicated for the treatment of adult patients with locally advanced or metastatic cholangiocarcinoma with an idh1 r132 mutation who were previously treated by at least one prior line of systemic therapy. approval url: https://www.ema.europa.eu/en/documents/product-information/tibsovo-epar-product-information_en.pdf", "if a patient with cholangiocarcinoma has idh1 p.r132h, one recommended therapy is ivosidenib. therapy type: targeted therapy. therapy strategy: idh1 inhibition. indication: tibsovo monotherapy is indicated for the treatment of adult patients with locally advanced or metastatic cholangiocarcinoma with an idh1 r132 mutation who were previously treated by at least one prior line of systemic therapy. approval url: https://www.ema.europa.eu/en/documents/product-information/tibsovo-epar-product-information_en.pdf", "if a patient with cholangiocarcinoma has idh1 p.r132l, one recommended therapy is ivosidenib. therapy type: targeted therapy. therapy strategy: idh1 inhibition. indication: tibsovo monotherapy is indicated for the treatment of adult patients with locally advanced or metastatic cholangiocarcinoma with an idh1 r132 mutation who were previously treated by at least one prior line of systemic therapy. approval url: https://www.ema.europa.eu/en/documents/product-information/tibsovo-epar-product-information_en.pdf", "if a patient with cholangiocarcinoma has idh1 p.r132s, one recommended therapy is ivosidenib. therapy type: targeted therapy. therapy strategy: idh1 inhibition. indication: tibsovo monotherapy is indicated for the treatment of adult patients with locally advanced or metastatic cholangiocarcinoma with an idh1 r132 mutation who were previously treated by at least one prior line of systemic therapy. approval url: https://www.ema.europa.eu/en/documents/product-information/tibsovo-epar-product-information_en.pdf", "if a patient with non-small cell lung cancer has wild type egfr, wild type alk, one recommended therapy is tremelimumab + carboplatin + durvalumab + pemetrexed. therapy type: immunotherapy + chemotherapy + immunotherapy + chemotherapy. therapy strategy: ctla-4 inhibition + platinum-based chemotherapy + pd-1/pd-l1 inhibition + antifolate. indication: tremelimumab astrazeneca in combination with durvalumab and platinum-based chemotherapy is indicated for the first-line treatment of adults with metastatic non-small cell lung cancer (nsclc) with no sensitising egfr mutations or alk positive mutations. approval url: https://www.ema.europa.eu/en/documents/product-information/tremelimumab-astrazeneca-epar-product-information_en.pdf", "if a patient with non-small cell lung cancer has wild type egfr, wild type alk, one recommended therapy is tremelimumab + durvalumab + pemetrexed + cisplatin. therapy type: immunotherapy + immunotherapy + chemotherapy + chemotherapy. therapy strategy: ctla-4 inhibition + pd-1/pd-l1 inhibition + antifolate + platinum-based chemotherapy. indication: tremelimumab astrazeneca in combination with durvalumab and platinum-based chemotherapy is indicated for the first-line treatment of adults with metastatic non-small cell lung cancer (nsclc) with no sensitising egfr mutations or alk positive mutations. approval url: https://www.ema.europa.eu/en/documents/product-information/tremelimumab-astrazeneca-epar-product-information_en.pdf", "if a patient with non-small cell lung cancer has wild type egfr, wild type alk, one recommended therapy is tremelimumab + durvalumab + gemcitabine + cisplatin. therapy type: immunotherapy + immunotherapy + chemotherapy + chemotherapy. therapy strategy: ctla-4 inhibition + pd-1/pd-l1 inhibition + antimetabolite + platinum-based chemotherapy. indication: tremelimumab astrazeneca in combination with durvalumab and platinum-based chemotherapy is indicated for the first-line treatment of adults with metastatic non-small cell lung cancer (nsclc) with no sensitising egfr mutations or alk positive mutations. approval url: https://www.ema.europa.eu/en/documents/product-information/tremelimumab-astrazeneca-epar-product-information_en.pdf", "if a patient with non-small cell lung cancer has wild type egfr, wild type alk, one recommended therapy is tremelimumab + carboplatin + durvalumab + gemcitabine. therapy type: immunotherapy + chemotherapy + immunotherapy + chemotherapy. therapy strategy: ctla-4 inhibition + platinum-based chemotherapy + pd-1/pd-l1 inhibition + antimetabolite. indication: tremelimumab astrazeneca in combination with durvalumab and platinum-based chemotherapy is indicated for the first-line treatment of adults with metastatic non-small cell lung cancer (nsclc) with no sensitising egfr mutations or alk positive mutations. approval url: https://www.ema.europa.eu/en/documents/product-information/tremelimumab-astrazeneca-epar-product-information_en.pdf", "if a patient with non-small cell lung cancer has wild type egfr, wild type alk, one recommended therapy is tremelimumab + carboplatin + durvalumab + nab-paclitaxel. therapy type: immunotherapy + chemotherapy + immunotherapy + chemotherapy. therapy strategy: ctla-4 inhibition + platinum-based chemotherapy + pd-1/pd-l1 inhibition + taxane-based chemotherapy. indication: tremelimumab astrazeneca in combination with durvalumab and platinum-based chemotherapy is indicated for the first-line treatment of adults with metastatic non-small cell lung cancer (nsclc) with no sensitising egfr mutations or alk positive mutations. approval url: https://www.ema.europa.eu/en/documents/product-information/tremelimumab-astrazeneca-epar-product-information_en.pdf", "if a patient with apl with pml-rara has pml::rara, one recommended therapy is arsenic trioxide. therapy type: targeted therapy. therapy strategy: pml::rara inhibition. indication: risenox is indicated for induction of remission, and consolidation in adult patients with either newly diagnosed low-to-intermediate risk acute promyelocytic leukemia (apl) (white blood cell count, <= 10 x 10^3 / ul) in combination with all-trans-retinoic acid (atra) or relapsed / refractory acute promyelocytic leukemia (apl) (previous treatment should have included a retinoid and chemotherapy). both contexts should be characterized by the presence of the t(15;17) translocation and/or the presence of the promyelocytic leukemia / retinoic-acid-receptor-alpha (pml/rar-alpha) gene. approval url: https://www.ema.europa.eu/en/documents/product-information/trisenox-epar-product-information_en.pdf", "if a patient with unresectable or metastatic invasive breast carcinoma has er negative, pr negative, her2-negative, one recommended therapy is sacituzumab govitecan. therapy type: targeted therapy. therapy strategy: topoisomerase inhibition. indication: trodelvy as monotherapy is indicated for the treatment of adult patients with unresectable or metastatic triple-negative breast cancer (mtnbc) who have received two or more prior systemic therapies, including at least one of them for advanced disease. approval url: https://www.ema.europa.eu/en/documents/product-information/trodelvy-epar-product-information_en.pdf", "if a patient with invasive breast carcinoma has her2-negative, er positive, one recommended therapy is sacituzumab govitecan. therapy type: targeted therapy. therapy strategy: topoisomerase inhibition. indication: trodelvy as monotherapy is indicated for the treatment of adult patients with unresectable or metastatic hormone receptor (hr)-positive, her2-negative breast cancer who have received endocrine-based therapy, and at least two additional systemic therapies in the advanced setting. approval url: https://www.ema.europa.eu/en/documents/product-information/trodelvy-epar-product-information_en.pdf", "if a patient with invasive breast carcinoma has pr positive, her2-negative, one recommended therapy is sacituzumab govitecan. therapy type: targeted therapy. therapy strategy: topoisomerase inhibition. indication: trodelvy as monotherapy is indicated for the treatment of adult patients with unresectable or metastatic hormone receptor (hr)-positive, her2-negative breast cancer who have received endocrine-based therapy, and at least two additional systemic therapies in the advanced setting. approval url: https://www.ema.europa.eu/en/documents/product-information/trodelvy-epar-product-information_en.pdf", "if a patient with invasive breast carcinoma has pr positive, her2-negative, er positive, one recommended therapy is sacituzumab govitecan. therapy type: targeted therapy. therapy strategy: topoisomerase inhibition. indication: trodelvy as monotherapy is indicated for the treatment of adult patients with unresectable or metastatic hormone receptor (hr)-positive, her2-negative breast cancer who have received endocrine-based therapy, and at least two additional systemic therapies in the advanced setting. approval url: https://www.ema.europa.eu/en/documents/product-information/trodelvy-epar-product-information_en.pdf", "if a patient with locally advanced or metastatic invasive breast carcinoma has her2-positive, one recommended therapy is trastuzumab + capecitabine + tucatinib. therapy type: targeted therapy + chemotherapy + targeted therapy. therapy strategy: her2 inhibition + thymidylate synthase inhibition + her2 inhibition. indication: tukysa is indicated in combination with trastuzumab and capecitabine for the treatment of adult patients with her2-positive locally advanced or metastatic breast cancer who have received at least 2 prior anti-her2 treatment regimens. approval url: https://www.ema.europa.eu/en/documents/product-information/tukysa-epar-product-information_en.pdf", "if a patient with invasive breast carcinoma has her2-positive, one recommended therapy is lapatinib + capecitabine. therapy type: targeted therapy + chemotherapy. therapy strategy: her2 inhibition + thymidylate synthase inhibition. indication: tyverb is indicated for the treatment of adult patients with breast cancer, whose tumours overexpress her2 (erbb2) in combination with capecitabine for patients with advanced or metastatic disease with progression following prior therapy, which must have included anthracyclines and taxanes and therapy with trastuzumab in the metastatic setting. approval url: https://www.ema.europa.eu/en/documents/product-information/tyverb-epar-product-information_en.pdf", "if a patient with invasive breast carcinoma has her2-positive, pr negative, er positive, one recommended therapy is trastuzumab + lapatinib. therapy type: targeted therapy + targeted therapy. therapy strategy: her2 inhibition + her2 inhibition. indication: tyverb is indicated for the treatment of adult patients with breast cancer, whose tumours overexpress her2 (erbb2) in combination with trastuzumab for patients with hormone receptor-negative metastatic disease that has progressed on prior trastuzumab therapy(ies) in combination with chemotherapy. approval url: https://www.ema.europa.eu/en/documents/product-information/tyverb-epar-product-information_en.pdf", "if a patient with invasive breast carcinoma has her2-positive, pr positive, er positive, one recommended therapy is lapatinib + letrozole. therapy type: targeted therapy + hormone therapy. therapy strategy: her2 inhibition + aromatase inhibition. indication: tyverb is indicated for the treatment of adult patients with breast cancer, whose tumours overexpress her2 (erbb2) in combination with an aromatase inhibitor for postmenopausal women with hormone receptor positive metastatic disease, not currently intended for chemotherapy. the patients in the registration study were not previously treated with trastuzumab or an aromatase inhibitor. no data are available on the efficacy of this combination relative to trastuzumab in combination with an aromatase inhibitor in this patient population. approval url: https://www.ema.europa.eu/en/documents/product-information/tyverb-epar-product-information_en.pdf", "if a patient with invasive breast carcinoma has erbb2 amplification, one recommended therapy is lapatinib + capecitabine. therapy type: targeted therapy + chemotherapy. therapy strategy: her2 inhibition + thymidylate synthase inhibition. indication: tyverb is indicated for the treatment of adult patients with breast cancer, whose tumours overexpress her2 (erbb2) in combination with capecitabine for patients with advanced or metastatic disease with progression following prior therapy, which must have included anthracyclines and taxanes and therapy with trastuzumab in the metastatic setting. approval url: https://www.ema.europa.eu/en/documents/product-information/tyverb-epar-product-information_en.pdf", "if a patient with invasive breast carcinoma has pr negative, er positive, erbb2 amplification, one recommended therapy is trastuzumab + lapatinib. therapy type: targeted therapy + targeted therapy. therapy strategy: her2 inhibition + her2 inhibition. indication: tyverb is indicated for the treatment of adult patients with breast cancer, whose tumours overexpress her2 (erbb2) in combination with trastuzumab for patients with hormone receptor-negative metastatic disease that has progressed on prior trastuzumab therapy(ies) in combination with chemotherapy. approval url: https://www.ema.europa.eu/en/documents/product-information/tyverb-epar-product-information_en.pdf", "if a patient with invasive breast carcinoma has pr positive, er positive, erbb2 amplification, one recommended therapy is lapatinib + letrozole. therapy type: targeted therapy + hormone therapy. therapy strategy: her2 inhibition + aromatase inhibition. indication: tyverb is indicated for the treatment of adult patients with breast cancer, whose tumours overexpress her2 (erbb2) in combination with an aromatase inhibitor for postmenopausal women with hormone receptor positive metastatic disease, not currently intended for chemotherapy. the patients in the registration study were not previously treated with trastuzumab or an aromatase inhibitor. no data are available on the efficacy of this combination relative to trastuzumab in combination with an aromatase inhibitor in this patient population. approval url: https://www.ema.europa.eu/en/documents/product-information/tyverb-epar-product-information_en.pdf", "if a patient with colorectal adenocarcinoma has wild type kras, wild type nras, one recommended therapy is panitumumab + oxaliplatin + fluorouracil. therapy type: targeted therapy + chemotherapy + chemotherapy. therapy strategy: egfr inhibition + platinum-based chemotherapy + thymidylate synthase inhibition. indication: vectibix is indicated for the treatment of adult patients with wild-type ras metastatic colorectal cancer (mcrc) in first-line in combination with folfox or folfiri. approval url: https://www.ema.europa.eu/en/documents/product-information/vectibix-epar-product-information_en.pdf", "if a patient with colorectal adenocarcinoma has wild type kras, wild type nras, one recommended therapy is panitumumab + fluorouracil + irinotecan. therapy type: targeted therapy + chemotherapy + chemotherapy. therapy strategy: egfr inhibition + thymidylate synthase inhibition + topoisomerase i inhibition. indication: vectibix is indicated for the treatment of adult patients with wild-type ras metastatic colorectal cancer (mcrc) in first-line in combination with folfox or folfiri. approval url: https://www.ema.europa.eu/en/documents/product-information/vectibix-epar-product-information_en.pdf", "if a patient with colorectal adenocarcinoma has wild type kras, wild type nras, one recommended therapy is panitumumab + fluorouracil + irinotecan. therapy type: targeted therapy + chemotherapy + chemotherapy. therapy strategy: egfr inhibition + thymidylate synthase inhibition + topoisomerase i inhibition. indication: vectibix is indicated for the treatment of adult patients with wild-type ras metastatic colorectal cancer (mcrc) in second-line in combination with folfiri for patients who have received first-line fluoropyrimidine-based chemotherapy (excluding irinotecan). approval url: https://www.ema.europa.eu/en/documents/product-information/vectibix-epar-product-information_en.pdf", "if a patient with colorectal adenocarcinoma has wild type kras, wild type nras, one recommended therapy is panitumumab. therapy type: targeted therapy. therapy strategy: egfr inhibition. indication: vectibix is indicated for the treatment of adult patients with wild-type ras metastatic colorectal cancer (mcrc) as monotherapy after failure of fluoropyrimidine-, oxaliplatin-, and irinotecan-containing chemotherapy regimens. approval url: https://www.ema.europa.eu/en/documents/product-information/vectibix-epar-product-information_en.pdf", "if a patient with chronic lymphocytic leukemia has tp53 somatic variants, one recommended therapy is venetoclax. therapy type: targeted therapy. therapy strategy: bcl2 inhibition. indication: venclyxto monotherapy is indicated for the treatment of cll in the presence of 17p deletion or tp53 mutation in adult patients who are unsuitable for or have failed a b-cell receptor pathway inhibitor. approval url: https://www.ema.europa.eu/en/documents/product-information/venclyxto-epar-product-information_en.pdf", "if a patient with chronic lymphocytic leukemia has tp53 deletion, one recommended therapy is venetoclax. therapy type: targeted therapy. therapy strategy: bcl2 inhibition. indication: venclyxto monotherapy is indicated for the treatment of cll in the presence of 17p deletion or tp53 mutation in adult patients who are unsuitable for or have failed a b-cell receptor pathway inhibitor. approval url: https://www.ema.europa.eu/en/documents/product-information/venclyxto-epar-product-information_en.pdf", "if a patient with chronic lymphocytic leukemia has 17p deletion, one recommended therapy is venetoclax. therapy type: targeted therapy. therapy strategy: bcl2 inhibition. indication: venclyxto monotherapy is indicated for the treatment of cll in the presence of 17p deletion or tp53 mutation in adult patients who are unsuitable for or have failed a b-cell receptor pathway inhibitor. approval url: https://www.ema.europa.eu/en/documents/product-information/venclyxto-epar-product-information_en.pdf", "if a patient with chronic lymphocytic leukemia has wild type tp53, one recommended therapy is venetoclax. therapy type: targeted therapy. therapy strategy: bcl2 inhibition. indication: venclyxto monotherapy is indicated for the treatment of cll in the absence of 17p deletion or tp53 mutation in adult patients who have failed chemoimmunotherapy and a b-cell receptor pathway inhibitor. approval url: https://www.ema.europa.eu/en/documents/product-information/venclyxto-epar-product-information_en.pdf", "if a patient with chronic lymphocytic leukemia has 17p deletion, one recommended therapy is venetoclax. therapy type: targeted therapy. therapy strategy: bcl2 inhibition. indication: venclyxto monotherapy is indicated for the treatment of cll in the absence of 17p deletion or tp53 mutation in adult patients who have failed chemoimmunotherapy and a b-cell receptor pathway inhibitor. approval url: https://www.ema.europa.eu/en/documents/product-information/venclyxto-epar-product-information_en.pdf", "if a patient with locally advanced or metastatic invasive breast carcinoma has her2-negative, er positive, one recommended therapy is anastrozole + abemaciclib. therapy type: hormone therapy + targeted therapy. therapy strategy: aromatase inhibition + cdk4/6 inhibition. indication: verzenios is indicated for the treatment of women with hormone receptor (hr)-positive, human epidermal growth factor receptor 2 (her2)-negative locally advanced or metastatic breast cancer in combination with an aromatase inhibitor or fulvestrant as initial endocrine-based therapy, or in women who have received prior endocrine therapy. approval url: https://www.ema.europa.eu/en/documents/product-information/verzenios-epar-product-information_en.pdf", "if a patient with locally advanced or metastatic invasive breast carcinoma has pr positive, her2-negative, one recommended therapy is anastrozole + abemaciclib. therapy type: hormone therapy + targeted therapy. therapy strategy: aromatase inhibition + cdk4/6 inhibition. indication: verzenios is indicated for the treatment of women with hormone receptor (hr)-positive, human epidermal growth factor receptor 2 (her2)-negative locally advanced or metastatic breast cancer in combination with an aromatase inhibitor or fulvestrant as initial endocrine-based therapy, or in women who have received prior endocrine therapy. approval url: https://www.ema.europa.eu/en/documents/product-information/verzenios-epar-product-information_en.pdf", "if a patient with locally advanced or metastatic invasive breast carcinoma has pr positive, her2-negative, er positive, one recommended therapy is anastrozole + abemaciclib. therapy type: hormone therapy + targeted therapy. therapy strategy: aromatase inhibition + cdk4/6 inhibition. indication: verzenios is indicated for the treatment of women with hormone receptor (hr)-positive, human epidermal growth factor receptor 2 (her2)-negative locally advanced or metastatic breast cancer in combination with an aromatase inhibitor or fulvestrant as initial endocrine-based therapy, or in women who have received prior endocrine therapy. approval url: https://www.ema.europa.eu/en/documents/product-information/verzenios-epar-product-information_en.pdf", "if a patient with locally advanced or metastatic invasive breast carcinoma has her2-negative, er positive, one recommended therapy is abemaciclib + letrozole. therapy type: targeted therapy + hormone therapy. therapy strategy: cdk4/6 inhibition + aromatase inhibition. indication: verzenios is indicated for the treatment of women with hormone receptor (hr)-positive, human epidermal growth factor receptor 2 (her2)-negative locally advanced or metastatic breast cancer in combination with an aromatase inhibitor or fulvestrant as initial endocrine-based therapy, or in women who have received prior endocrine therapy. approval url: https://www.ema.europa.eu/en/documents/product-information/verzenios-epar-product-information_en.pdf", "if a patient with locally advanced or metastatic invasive breast carcinoma has pr positive, her2-negative, one recommended therapy is abemaciclib + letrozole. therapy type: targeted therapy + hormone therapy. therapy strategy: cdk4/6 inhibition + aromatase inhibition. indication: verzenios is indicated for the treatment of women with hormone receptor (hr)-positive, human epidermal growth factor receptor 2 (her2)-negative locally advanced or metastatic breast cancer in combination with an aromatase inhibitor or fulvestrant as initial endocrine-based therapy, or in women who have received prior endocrine therapy. approval url: https://www.ema.europa.eu/en/documents/product-information/verzenios-epar-product-information_en.pdf", "if a patient with locally advanced or metastatic invasive breast carcinoma has pr positive, her2-negative, er positive, one recommended therapy is abemaciclib + letrozole. therapy type: targeted therapy + hormone therapy. therapy strategy: cdk4/6 inhibition + aromatase inhibition. indication: verzenios is indicated for the treatment of women with hormone receptor (hr)-positive, human epidermal growth factor receptor 2 (her2)-negative locally advanced or metastatic breast cancer in combination with an aromatase inhibitor or fulvestrant as initial endocrine-based therapy, or in women who have received prior endocrine therapy. approval url: https://www.ema.europa.eu/en/documents/product-information/verzenios-epar-product-information_en.pdf", "if a patient with locally advanced or metastatic invasive breast carcinoma has her2-negative, er positive, one recommended therapy is fulvestrant + abemaciclib. therapy type: hormone therapy + targeted therapy. therapy strategy: estrogen receptor inhibition + cdk4/6 inhibition. indication: verzenios is indicated for the treatment of women with hormone receptor (hr)-positive, human epidermal growth factor receptor 2 (her2)-negative locally advanced or metastatic breast cancer in combination with an aromatase inhibitor or fulvestrant as initial endocrine-based therapy, or in women who have received prior endocrine therapy. approval url: https://www.ema.europa.eu/en/documents/product-information/verzenios-epar-product-information_en.pdf", "if a patient with locally advanced or metastatic invasive breast carcinoma has pr positive, her2-negative, one recommended therapy is fulvestrant + abemaciclib. therapy type: hormone therapy + targeted therapy. therapy strategy: estrogen receptor inhibition + cdk4/6 inhibition. indication: verzenios is indicated for the treatment of women with hormone receptor (hr)-positive, human epidermal growth factor receptor 2 (her2)-negative locally advanced or metastatic breast cancer in combination with an aromatase inhibitor or fulvestrant as initial endocrine-based therapy, or in women who have received prior endocrine therapy. approval url: https://www.ema.europa.eu/en/documents/product-information/verzenios-epar-product-information_en.pdf", "if a patient with locally advanced or metastatic invasive breast carcinoma has pr positive, her2-negative, er positive, one recommended therapy is fulvestrant + abemaciclib. therapy type: hormone therapy + targeted therapy. therapy strategy: estrogen receptor inhibition + cdk4/6 inhibition. indication: verzenios is indicated for the treatment of women with hormone receptor (hr)-positive, human epidermal growth factor receptor 2 (her2)-negative locally advanced or metastatic breast cancer in combination with an aromatase inhibitor or fulvestrant as initial endocrine-based therapy, or in women who have received prior endocrine therapy. approval url: https://www.ema.europa.eu/en/documents/product-information/verzenios-epar-product-information_en.pdf", "if a patient with any solid tumor has v::ntrk1, one recommended therapy is larotrectinib. therapy type: targeted therapy. therapy strategy: ntrk inhibition. indication: vitrakvi as monotherapy is indicated for the treatment of adult and paediatric patients with solid tumours that display a neurotrophic tyrosine receptor kinase (ntrk) gene fusion, who have a disease that is locally advanced, metastatic or where surgical resection is likely to result in severe morbidity, and who have no satisfactory treatment options. approval url: https://www.ema.europa.eu/en/documents/product-information/vitrakvi-epar-product-information_en.pdf", "if a patient with any solid tumor has v::ntrk2, one recommended therapy is larotrectinib. therapy type: targeted therapy. therapy strategy: ntrk inhibition. indication: vitrakvi as monotherapy is indicated for the treatment of adult and paediatric patients with solid tumours that display a neurotrophic tyrosine receptor kinase (ntrk) gene fusion, who have a disease that is locally advanced, metastatic or where surgical resection is likely to result in severe morbidity, and who have no satisfactory treatment options. approval url: https://www.ema.europa.eu/en/documents/product-information/vitrakvi-epar-product-information_en.pdf", "if a patient with any solid tumor has v::ntrk3, one recommended therapy is larotrectinib. therapy type: targeted therapy. therapy strategy: ntrk inhibition. indication: vitrakvi as monotherapy is indicated for the treatment of adult and paediatric patients with solid tumours that display a neurotrophic tyrosine receptor kinase (ntrk) gene fusion, who have a disease that is locally advanced, metastatic or where surgical resection is likely to result in severe morbidity, and who have no satisfactory treatment options. approval url: https://www.ema.europa.eu/en/documents/product-information/vitrakvi-epar-product-information_en.pdf", "if a patient with non-small cell lung cancer has egfr oncogenic variants, one recommended therapy is dacomitinib. therapy type: targeted therapy. therapy strategy: egfr inhibition. indication: vizimpro, as monotherapy, is indicated for the first-line treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (nsclc) with epidermal growth factor receptor (egfr)-activating mutations. approval url: https://www.ema.europa.eu/en/documents/product-information/vizimpro-epar-product-information_en.pdf", "if a patient with non-small cell lung cancer has v::alk, one recommended therapy is crizotinib. therapy type: targeted therapy. therapy strategy: alk inhibition + met inhibition + ros1 inhibition. indication: xalkori as monotherapy is indicated for the first-line treatment of adults with anaplastic lymphoma kinase (alk)-positive advanced non-small cell lung cancer (nsclc). approval url: https://www.ema.europa.eu/en/documents/product-information/xalkori-epar-product-information_en.pdf", "if a patient with non-small cell lung cancer has v::alk, one recommended therapy is crizotinib. therapy type: targeted therapy. therapy strategy: alk inhibition + met inhibition + ros1 inhibition. indication: xalkori as monotherapy is indicated for the treatment of adults with previously treated anaplastic lymphoma kinase (alk)-positive advanced non-small cell lung cancer (nsclc). approval url: https://www.ema.europa.eu/en/documents/product-information/xalkori-epar-product-information_en.pdf", "if a patient with non-small cell lung cancer has v::ros1, one recommended therapy is crizotinib. therapy type: targeted therapy. therapy strategy: alk inhibition + met inhibition + ros1 inhibition. indication: xalkori as monotherapy is indicated for the treatment of adults with ros1-positive advanced non-small cell lung cancer (nsclc). approval url: https://www.ema.europa.eu/en/documents/product-information/xalkori-epar-product-information_en.pdf", "if a patient with anaplastic large cell lymphoma has v::alk, one recommended therapy is crizotinib. therapy type: targeted therapy. therapy strategy: alk inhibition + met inhibition + ros1 inhibition. indication: xalkori as monotherapy is indicated for the treatment of paediatric patients (age >= 1 to <18 years) with relapsed or refractory systemic anaplastic lymphoma kinase (alk)-positive anaplastic large cell lymphoma (alcl). approval url: https://www.ema.europa.eu/en/documents/product-information/xalkori-epar-product-information_en.pdf", "if a patient with inflammatory myofibroblastic tumor has v::alk, one recommended therapy is crizotinib. therapy type: targeted therapy. therapy strategy: alk inhibition + met inhibition + ros1 inhibition. indication: xalkori as monotherapy is indicated for the treatment of paediatric patients (age >= 1 to <18 years) with recurrent or refractory anaplastic lymphoma kinase (alk)-positive unresectable inflammatory myofibroblastic tumour (imt). approval url: https://www.ema.europa.eu/en/documents/product-information/xalkori-epar-product-information_en.pdf", "if a patient with acute myeloid leukemia has flt3-itd, one recommended therapy is gilteritinib. therapy type: targeted therapy. therapy strategy: flt3 inhibition. indication: xospata is indicated as monotherapy for the treatment of adult patients who have relapsed or refractory acute myeloid leukaemia (aml) with a flt3 mutation. approval url: https://www.ema.europa.eu/en/documents/product-information/xospata-epar-product-information_en.pdf", "if a patient with acute myeloid leukemia has flt3 p.d835y, one recommended therapy is gilteritinib. therapy type: targeted therapy. therapy strategy: flt3 inhibition. indication: xospata is indicated as monotherapy for the treatment of adult patients who have relapsed or refractory acute myeloid leukaemia (aml) with a flt3 mutation. approval url: https://www.ema.europa.eu/en/documents/product-information/xospata-epar-product-information_en.pdf", "if a patient with non-small cell lung cancer has wild type egfr, wild type alk, one recommended therapy is carboplatin + nivolumab + ipilimumab + pemetrexed. therapy type: chemotherapy + immunotherapy + immunotherapy + chemotherapy. therapy strategy: platinum-based chemotherapy + pd-1/pd-l1 inhibition + ctla-4 inhibition + antifolate. indication: yervoy in combination with nivolumab and 2 cycles of platinum-based chemotherapy is indicated for the first-line treatment of metastatic non-small cell lung cancer in adults whose tumours have no sensitising egfr mutation or alk translocation. approval url: https://www.ema.europa.eu/en/documents/product-information/yervoy-epar-product-information_en.pdf", "if a patient with non-small cell lung cancer has wild type egfr, wild type alk, one recommended therapy is nivolumab + ipilimumab + pemetrexed + cisplatin. therapy type: immunotherapy + immunotherapy + chemotherapy + chemotherapy. therapy strategy: pd-1/pd-l1 inhibition + ctla-4 inhibition + antifolate + platinum-based chemotherapy. indication: yervoy in combination with nivolumab and 2 cycles of platinum-based chemotherapy is indicated for the first-line treatment of metastatic non-small cell lung cancer in adults whose tumours have no sensitising egfr mutation or alk translocation. approval url: https://www.ema.europa.eu/en/documents/product-information/yervoy-epar-product-information_en.pdf", "if a patient with non-small cell lung cancer has wild type egfr, wild type alk, one recommended therapy is carboplatin + paclitaxel + nivolumab + ipilimumab. therapy type: chemotherapy + chemotherapy + immunotherapy + immunotherapy. therapy strategy: platinum-based chemotherapy + taxane-based chemotherapy + pd-1/pd-l1 inhibition + ctla-4 inhibition. indication: yervoy in combination with nivolumab and 2 cycles of platinum-based chemotherapy is indicated for the first-line treatment of metastatic non-small cell lung cancer in adults whose tumours have no sensitising egfr mutation or alk translocation. approval url: https://www.ema.europa.eu/en/documents/product-information/yervoy-epar-product-information_en.pdf", "if a patient with colorectal adenocarcinoma has msi-h, one recommended therapy is nivolumab + ipilimumab. therapy type: immunotherapy + immunotherapy. therapy strategy: pd-1/pd-l1 inhibition + ctla-4 inhibition. indication: yervoy in combination with nivolumab is indicated for the treatment of adult patients with mismatch repair deficient or microsatellite instability-high metastatic colorectal cancer after prior fluoropyrimidine-based combination chemotherapy. approval url: https://www.ema.europa.eu/en/documents/product-information/yervoy-epar-product-information_en.pdf", "if a patient with colorectal adenocarcinoma has dmmr, one recommended therapy is nivolumab + ipilimumab. therapy type: immunotherapy + immunotherapy. therapy strategy: pd-1/pd-l1 inhibition + ctla-4 inhibition. indication: yervoy in combination with nivolumab is indicated for the treatment of adult patients with mismatch repair deficient or microsatellite instability-high metastatic colorectal cancer after prior fluoropyrimidine-based combination chemotherapy. approval url: https://www.ema.europa.eu/en/documents/product-information/yervoy-epar-product-information_en.pdf", "if a patient with esophageal squamous cell carcinoma has pd-l1 >= 1%, one recommended therapy is nivolumab + ipilimumab. therapy type: immunotherapy + immunotherapy. therapy strategy: pd-1/pd-l1 inhibition + ctla-4 inhibition. indication: yervoy in combination with nivolumab is indicated for the first-line treatment of adult patients with unresectable advanced, recurrent or metastatic oesophageal squamous cell carcinoma with tumour cell pd-l1 expression >= 1%. approval url: https://www.ema.europa.eu/en/documents/product-information/yervoy-epar-product-information_en.pdf", "if a patient with melanoma has braf p.v600e, one recommended therapy is vemurafenib. therapy type: targeted therapy. therapy strategy: b-raf inhibition. indication: vemurafenib is indicated in monotherapy for the treatment of adult patients with braf v600 mutation- positive unresectable or metastatic melanoma. approval url: https://www.ema.europa.eu/en/documents/product-information/zelboraf-epar-product-information_en.pdf", "if a patient with melanoma has braf p.v600k, one recommended therapy is vemurafenib. therapy type: targeted therapy. therapy strategy: b-raf inhibition. indication: vemurafenib is indicated in monotherapy for the treatment of adult patients with braf v600 mutation- positive unresectable or metastatic melanoma. approval url: https://www.ema.europa.eu/en/documents/product-information/zelboraf-epar-product-information_en.pdf", "if a patient with chronic lymphocytic leukemia has tp53 deletion, one recommended therapy is idelalisib + rituximab. therapy type: targeted therapy + immunotherapy. therapy strategy: pi3k/akt/mtor inhibition + cd20 inhibition. indication: zydelig is indicated in combination with rituximab for the treatment of adult patients with chronic lymphocytic leukaemia (cll) as first line treatment in the presence of 17p deletion or tp53 mutation in patients who are not eligible for any other therapies. approval url: https://www.ema.europa.eu/en/documents/product-information/zydelig-epar-product-information_en.pdf", "if a patient with chronic lymphocytic leukemia has tp53 somatic variants, one recommended therapy is idelalisib + rituximab. therapy type: targeted therapy + immunotherapy. therapy strategy: pi3k/akt/mtor inhibition + cd20 inhibition. indication: zydelig is indicated in combination with rituximab for the treatment of adult patients with chronic lymphocytic leukaemia (cll) as first line treatment in the presence of 17p deletion or tp53 mutation in patients who are not eligible for any other therapies. approval url: https://www.ema.europa.eu/en/documents/product-information/zydelig-epar-product-information_en.pdf", "if a patient with chronic lymphocytic leukemia has 17p deletion, one recommended therapy is idelalisib + rituximab. therapy type: targeted therapy + immunotherapy. therapy strategy: pi3k/akt/mtor inhibition + cd20 inhibition. indication: zydelig is indicated in combination with rituximab for the treatment of adult patients with chronic lymphocytic leukaemia (cll) as first line treatment in the presence of 17p deletion or tp53 mutation in patients who are not eligible for any other therapies. approval url: https://www.ema.europa.eu/en/documents/product-information/zydelig-epar-product-information_en.pdf", "if a patient with non-small cell lung cancer has v::alk, one recommended therapy is ceritinib. therapy type: targeted therapy. therapy strategy: alk inhibition. indication: zykadia as monotherapy is indicated for the first-line treatment of adult patients with anaplastic lymphoma kinase (alk)-positive advanced non-small cell lung cancer (nsclc). approval url: https://www.ema.europa.eu/en/documents/product-information/zykadia-epar-product-information_en.pdf", "if a patient with non-small cell lung cancer has v::alk, one recommended therapy is ceritinib. therapy type: targeted therapy. therapy strategy: alk inhibition. indication: zykadia as monotherapy is indicated for the treatment of adult patients with anaplastic lymphoma kinase (alk)-positive advanced non-small cell lung cancer (nsclc) previously treated with crizotinib. approval url: https://www.ema.europa.eu/en/documents/product-information/zykadia-epar-product-information_en.pdf", "if a patient with non-small cell lung cancer has wild type egfr, wild type alk, pd-l1 >= 50%, one recommended therapy is carboplatin + tislelizumab + pemetrexed. therapy type: chemotherapy + immunotherapy + chemotherapy. therapy strategy: platinum-based chemotherapy + pd-1/pd-l1 inhibition + antifolate. indication: tevimbra in combination with pemetrexed and platinum-containing chemotherapy is indicated for the first-line treatment of adult patients with non-squamous nsclc whose tumors have pd-l1 expression on >= 50% of tumor cells with no egfr or alk positive mutations and who have (i) locally advanced nsclc and are not candidates for surgical resection or platinum-based chemoradiation, or (ii) metastatic nsclc. approval url: https://www.ema.europa.eu/en/documents/product-information/tevimbra-epar-product-information_en.pdf", "if a patient with non-small cell lung cancer has wild type egfr, wild type alk, pd-l1 >= 50%, one recommended therapy is tislelizumab + pemetrexed + cisplatin. therapy type: immunotherapy + chemotherapy + chemotherapy. therapy strategy: pd-1/pd-l1 inhibition + antifolate + platinum-based chemotherapy. indication: tevimbra in combination with pemetrexed and platinum-containing chemotherapy is indicated for the first-line treatment of adult patients with non-squamous nsclc whose tumors have pd-l1 expression on >= 50% of tumor cells with no egfr or alk positive mutations and who have (i) locally advanced nsclc and are not candidates for surgical resection or platinum-based chemoradiation, or (ii) metastatic nsclc. approval url: https://www.ema.europa.eu/en/documents/product-information/tevimbra-epar-product-information_en.pdf", "if a patient with non-small cell lung cancer has egfr exon 20 (insertion), one recommended therapy is carboplatin + amivantamab + pemetrexed. therapy type: chemotherapy + targeted therapy + chemotherapy. therapy strategy: platinum-based chemotherapy + egfr inhibition + antifolate. indication: rybrevant is indicated in combination with carboplatin and pemetrexed for the first-line treatment of adult patients with advanced non-small cell lung cancer (nsclc) with activating egfr exon 20 insertion mutations. approval url: https://www.ema.europa.eu/en/documents/product-information/rybrevant-epar-product-information_en.pdf", "if a patient with non-small cell lung cancer has egfr exon 20 (insertion), one recommended therapy is amivantamab. therapy type: targeted therapy. therapy strategy: egfr inhibition. indication: rybrevant is indicated as monotherapy for treatment of adult patients with advanced nsclc with activating egfr exon 20 insertion mutations, after failure of platinum-based chemotherapy. approval url: https://www.ema.europa.eu/en/documents/product-information/rybrevant-epar-product-information_en.pdf", "if a patient with locally advanced or metastatic invasive breast carcinoma has her2-negative, er positive, pik3ca somatic variants, one recommended therapy is fulvestrant + capivasertib. therapy type: hormone therapy + targeted therapy. therapy strategy: estrogen receptor inhibition + pi3k/akt/mtor inhibition. indication: truqap is indicated in combination with fulvestrant for the treatment of adult patients with oestrogen receptor (er)-positive, her2-negative locally advanced or metastatic breast cancer with one or more pik3ca/akt1/pten-alterations following recurrence or progression on or after an endocrine-based regimen. in pre- or perimenopausal women, truqap plus fulvestrant should be combined with a luteinising hormone releasing hormone (lhrh) agonist. for men, administration of lhrh agonist according to current clinical practices should be considered. approval url: https://www.ema.europa.eu/en/documents/product-information/truqap-epar-product-information_en.pdf", "if a patient with locally advanced or metastatic invasive breast carcinoma has pik3ca amplification, her2-negative, er positive, one recommended therapy is fulvestrant + capivasertib. therapy type: hormone therapy + targeted therapy. therapy strategy: estrogen receptor inhibition + pi3k/akt/mtor inhibition. indication: truqap is indicated in combination with fulvestrant for the treatment of adult patients with oestrogen receptor (er)-positive, her2-negative locally advanced or metastatic breast cancer with one or more pik3ca/akt1/pten-alterations following recurrence or progression on or after an endocrine-based regimen. in pre- or perimenopausal women, truqap plus fulvestrant should be combined with a luteinising hormone releasing hormone (lhrh) agonist. for men, administration of lhrh agonist according to current clinical practices should be considered. approval url: https://www.ema.europa.eu/en/documents/product-information/truqap-epar-product-information_en.pdf", "if a patient with locally advanced or metastatic invasive breast carcinoma has akt1 amplification, her2-negative, er positive, one recommended therapy is fulvestrant + capivasertib. therapy type: hormone therapy + targeted therapy. therapy strategy: estrogen receptor inhibition + pi3k/akt/mtor inhibition. indication: truqap is indicated in combination with fulvestrant for the treatment of adult patients with oestrogen receptor (er)-positive, her2-negative locally advanced or metastatic breast cancer with one or more pik3ca/akt1/pten-alterations following recurrence or progression on or after an endocrine-based regimen. in pre- or perimenopausal women, truqap plus fulvestrant should be combined with a luteinising hormone releasing hormone (lhrh) agonist. for men, administration of lhrh agonist according to current clinical practices should be considered. approval url: https://www.ema.europa.eu/en/documents/product-information/truqap-epar-product-information_en.pdf", "if a patient with locally advanced or metastatic invasive breast carcinoma has akt1 somatic variants, her2-negative, er positive, one recommended therapy is fulvestrant + capivasertib. therapy type: hormone therapy + targeted therapy. therapy strategy: estrogen receptor inhibition + pi3k/akt/mtor inhibition. indication: truqap is indicated in combination with fulvestrant for the treatment of adult patients with oestrogen receptor (er)-positive, her2-negative locally advanced or metastatic breast cancer with one or more pik3ca/akt1/pten-alterations following recurrence or progression on or after an endocrine-based regimen. in pre- or perimenopausal women, truqap plus fulvestrant should be combined with a luteinising hormone releasing hormone (lhrh) agonist. for men, administration of lhrh agonist according to current clinical practices should be considered. approval url: https://www.ema.europa.eu/en/documents/product-information/truqap-epar-product-information_en.pdf", "if a patient with locally advanced or metastatic invasive breast carcinoma has pten nonsense variants, her2-negative, er positive, one recommended therapy is fulvestrant + capivasertib. therapy type: hormone therapy + targeted therapy. therapy strategy: estrogen receptor inhibition + pi3k/akt/mtor inhibition. indication: truqap is indicated in combination with fulvestrant for the treatment of adult patients with oestrogen receptor (er)-positive, her2-negative locally advanced or metastatic breast cancer with one or more pik3ca/akt1/pten-alterations following recurrence or progression on or after an endocrine-based regimen. in pre- or perimenopausal women, truqap plus fulvestrant should be combined with a luteinising hormone releasing hormone (lhrh) agonist. for men, administration of lhrh agonist according to current clinical practices should be considered. approval url: https://www.ema.europa.eu/en/documents/product-information/truqap-epar-product-information_en.pdf", "if a patient with locally advanced or metastatic invasive breast carcinoma has pten frameshift variants, her2-negative, er positive, one recommended therapy is fulvestrant + capivasertib. therapy type: hormone therapy + targeted therapy. therapy strategy: estrogen receptor inhibition + pi3k/akt/mtor inhibition. indication: truqap is indicated in combination with fulvestrant for the treatment of adult patients with oestrogen receptor (er)-positive, her2-negative locally advanced or metastatic breast cancer with one or more pik3ca/akt1/pten-alterations following recurrence or progression on or after an endocrine-based regimen. in pre- or perimenopausal women, truqap plus fulvestrant should be combined with a luteinising hormone releasing hormone (lhrh) agonist. for men, administration of lhrh agonist according to current clinical practices should be considered. approval url: https://www.ema.europa.eu/en/documents/product-information/truqap-epar-product-information_en.pdf", "if a patient with locally advanced or metastatic invasive breast carcinoma has pten splice site variants, her2-negative, er positive, one recommended therapy is fulvestrant + capivasertib. therapy type: hormone therapy + targeted therapy. therapy strategy: estrogen receptor inhibition + pi3k/akt/mtor inhibition. indication: truqap is indicated in combination with fulvestrant for the treatment of adult patients with oestrogen receptor (er)-positive, her2-negative locally advanced or metastatic breast cancer with one or more pik3ca/akt1/pten-alterations following recurrence or progression on or after an endocrine-based regimen. in pre- or perimenopausal women, truqap plus fulvestrant should be combined with a luteinising hormone releasing hormone (lhrh) agonist. for men, administration of lhrh agonist according to current clinical practices should be considered. approval url: https://www.ema.europa.eu/en/documents/product-information/truqap-epar-product-information_en.pdf", "if a patient with locally advanced or metastatic invasive breast carcinoma has her2-negative, er positive, pten deletion, one recommended therapy is fulvestrant + capivasertib. therapy type: hormone therapy + targeted therapy. therapy strategy: estrogen receptor inhibition + pi3k/akt/mtor inhibition. indication: truqap is indicated in combination with fulvestrant for the treatment of adult patients with oestrogen receptor (er)-positive, her2-negative locally advanced or metastatic breast cancer with one or more pik3ca/akt1/pten-alterations following recurrence or progression on or after an endocrine-based regimen. in pre- or perimenopausal women, truqap plus fulvestrant should be combined with a luteinising hormone releasing hormone (lhrh) agonist. for men, administration of lhrh agonist according to current clinical practices should be considered. approval url: https://www.ema.europa.eu/en/documents/product-information/truqap-epar-product-information_en.pdf", "if a patient with bladder urothelial carcinoma has fgfr2::bicc1, one recommended therapy is erdafitinib. therapy type: targeted therapy. therapy strategy: fgfr inhibition. indication: balversa as monotherapy is indicated for the treatment of adult patients with unresectable or metastatic urothelial carcinoma (uc), harbouring susceptible fgfr3 genetic alterations who have previously received at least one line of therapy containing a pd-1 or pd-l1 inhibitor in the unresectable or metastatic treatment setting. approval url: https://www.ema.europa.eu/en/documents/product-information/balversa-epar-product-information_en.pdf", "if a patient with bladder urothelial carcinoma has fgfr2::casp7, one recommended therapy is erdafitinib. therapy type: targeted therapy. therapy strategy: fgfr inhibition. indication: balversa as monotherapy is indicated for the treatment of adult patients with unresectable or metastatic urothelial carcinoma (uc), harbouring susceptible fgfr3 genetic alterations who have previously received at least one line of therapy containing a pd-1 or pd-l1 inhibitor in the unresectable or metastatic treatment setting. approval url: https://www.ema.europa.eu/en/documents/product-information/balversa-epar-product-information_en.pdf", "if a patient with bladder urothelial carcinoma has fgfr3::tacc3, one recommended therapy is erdafitinib. therapy type: targeted therapy. therapy strategy: fgfr inhibition. indication: balversa as monotherapy is indicated for the treatment of adult patients with unresectable or metastatic urothelial carcinoma (uc), harbouring susceptible fgfr3 genetic alterations who have previously received at least one line of therapy containing a pd-1 or pd-l1 inhibitor in the unresectable or metastatic treatment setting. approval url: https://www.ema.europa.eu/en/documents/product-information/balversa-epar-product-information_en.pdf", "if a patient with bladder urothelial carcinoma has fgfr3::baiap2l1, one recommended therapy is erdafitinib. therapy type: targeted therapy. therapy strategy: fgfr inhibition. indication: balversa as monotherapy is indicated for the treatment of adult patients with unresectable or metastatic urothelial carcinoma (uc), harbouring susceptible fgfr3 genetic alterations who have previously received at least one line of therapy containing a pd-1 or pd-l1 inhibitor in the unresectable or metastatic treatment setting. approval url: https://www.ema.europa.eu/en/documents/product-information/balversa-epar-product-information_en.pdf", "if a patient with bladder urothelial carcinoma has fgfr3 p.r248c, one recommended therapy is erdafitinib. therapy type: targeted therapy. therapy strategy: fgfr inhibition. indication: balversa as monotherapy is indicated for the treatment of adult patients with unresectable or metastatic urothelial carcinoma (uc), harbouring susceptible fgfr3 genetic alterations who have previously received at least one line of therapy containing a pd-1 or pd-l1 inhibitor in the unresectable or metastatic treatment setting. approval url: https://www.ema.europa.eu/en/documents/product-information/balversa-epar-product-information_en.pdf", "if a patient with bladder urothelial carcinoma has fgfr3 p.s249c, one recommended therapy is erdafitinib. therapy type: targeted therapy. therapy strategy: fgfr inhibition. indication: balversa as monotherapy is indicated for the treatment of adult patients with unresectable or metastatic urothelial carcinoma (uc), harbouring susceptible fgfr3 genetic alterations who have previously received at least one line of therapy containing a pd-1 or pd-l1 inhibitor in the unresectable or metastatic treatment setting. approval url: https://www.ema.europa.eu/en/documents/product-information/balversa-epar-product-information_en.pdf", "if a patient with bladder urothelial carcinoma has fgfr3 p.g370c, one recommended therapy is erdafitinib. therapy type: targeted therapy. therapy strategy: fgfr inhibition. indication: balversa as monotherapy is indicated for the treatment of adult patients with unresectable or metastatic urothelial carcinoma (uc), harbouring susceptible fgfr3 genetic alterations who have previously received at least one line of therapy containing a pd-1 or pd-l1 inhibitor in the unresectable or metastatic treatment setting. approval url: https://www.ema.europa.eu/en/documents/product-information/balversa-epar-product-information_en.pdf", "if a patient with bladder urothelial carcinoma has fgfr3 p.y373c, one recommended therapy is erdafitinib. therapy type: targeted therapy. therapy strategy: fgfr inhibition. indication: balversa as monotherapy is indicated for the treatment of adult patients with unresectable or metastatic urothelial carcinoma (uc), harbouring susceptible fgfr3 genetic alterations who have previously received at least one line of therapy containing a pd-1 or pd-l1 inhibitor in the unresectable or metastatic treatment setting. approval url: https://www.ema.europa.eu/en/documents/product-information/balversa-epar-product-information_en.pdf", "if a patient with adenocarcinoma of the gastroesophageal junction has her2-negative, cldn18.2 >= 75%, one recommended therapy is oxaliplatin + fluorouracil + zolbetuximab. therapy type: chemotherapy + chemotherapy + immunotherapy. therapy strategy: platinum-based chemotherapy + thymidylate synthase inhibition + cldn18.2 inhibition. indication: vyloy, in combination with fluoropyrimidine- and platinum-containing chemotherapy, is indicated for the first-line treatment of adult patients with locally advanced unresectable or metastatic her2-negative gastric or gastro-oesophageal junction (gej) adenocarcinoma whose tumours are claudin (cldn) 18.2 positive. approval url: https://www.ema.europa.eu/en/documents/product-information/vyloy-epar-product-information_en.pdf", "if a patient with adenocarcinoma of the gastroesophageal junction has her2-negative, cldn18.2 >= 75%, one recommended therapy is oxaliplatin + zolbetuximab + capecitabine. therapy type: chemotherapy + immunotherapy + chemotherapy. therapy strategy: platinum-based chemotherapy + cldn18.2 inhibition + thymidylate synthase inhibition. indication: vyloy, in combination with fluoropyrimidine- and platinum-containing chemotherapy, is indicated for the first-line treatment of adult patients with locally advanced unresectable or metastatic her2-negative gastric or gastro-oesophageal junction (gej) adenocarcinoma whose tumours are claudin (cldn) 18.2 positive. approval url: https://www.ema.europa.eu/en/documents/product-information/vyloy-epar-product-information_en.pdf", "if a patient with invasive breast carcinoma has her2-negative, er positive, one recommended therapy is tamoxifen + abemaciclib. therapy type: hormone therapy + targeted therapy. therapy strategy: estrogen receptor inhibition + cdk4/6 inhibition. indication: verzenios in combination with endocrine therapy is indicated for the adjuvant treatment of adult patients with hormone receptor (hr)-positive, human epidermal growth factor receptor 2 (her2)-negative, node-positive early breast cancer at high risk of recurrence. approval url: https://www.ema.europa.eu/en/documents/product-information/verzenios-epar-product-information_en.pdf", "if a patient with invasive breast carcinoma has pr positive, her2-negative, one recommended therapy is tamoxifen + abemaciclib. therapy type: hormone therapy + targeted therapy. therapy strategy: estrogen receptor inhibition + cdk4/6 inhibition. indication: verzenios in combination with endocrine therapy is indicated for the adjuvant treatment of adult patients with hormone receptor (hr)-positive, human epidermal growth factor receptor 2 (her2)-negative, node-positive early breast cancer at high risk of recurrence. approval url: https://www.ema.europa.eu/en/documents/product-information/verzenios-epar-product-information_en.pdf", "if a patient with invasive breast carcinoma has pr positive, her2-negative, er positive, one recommended therapy is tamoxifen + abemaciclib. therapy type: hormone therapy + targeted therapy. therapy strategy: estrogen receptor inhibition + cdk4/6 inhibition. indication: verzenios in combination with endocrine therapy is indicated for the adjuvant treatment of adult patients with hormone receptor (hr)-positive, human epidermal growth factor receptor 2 (her2)-negative, node-positive early breast cancer at high risk of recurrence. approval url: https://www.ema.europa.eu/en/documents/product-information/verzenios-epar-product-information_en.pdf", "if a patient with invasive breast carcinoma has her2-negative, er positive, one recommended therapy is anastrozole + abemaciclib. therapy type: hormone therapy + targeted therapy. therapy strategy: aromatase inhibition + cdk4/6 inhibition. indication: verzenios in combination with endocrine therapy is indicated for the adjuvant treatment of adult patients with hormone receptor (hr)-positive, human epidermal growth factor receptor 2 (her2)-negative, node-positive early breast cancer at high risk of recurrence. approval url: https://www.ema.europa.eu/en/documents/product-information/verzenios-epar-product-information_en.pdf", "if a patient with invasive breast carcinoma has pr positive, her2-negative, one recommended therapy is anastrozole + abemaciclib. therapy type: hormone therapy + targeted therapy. therapy strategy: aromatase inhibition + cdk4/6 inhibition. indication: verzenios in combination with endocrine therapy is indicated for the adjuvant treatment of adult patients with hormone receptor (hr)-positive, human epidermal growth factor receptor 2 (her2)-negative, node-positive early breast cancer at high risk of recurrence. approval url: https://www.ema.europa.eu/en/documents/product-information/verzenios-epar-product-information_en.pdf", "if a patient with invasive breast carcinoma has pr positive, her2-negative, er positive, one recommended therapy is anastrozole + abemaciclib. therapy type: hormone therapy + targeted therapy. therapy strategy: aromatase inhibition + cdk4/6 inhibition. indication: verzenios in combination with endocrine therapy is indicated for the adjuvant treatment of adult patients with hormone receptor (hr)-positive, human epidermal growth factor receptor 2 (her2)-negative, node-positive early breast cancer at high risk of recurrence. approval url: https://www.ema.europa.eu/en/documents/product-information/verzenios-epar-product-information_en.pdf", "if a patient with invasive breast carcinoma has her2-negative, er positive, one recommended therapy is abemaciclib + letrozole. therapy type: targeted therapy + hormone therapy. therapy strategy: cdk4/6 inhibition + aromatase inhibition. indication: verzenios in combination with endocrine therapy is indicated for the adjuvant treatment of adult patients with hormone receptor (hr)-positive, human epidermal growth factor receptor 2 (her2)-negative, node-positive early breast cancer at high risk of recurrence. approval url: https://www.ema.europa.eu/en/documents/product-information/verzenios-epar-product-information_en.pdf", "if a patient with invasive breast carcinoma has pr positive, her2-negative, one recommended therapy is abemaciclib + letrozole. therapy type: targeted therapy + hormone therapy. therapy strategy: cdk4/6 inhibition + aromatase inhibition. indication: verzenios in combination with endocrine therapy is indicated for the adjuvant treatment of adult patients with hormone receptor (hr)-positive, human epidermal growth factor receptor 2 (her2)-negative, node-positive early breast cancer at high risk of recurrence. approval url: https://www.ema.europa.eu/en/documents/product-information/verzenios-epar-product-information_en.pdf", "if a patient with invasive breast carcinoma has pr positive, her2-negative, er positive, one recommended therapy is abemaciclib + letrozole. therapy type: targeted therapy + hormone therapy. therapy strategy: cdk4/6 inhibition + aromatase inhibition. indication: verzenios in combination with endocrine therapy is indicated for the adjuvant treatment of adult patients with hormone receptor (hr)-positive, human epidermal growth factor receptor 2 (her2)-negative, node-positive early breast cancer at high risk of recurrence. approval url: https://www.ema.europa.eu/en/documents/product-information/verzenios-epar-product-information_en.pdf", "if a patient with invasive breast carcinoma has pr positive, her2-negative, er positive, one recommended therapy is exemestane + abemaciclib. therapy type: hormone therapy + targeted therapy. therapy strategy: aromatase inhibition + cdk4/6 inhibition. indication: verzenios in combination with endocrine therapy is indicated for the adjuvant treatment of adult patients with hormone receptor (hr)-positive, human epidermal growth factor receptor 2 (her2)-negative, node-positive early breast cancer at high risk of recurrence. approval url: https://www.ema.europa.eu/en/documents/product-information/verzenios-epar-product-information_en.pdf", "if a patient with invasive breast carcinoma has her2-negative, er positive, one recommended therapy is exemestane + abemaciclib. therapy type: hormone therapy + targeted therapy. therapy strategy: aromatase inhibition + cdk4/6 inhibition. indication: verzenios in combination with endocrine therapy is indicated for the adjuvant treatment of adult patients with hormone receptor (hr)-positive, human epidermal growth factor receptor 2 (her2)-negative, node-positive early breast cancer at high risk of recurrence. approval url: https://www.ema.europa.eu/en/documents/product-information/verzenios-epar-product-information_en.pdf", "if a patient with invasive breast carcinoma has pr positive, her2-negative, one recommended therapy is exemestane + abemaciclib. therapy type: hormone therapy + targeted therapy. therapy strategy: aromatase inhibition + cdk4/6 inhibition. indication: verzenios in combination with endocrine therapy is indicated for the adjuvant treatment of adult patients with hormone receptor (hr)-positive, human epidermal growth factor receptor 2 (her2)-negative, node-positive early breast cancer at high risk of recurrence. approval url: https://www.ema.europa.eu/en/documents/product-information/verzenios-epar-product-information_en.pdf", "if a patient with acute lymphoid leukemia has bcr::abl1, cd19 +, one recommended therapy is blinatumomab. therapy type: immunotherapy. therapy strategy: cd19 inhibition. indication: blincyto is indicated as monotherapy as part of consolidation therapy for the treatment of adult patients with newly diagnosed philadelphia chromosome negative cd19 positive b-cell precusor acute lymphoblastic leukaemia (all). approval url: https://www.ema.europa.eu/en/documents/product-information/blincyto-epar-product-information_en.pdf", "if a patient with chronic myelogenous leukemia has bcr::abl1, one recommended therapy is bosutinib. therapy type: targeted therapy. therapy strategy: bcr-abl inhibition. indication: bosulif is indicated for the treatment of adult and paediatric patients aged 6 years and older with cp ph+ cml previously treated with one or more tyrosine kinase inhibitor(s) [tki(s)] and for whom imatinib, nilotinib and dasatinib are not considered appropriate treatment options. approval url: https://www.ema.europa.eu/en/documents/product-information/bosulif-epar-product-information_en.pdf", "if a patient with chronic myelogenous leukemia has bcr::abl1, one recommended therapy is bosutinib. therapy type: targeted therapy. therapy strategy: bcr-abl inhibition. indication: bosulif is indicated for the treatment of adult and paediatric patients aged 6 years and older with newly-diagnosed chronic phase (cp) philadelphia chromosome-positive chronic myelogenous leukaemia (ph+ cml). approval url: https://www.ema.europa.eu/en/documents/product-information/bosulif-epar-product-information_en.pdf", "if a patient with chronic myelogenous leukemia has bcr::abl1, one recommended therapy is bosutinib. therapy type: targeted therapy. therapy strategy: bcr-abl inhibition. indication: bosulif is indicated for the treatment of adult patients with accelerated phase (ap), and blast phase (bp) ph+ cml previously treated with one or more tyrosine kinase inhibitor(s) [tki(s)] and for whom imatinib, nilotinib and dasatinib are not considered appropriate treatment options. approval url: https://www.ema.europa.eu/en/documents/product-information/bosulif-epar-product-information_en.pdf", "if a patient with chronic myelogenous leukemia has bcr::abl1, one recommended therapy is bosutinib. therapy type: targeted therapy. therapy strategy: bcr-abl inhibition. indication: bosulif is indicated for the treatment of adult and paediatric patients aged 6 years and older with cp ph+ cml previously treated with one or more tyrosine kinase inhibitor(s) [tki(s)] and for whom imatinib, nilotinib and dasatinib are not considered appropriate treatment options. approval url: https://www.ema.europa.eu/en/documents/product-information/bosulif-epar-product-information_en.pdf", "if a patient with non-small cell lung cancer has egfr somatic variants, one recommended therapy is datopotamab deruxtecan. therapy type: targeted therapy. therapy strategy: topoisomerase inhibition + trop-2 directed antibody. indication: enhertu as monotherapy is indicated for the treatment of adult patients with unresectable or metastatic hormone receptor (hr)-positive, her2-low or her2-ultralow breast cancer who have received at least one endocrine therapy in the metastatic setting and who are not considered suitable for endocrine therapy as the next line of treatment. approval url: https://www.ema.europa.eu/en/documents/product-information/enhertu-epar-product-information_en.pdf", "if a patient with non-small cell lung cancer has egfr exon 19 (deletion), one recommended therapy is datopotamab deruxtecan. therapy type: targeted therapy. therapy strategy: topoisomerase inhibition + trop-2 directed antibody. indication: enhertu as monotherapy is indicated for the treatment of adult patients with unresectable or metastatic hormone receptor (hr)-positive, her2-low or her2-ultralow breast cancer who have received at least one endocrine therapy in the metastatic setting and who are not considered suitable for endocrine therapy as the next line of treatment. approval url: https://www.ema.europa.eu/en/documents/product-information/enhertu-epar-product-information_en.pdf", "if a patient with non-small cell lung cancer has egfr p.l858r, one recommended therapy is datopotamab deruxtecan. therapy type: targeted therapy. therapy strategy: topoisomerase inhibition + trop-2 directed antibody. indication: enhertu as monotherapy is indicated for the treatment of adult patients with unresectable or metastatic hormone receptor (hr)-positive, her2-low or her2-ultralow breast cancer who have received at least one endocrine therapy in the metastatic setting and who are not considered suitable for endocrine therapy as the next line of treatment. approval url: https://www.ema.europa.eu/en/documents/product-information/enhertu-epar-product-information_en.pdf", "if a patient with non-small cell lung cancer has egfr p.t790m, one recommended therapy is datopotamab deruxtecan. therapy type: targeted therapy. therapy strategy: topoisomerase inhibition + trop-2 directed antibody. indication: enhertu as monotherapy is indicated for the treatment of adult patients with unresectable or metastatic hormone receptor (hr)-positive, her2-low or her2-ultralow breast cancer who have received at least one endocrine therapy in the metastatic setting and who are not considered suitable for endocrine therapy as the next line of treatment. approval url: https://www.ema.europa.eu/en/documents/product-information/enhertu-epar-product-information_en.pdf", "if a patient with invasive breast carcinoma has egfr exon 20 (insertion), one recommended therapy is datopotamab deruxtecan. therapy type: targeted therapy. therapy strategy: topoisomerase inhibition + trop-2 directed antibody. indication: enhertu as monotherapy is indicated for the treatment of adult patients with unresectable or metastatic hormone receptor (hr)-positive, her2-low or her2-ultralow breast cancer who have received at least one endocrine therapy in the metastatic setting and who are not considered suitable for endocrine therapy as the next line of treatment. approval url: https://www.ema.europa.eu/en/documents/product-information/enhertu-epar-product-information_en.pdf", "if a patient with invasive breast carcinoma has her2-negative, er positive, one recommended therapy is datopotamab deruxtecan. therapy type: targeted therapy. therapy strategy: topoisomerase inhibition + trop-2 directed antibody. indication: enhertu as monotherapy is indicated for the treatment of adult patients with unresectable or metastatic hormone receptor (hr)-positive, her2-low or her2-ultralow breast cancer who have received at least one endocrine therapy in the metastatic setting and who are not considered suitable for endocrine therapy as the next line of treatment. approval url: https://www.ema.europa.eu/en/documents/product-information/enhertu-epar-product-information_en.pdf", "if a patient with chronic myeloid leukemia, bcr-abl1+ has bcr::abl1, one recommended therapy is imatinib. therapy type: targeted therapy. therapy strategy: bcr-abl inhibition + c-kit inhibition + pdgf-r inhibition. indication: glivec is indicated for the treatment of adult and paediatric patients with newly diagnosed philadelphia chromosome (bcr-abl) positive (ph+) chronic myeloid leukaemia (cml) for whom bone marrow transplantation is not considered as the first line of treatment. approval url: https://www.ema.europa.eu/en/documents/product-information/glivec-epar-product-information_en.pdf", "if a patient with chronic myeloid leukemia, bcr-abl1+ has bcr::abl1, one recommended therapy is imatinib. therapy type: targeted therapy. therapy strategy: bcr-abl inhibition + c-kit inhibition + pdgf-r inhibition. indication: glivec is indicated for the treatment of adult and paediatric patients with ph+ cml in chronic phase after failure of interferon-alpha therapy, or in accelerated phase or blast crisis. approval url: https://www.ema.europa.eu/en/documents/product-information/glivec-epar-product-information_en.pdf", "if a patient with non-small cell lung cancer has wild type egfr, wild type alk, one recommended therapy is carboplatin + paclitaxel + durvalumab. therapy type: chemotherapy + chemotherapy + immunotherapy. therapy strategy: platinum-based chemotherapy + taxane-based chemotherapy + pd-1/pd-l1 inhibition. indication: imfinzi in combination with platinum-based chemotherapy as neoadjuvant treatment, followed by imfinzi as monotherapy as adjuvant treatment, is indicated for the treatment of adults with resectable nsclc at high risk of recurrence and no egfr mutations or alk rearrangements. approval url: https://www.ema.europa.eu/en/documents/product-information/imfinzi-epar-product-information_en.pdf", "if a patient with non-small cell lung cancer has wild type egfr, wild type alk, one recommended therapy is durvalumab + gemcitabine + cisplatin. therapy type: immunotherapy + chemotherapy + chemotherapy. therapy strategy: pd-1/pd-l1 inhibition + antimetabolite + platinum-based chemotherapy. indication: imfinzi in combination with platinum-based chemotherapy as neoadjuvant treatment, followed by imfinzi as monotherapy as adjuvant treatment, is indicated for the treatment of adults with resectable nsclc at high risk of recurrence and no egfr mutations or alk rearrangements. approval url: https://www.ema.europa.eu/en/documents/product-information/imfinzi-epar-product-information_en.pdf", "if a patient with non-small cell lung cancer has wild type egfr, wild type alk, one recommended therapy is durvalumab + pemetrexed + cisplatin. therapy type: immunotherapy + chemotherapy + chemotherapy. therapy strategy: pd-1/pd-l1 inhibition + antifolate + platinum-based chemotherapy. indication: imfinzi in combination with platinum-based chemotherapy as neoadjuvant treatment, followed by imfinzi as monotherapy as adjuvant treatment, is indicated for the treatment of adults with resectable nsclc at high risk of recurrence and no egfr mutations or alk rearrangements. approval url: https://www.ema.europa.eu/en/documents/product-information/imfinzi-epar-product-information_en.pdf", "if a patient with non-small cell lung cancer has wild type egfr, wild type alk, one recommended therapy is carboplatin + durvalumab + pemetrexed. therapy type: chemotherapy + immunotherapy + chemotherapy. therapy strategy: platinum-based chemotherapy + pd-1/pd-l1 inhibition + antifolate. indication: imfinzi in combination with platinum-based chemotherapy as neoadjuvant treatment, followed by imfinzi as monotherapy as adjuvant treatment, is indicated for the treatment of adults with resectable nsclc at high risk of recurrence and no egfr mutations or alk rearrangements. approval url: https://www.ema.europa.eu/en/documents/product-information/imfinzi-epar-product-information_en.pdf"]